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Recently, the twin-arginine translocation (Tat) pathway has raised interest due to reports of its 
unique proofreading ability to export correctly folded proteins. However, only a few recombinant 
proteins fused to an N-terminal Tat signal peptide have been reported to be exported via Tat. The 
hypothesis for this thesis was to evaluate whether the range of proteins of interest that can be 
exported by the Tat pathway can be extended by C-terminally fusing them to a natural Tat substrate 
(NTS). Thus, the NTS would act as a soluble carrier to improve cytoplasmic solubility and facilitate 
Tat export. Moreover, the CyDisCo technology enabling cytoplasmic formation of disulphide bonds 
was investigated to reach this goal. 
Initially, a robust fractionation method was developed to assess protein localisation with due 
diligence. A panel of NTS and reporter proteins were evaluated for the respective role of the soluble 
carrier and the protein of interest. None of the selected NTS and only PhoA and hGH of the tested 
reporter proteins were shown to export specifically via Tat. After the review of the fusion design to 
use the valid reporter proteins as the soluble carrier, three proteins of interest were expressed with 
and without the soluble carriers. This fusion strategy did not extend Tat acceptance. Overall, this 
project confirmed the difficulty to export a recombinant protein via the Tat pathway. Additionally, 
CyDisCo was demonstrated to improve expression of recombinant proteins but did not form native 
disulphide bonds. 
However, this project revealed unexpected export of sfGFP, hGH and FABP4 including the 
recombinant proteins fused to hGH without a signal peptide. This unidentified translocation 
mechanism(s) needs further characterisation which can lead to the discovery of a new export 
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1.1. General introduction 
Proteins are required in academic research, the pharmaceutical, food and textile industries. They 
have multiple usage such as therapeutics, research proteins, cooking enzymes and proteases in 
laundry detergents. Proteins used as biopharmaceutical medicines encompass antibodies as well as 
non-antibody molecules and in 2016, represented US$ 228 billion in global sales (Moorkens et al., 
2017). These proteins are produced as recombinant proteins for development and manufacture at 
laboratory and large scales for both academic and industrial applications. They can be produced in 
eukaryotic (mammalian cells, insect cells, yeast, plant) or prokaryotic (bacteria) systems (Gasser et 
al., 2013, Butler and Spearman, 2014, Stolt-Bergner et al., 2018, Sack et al., 2015, Chen, 2012). The 
most popular hosts are mammalian cells and bacteria. The latter were historically the first developed 
hosts for recombinant protein production thanks to their quick generation time, easy manipulation, 
low cost equipment and high productivity (Terpe, 2006). However, in many occurrences, bacteria 
are not able to produce active heterologous proteins as some tend to form instable polypeptides 
which aggregate and end up as inclusion bodies due to the lack of access of different machineries 
(Golgi apparatus, endoplasmic reticulum) or necessary chaperones (García-Fruitós, 2010). Many 
engineering works have emerged in the past decades to contour these limitations to render bacteria 
even more attractive for recombinant protein production (section 1.4.5). On the other hand, 
mammalian cells are the systems of choice for glycosylated therapeutic protein production. The main 
drawbacks of these hosts are the high cost brought by the slow cell growth, expensive media and 
specialized equipment needed for culture conditions. 
Amongst bacterial systems, both Gram-positive and Gram-negative strains are used and therefore 
offer different advantages made possible by way of their cell wall organization. The cell wall of Gram-
positive bacteria consists of a thin periplasmic space between a thick peptidoglycan layer and the 
cell membrane as represented in Figure 1-1 (Matias and Beveridge, 2005). In Gram negative bacteria, 




membranes (Figure 1-1). In terms of recombinant protein production, this difference is translated 
by the ease of protein excretion in Gram-positive compared to Gram-negative bacteria. Indeed, 
species like Bacillus subtilis are often used for production of proteins intended for secretion into the 
extra-cellular medium (Song et al., 2015). Other bacterial expression systems have emerged like the 
Gram-positive Lactococcus lactis and the Gram-negative Pseudomonas (Chen, 2012). For instance, 
proteins production in Pseudomonas fluorescens is less dependent on oxygen concentration, does 
not accumulate acetate and gave a yield greater than 30 times higher compared to production in E. 
coli (Huang et al., 2007). This species can also be used for periplasmic export, but its pathogenicity 
refrains the development as a production platform especially for therapeutics (Retallack et al., 2007, 
Scales et al., 2014). Additionally, Lactococcus lactis is largely used for the production of membrane 
proteins due its single membrane cell envelope but the protein production titers have never been 
reported higher than 300 mg/L (Chen, 2012). 
 
 
Figure 1-1: Diagram of bacterial envelopes 
 
Somatostatin was, in 1977, the first human recombinant protein to be generated (Itakura et al., 
1977) and in 1982, human insulin was the first commercial recombinant drug to receive approval 
from the US food and drug administration (Johnson, 1983). Both proteins were produced in E. coli 
and since then, this species has been used extensively for recombinant protein production platform. 




competent authorities were produced in E. coli (Ferrer-Miralles et al., 2009). The various 
therapeutics produced by this bacterium include interferons, insulins and monoclonal antibodies 
(Jozala et al., 2016, Baeshen et al., 2015, Sanchez-Garcia et al., 2016). E. coli offers several additional 
advantages including fast growth kinetics, high cell density and the availability of non-pathogenic 
species (Rosano and Ceccarelli, 2014). 
 
1.2. The Escherichia coli K12 strain as a production host 
As mentioned in section 1.1, E. coli is used as the first-choice microorganism for recombinant protein 
production but many strains from this species are pathogenic to humans (Croxen et al., 2013). 
However, the descendants of a non-pathogenic isolate, E. coli K12 (Tatum and Lederberg, 1947) have 
given rise to strains such as MG1655 and W3110 which are routinely used for recombinant protein 
expression (Daegelen et al., 2009). K12 derivatives do not possess the F plasmid necessary for 
conjugation and are therefore designated F- and are defective for lambda lysogeny (λ). Many 
examples of successful protein expression in E. coli K12 strains can be found for expression of a 
research protein at laboratory scale such as interleukin 3 (Hercus et al., 2013), amylases (Zafar et al., 
2016), myosines (Pylypenko et al., 2016). Also, such strains are used to produce therapeutics at 
industrial scale (Huang et al., 2012) including the enzyme Glucarpidase (Voraxaze®) used to treat 
delayed methotrexate clearance in patients with renal failure (Rattu et al., 2013), the pegylated Fab’ 
fragment Certolizumab pegol (Cimzia®) for the treatment of rheumatoid arthritis in combination 
with methotrexate (Goel and Stephens, 2010), the human growth hormone (hGH) produced in the 
periplasm (de Oliveira et al., 1999) and the human stem cell factor in fusion with erythropoietin (Su 
et al., 2006). For the present study, the E. coli K12 W3110 strain was selected has the host since it is 
used routinely in-house for periplasmic expression of antibody fragments (section 3.6.). 
Furthermore, a plethora of parameters need to be considered in order to optimize the recombinant 
protein production process in the selected host strain. Examples of such parameters are listed in 




periplasm or the extra-cellular medium. Hence, the localisation of the protein of interest within the 
cell impacts the purification process and product quality. Periplasmic expression was previously 
associated with lower production yields than cytoplasmic expression but recent studies have 
demonstrated than protein can be expressed to up to 1.1 g/L or even 2.4 g/L in the periplasm of E. 
coli (Matos et al., 2012, Ellis et al., 2017). 
 
Table 1-1: Parameters to consider for recombinant protein expression optimization 




antibiotic resistance, plasmid 
addiction system 
Rosano and Ceccarelli 
(2014), Goh and Good 
(2008) 
Copy number 
Low (SC101), moderate (p15A), 
high (pUC) copy numbers 
Friehs (2004) 
Induction system 
IPTG inducible (tac), arabinose 
inducible (pRHaBAD) promoters 
de Boer et al. (1983), 





RBS and promoter strengths 
Mutalik et al. (2013), Li 
and Zhang (2014) 
Codon usage   Plotkin and Kudla (2011) 
Gene 
organization 




His, FLAG, V5, HA, SUMO, MBP, 
GST 
Kosobokova et al. (2016) 
Cleavage site TEV, thrombin cleavage sites Kosobokova et al. (2016) 
Signal peptide 





GroEL, GroES, Trigger factor Gräslund et al. (2008) 
Culture 
condition 
Mode of culture 
Batch, fed-batch, continuous 
fermentation 
Costa et al. (2014) 
Container  




Rich or minimum, defined or 
undefined 
Arya et al. (2015) 
Temperature Optimal, suboptimal Costa et al. (2014) 
Agitation   Overton (2014) 
Induction level   Overton (2014) 





1.3. Secretion systems in Escherichia coli 
E. coli possesses several ways to transport proteins from the cytoplasm into the periplasm (export) 
or to the extra-cellular medium (secretion). Gram-negative bacteria possess eight known pathways 
to transport proteins across the biological membranes (Green and Mecsas, 2016). They are listed as 
the general secretory (Sec), twin-arginine translocation (Tat), TypeI, TypeII, TypeIII, TypeIV, TypeV 
and TypeVI pathways. The Sec and Tat pathways have been exploited for recombinant protein 
production whereas the remaining systems are involved in bacterial virulence (Green and Mecsas, 
2016). 
1.3.1. The Sec pathway 
The Sec pathway is an essential pathway used by around 96 % of E. coli exportome of which 60 % 
are inner membrane proteins and the remaining 40 % are outer membrane, periplasmic and 
secreted proteins (Yu et al., 2010). It allows substrate proteins to translocate into or across the 
plasma membrane as unfolded polypeptide chains using two mechanisms: the SecB and the signal 
recognition particle (SRP) pathways (Pugsley, 1993). De novo translated polypeptides are exported 
by Sec in three stages: firstly, they are targeted to the Sec machinery via a N-terminal signal peptide 
and sorted to the SecB or SRP pathways. Secondly, they are translocated across or into the inner 
membrane and finally, the signal peptide is cleaved by membrane anchored peptidase prior to 
release of the preprotein. 
1.3.1.1. Sec-specific signal peptides 
Sec substrates are targeted for Sec translocation via specific signal sequences borne at their N-
termini (Green and Mecsas, 2016). SRP targets highly hydrophobic signal peptides to the SecYEG 
channel in a co-translational way whereas SecB recognizes a less hydrophobic signal peptide. The 
signal peptides are typically 18-27 residues long and can be divided into three regions as described 
in Figure 1-2 (Gouridis et al., 2009). The n-region is located at the amino terminal and is characterised 
by a net positive charge. One or more basic residues are responsible for the positive charge(s) of the 




one substrate to the other and can influence protein synthesis and translocation rates (Caspers et 
al., 2010). Moreover, the net charge should be maintained to a positive value, otherwise the 
translocation rate can suffer significant reduction (Inouye et al., 1982). For instance, a cutinase from 
the fungus Fusarium solan pisi was expressed in Bacillus subtilis fused to the signal peptide of AmyE 
(Caspers et al., 2010). The authors found that Phe2Asp, Phe2Glu or Lys4Leu mutation, each lowering 
the net charge from +3 to +2, led to a three-fold increase in terms of secretion and activity. Screening 
the net charge of signal peptides for a selected recombinant protein can lead to improved secretion 
yields but is protein specific (Puziss et al., 1992, Nesmeyanova et al., 1997, Ismail et al., 2011). 
 
 
Figure 1-2: General features of a Sec-specific signal peptide 
The Sec signal peptide is composed of a positively charged amino-terminal region (n-region), followed by a 
hydrophobic region (h-region) which forms an α-helix upon binding to SecA, and is terminated by a carboxyl-
terminal region (c-region) containing a signal peptidase cleavage site (AXA). The lengths are indicated in amino 
acid residues. + means positively charges. 
 
The following region is the h-region of 8 to 12 amino acid residues characterised by its hydrophobicity 
and its helical propensity (Figure 1-2). Decreasing the hydrophobicity, by deletion or mutation of 
amino acid residues, considerably decreases protein export resulting in cytoplasmic accumulation in 
a misfolded state (Izard and Kendall, 1994, Suominen et al., 1995). Although, the possible deflection 
from the SRP to the SecB pathways was not investigated. The low hydrophobicity can exceed a limit, 
resulting in a significant decrease in translocation of native Sec substrates. For instance, a minimum 




export (Rusch et al., 1994). On the other hand, mutating the h-region to increase the hydrophobicity 
by the addition of leucine(s) has proven to increase secretion efficiency (Chen et al., 1996) but again, 
the re-routing of nascent polypeptide from SecB to SRP was not assessed. Moreover, introducing a 
helix breaker reduces the affinity of SRP for the highly hydrophobic signal peptides. Similarly, an 
extension to this helix by mutating glycine for cysteine or leucine residues shifted the affinity of the 
PhoE signal peptide towards SRP (Adams et al., 2002). 
The C-terminal region of a Sec signal peptide is named the c-region and contains a cleavage site to 
allow release of the mature domain into the periplasm or into the membrane for integral substrates 
(Figure 1-2). This region should be at least five residues long to ensure export and cleavage efficiency 
(Suominen et al., 1995). During export, the signal peptide becomes embedded into the SecYEG 
translocon and upon complete translocation of the nascent polypeptide into the periplasm, it is 
cleaved by the signal peptidase I, LepB which is located on the outer leaf of the inner membrane 
(Date, 1983). This enzyme recognizes a 3 amino acid motif where the -1 and -3 positions before the 
cleavage site favour residues with small neutral chains (von Heijne, 1984). Since the common residue 
at these positions is alanine, the motif is often referred to as AXA (Karamyshev et al., 1998). Protein 
export levels can be optimized by mutating the c-region since it is strongly influenced by signal 
peptide cleavage efficiency (Low et al., 2013). Indeed, a relatively large residue (i.e. phenylalanine, 
tyrosine, leucine and histidine) at position -2, an alanine at position -6 and hydrophobic residues (i.e. 
phenylalanine) at position -7 to -10 have been shown for more effective signal peptide cleavage. 
LepB is an essential enzyme in E. coli, hence no study determining the faith of Sec substrates after 
translocation was conducted (Mora et al., 2015). To conclude, no single known signal peptide will 
export all recombinant proteins into the periplasm via Sec. Therefore, a screen and optimization of 
signal peptides is necessary to obtain optimum yields of a specific recombinant protein, as depicted 






Figure 1-3: Bacterial Sec pathway 
Polypeptides exported to the periplasm by the Sec pathway can be routed either via the post-translational 
SecB (1) or the co-translational SRP (2) systems. 1 - After binding the signal peptide (SP), SecB prevents folding 
of the native polypeptide (NPP) and recruits SecA which targets the complex to the SecYEG translocase. Using 
ATP hydrolysis and the proton motive force (PMF), the polypeptide is transported across the cytoplasmic 
membrane, where the signal peptidase cleaves the SP before the release and folding of the mature protein. 2 
- The SRP complex is made of the Ffh protein and the small 4.5S RNA which binds to the hydrophobic domains 
of the SP to prevent aggregation. This ribo-complex is targeted to the SecYEG translocon via the docking 
protein FtsY. The polypeptide is transported during translation using GTP hydrolysis and the PMF. The mature 
protein can be either integrated into the membrane or released into the periplasm. Figure adapted from Green 
and Mecsas (2016) and Freudl (2018). 
 
1.3.1.2. The SecB pathway 
SecB substrates, targeted to the periplasm or to the extra-cellular medium, are transported through 
the inner membrane via the SecB pathway in a post-translational manner (Tsirigotaki et al., 2017). 
SecB is a non-essential protein which, when knocked-out, leaves the cell with a strong cold-sensitive 
phenotype below 23°C, as well as sensitivity to many compounds including ethanol, copper and 
triclosan (Sala et al., 2014). The SecB protein is a cytoplasmic homotetrameric chaperone which 
binds to either completely or partially synthesized nascent polypeptides via the interaction with a 
specific signal peptide (Green and Mecsas, 2016). This interaction prevents the polypeptide from 




(Figure 1-3). The latter directs this complex, composed of the substrate and SecB, to the SecYEG 
membrane channel. Translocation is initiated by SecA which pulls the polypeptide into the SecYEG 
channel using ATP hydrolysis as energy source. In the late stage of the polypeptide translocation, 
SecA detaches from the signal peptide and is released into the cytoplasm while the proton motive 
force pulls the polypeptide completely through the channel (Tsirigotaki et al., 2017). The movement 
of protons and preproteins is enabled by the accessory factor SecDF, a periplasmic complex 
embedded in the inner membrane (Tsukazaki et al., 2011). The signal peptide is then cleaved by the 
membrane-anchored signal peptidase II (LspA) for lipoproteins or by the signal peptidase I (LepB) for 
other substrates which allows the release of the polypeptide into the periplasm (Yu et al., 1984). 
Once in the periplasm, the mature protein folds and can be exported further to its destination via 
either the Type II or the Type V secretion systems (section 1.3.3). 
1.3.1.3. The SRP pathway 
The SRP pathway is utilized by polypeptides whose unfolded status cannot be maintained by SecB or 
possess hydrophobic patches (corresponding to future transmembrane domains) which cannot be 
processed by the SecB pathway. Such polypeptides are exported into the periplasm or inserted into 
the membrane via the SRP pathway in a co-translational manner (Green and Mecsas, 2016). The SRP 
is a ribonucleoprotein complex composed of the fifty-four homologue (Ffh) protein and a small 4.5S 
RNA (Tsirigotaki et al., 2017). SRP binds to ribosomes but is only kinetically stabilised by nascent 
polypeptide through the recognition of a specific signal peptide or transmembrane domains after 
which, it temporarily halts translation at the ribosome (Tsirigotaki et al., 2017). The SRP-polypeptide 
complex, also known as the ribo-complex, then binds to the, inner membrane-located, docking 
protein FtsY which transfers the complex to the SecYEG channel (Figure 1-3). This event obtains the 
necessary energy from the hydrolysis of GTP by the GTPase domains of Ffh and FtsY which triggers 
the release of SRP and reinitiates the translation. The polypeptide is synthetized directly into the 
SecYEG channel which uses the proton motive force to pull the nascent chain through. For 




inner membrane while the chaperone PpiD is considered to run a quality control on transmembrane 
domains exiting the SecYEG channel (Sachelaru et al., 2014). Finally, the signal peptide is cleaved by 
LepB during the later stages of the membrane protein insertion or periplasmic release (Auclair et al., 
2012). 
1.3.1.4. Recombinant protein export via Sec 
Since its discovery, the Sec pathway has been used in expression systems to export recombinant 
proteins into the periplasm of E. coli. By fusing a Sec signal peptide to the N-terminus of the protein 
of interest, heterologous proteins can be translocated either by the SecB or the SRP pathway 
depending on the signal peptide selected. For example, active human epidermal growth factor, 
parathyroid hormone and the T cell receptor glycoprotein were successfully produced in the 
periplasm via SecB export using the native signal peptide of the E. coli outer membrane protein, 
OmpA (OmpASP) (Sutherlan and Wong, 1993). The ice-structuring protein A and the chitonase 
enzyme from Bacillus subtilis were successfully expressed in the periplasm of E. coli using OmpASP to 
16 and 18.5 mg/L in shake flask respectively (Tong et al., 2000, Pechsrichuang et al., 2016). Sec 
offered a viable alternative for these proteins for which cytoplasmic expression led to lower yields 
(Pechsrichuang et al., 2013, Rivas et al., 2000). Therapeutic proteins such as Fab’ fragments can also 
be expressed in the periplasm via Sec. Also, using an OmpA SP, a Fab’ fragment was expressed to 2.4 
g/L in batch-fed fermentation (Ellis et al., 2017). It is important to note here, that this high yield was 
obtained using an engineered strain lacking the protease Tsp and co-expressing the chaperone DsbC 
(section 1.3.1.4. for more details). 
1.3.2. The twin arginine translocation pathway 
The twin arginine translocation (Tat) pathway is an alternative to Sec for proteins to cross the plasma 
membrane in bacteria. The major difference is that Sec exports unfolded polypeptide chains into the 
periplasm whereas Tat transports only folded proteins (Patel et al., 2014). Sec is used for 
translocation of about 98 % of E. coli exportome (Orfanoudaki and Economou, 2014). Of the 




The proteins exported by the Tat translocon are involved in respiratory metabolism, virulence, cell 
division, phosphate, copper and iron metabolism and cell wall formation (Palmer and Berks, 2012). 
The utility of the Tat machinery instead of Sec can be physiologically rationalised as a prerequisite 
for: (i) the insertion of complex co-factors, (ii) the prevention of periplasmic metal ions competing 
for insertion into the active site, (iii) the transport of hetero-oligomeric complexes which require 
cytoplasmic assembly, (iv) the instability of some unfolded proteins in the periplasm and (v) the 
requirement of cytoplasmic protein for folding and maturation (Palmer and Berks, 2012). 
1.3.2.1. The role of Tat through its substrates 
The total amount of substrates exported via Tat is estimated to be around 30 proteins for enteric 
bacteria but the number fluctuates between bacterial species (Palmer and Berks, 2012). The reason 
behind the absence of an absolute value is that many substrates are putative, determined from 
bioinformatic predictions and have not been experimentally confirmed. For instance, Tullman-Ercek 
et al. (2007) listed 27 potential Tat substrates by testing Tat export of the predicted Tat signal 
peptides when fused to the maltose binding protein (Appendix 1). 
TorA is a trimethylamine N-oxide reductase from the molybdoenzyme family and is encoded by the 
torCAD operon (Mejean et al., 1994). The connection between the double arginine motif within its 
signal peptide and its periplasmic localisation was made and TorA was one of the first Tat substrates 
to be discovered (Weiner et al., 1998, Santini et al., 1998). Indeed, the protein is involved in 
anaerobic respiration which explains its periplasmic localisation. TorA requires a molybdenum 
cofactor for activity, therefore justifying the need for Tat export. Moreover, TorA requires the 
chaperone TorD for cytoplasmic maturation, cofactor binding and addressing the correctly folded 
proteins to the Tat system (Pommier et al., 1998, Ilbert et al., 2003, Ilbert et al., 2004, Oresnik et al., 
2001, Jack et al., 2004). 
DmsA also belongs to the molybdoenzyme family and is a subunit of the dimethyl sulfoxide (DMSO) 
reductase which reduces S- and N-oxides (Yokoyama and Leimkuhler, 2015). The protein binds to a 




al., 2008, Ray et al., 2003). The DMSO reductase is a complex containing the DmsA, DmsB and DmsC 
subunits. The DmsC is an integral transmembrane protein whereas DmsA and DmsB are soluble 
periplasmic proteins. The correctly folded DmsAB complex is co-transported via the Tat pathway 
thanks to the specific signal peptide of DmsA. 
NapA, FdnG and FdoG are subunits of other molybdoenzymes exported via Tat to the periplasm. 
They are first matured in the cytoplasm by their respective NapD, FdhD and FdhD chaperones and 
associates in complex with their respective NapB, FdnH and FdoH partners prior to export (Yokoyama 
and Leimkuhler, 2015). NapAB is a nitrate reductase while FdnGH and FdoGH complexes associates 
with their respective FdnI and FdoI subunits in the periplasm to form the active FdnGHI and FdoGHI 
formate dehydrogenase complexes (Jormakka et al., 2002, Yokoyama and Leimkuhler, 2015). 
In a different tone, FhuD and SufI are examples of monomeric Tat substrates which do not contain a 
complex cofactor (Ize et al., 2004, Samaluru et al., 2007). They bind, however, to an iron and copper 
metal ion respectively. FhuD is involved in the Fe(III) import system and SufI is involved in cell division 
under stress conditions (Koster, 1991, Samaluru et al., 2007). 
1.3.2.2. Tat-specific signal peptides 
In the same way as Sec, Tat substrates bear a specific N-terminal signal peptide to drive export (Patel 
et al., 2014). Some examples are detailed in the Appendix 2. They share the tripartite structure with 
respect to the n-, h- and c-region including the AXA motif allowing release of the mature domain 
upon translocation (Figure 1-4). However, several differences between these signal peptides allow 
selective targeting of the protein to its rightful pathway. Tat signal peptides are in average 14 
residues longer with an average length of 38 compared to 24 amino acids for Sec signal peptides 
(Cristobal et al., 1999). But the main features which prevent Tat substrates from being mistargeted 
to Sec, are the lower hydrophobicity of the h-region, a conserved motif and the basic residues of the 
c-region (Berks et al., 2000, Palmer and Berks, 2012). Considerably increasing the hydrophobicity of 
the h-region was found to lead an artificial Tat substrate away from the Tat translocon towards Sec 




motif is located at the junction of the n- and the c-region and contains a characteristic twin-arginine 
giving the translocase its name (Berks, 1996). Mutating both arginine residues to lysine on the natural 
Tat signal peptide of SufI completely abolished Tat export (Yahr and Wickner, 2001). But the 
mutation of one of its arginine to lysine resulted in reduced Tat export efficiency (Stanley et al., 
2000). Also, mutation of the first arginine to glutamate was reported to abolish the export of β-
lactamase bearing the Tat signal peptide of Desulfovibrio vuljpis hydrogenase while mutation to a 
range of other residues (valine, isoleucine, lysine and glutamine) only reduced Tat secretion yield 
(Niviere et al., 1992). The last Sec-repelling feature is the presence of basic residues in the c-region. 
Indeed, mutating these residues to the polar asparagine or glutamine, allowed Sec export (Cristobal 
et al., 1999, Berks et al., 2000, DeLisa et al., 2002). Despite the Sec-avoidance features, 16 of the 27 
signal peptides identified by Tullman-Ercek et al. (2007) including DmsA, FhuD and SufI have been 
found to be promiscuous when expressed in fusion with MBP. 
 
 
Figure 1-4: General features of a Tat-specific signal peptide 
The Tat signal peptide is composed of the basic amino-terminal region (n-region), followed by the hydrophobic 
region (h-region) and terminated by the carboxyl-terminal region (c-region) containing a signal peptidase 
cleavage site (AXA). The consensus motif S/T-R-R-X-F-L-K is located at the junction of the n- and the h-regions. 
 
1.3.2.3. Components of Tat 
Five proteins are reported to be involved in the Tat pathway in E. coli: the four integral membrane 
proteins TatA, TatB, TatC and TatE and the cytoplasmic protein TatD (Figure 1-5A). TatA is a small 89 
amino acid long (9.7 kDa) protein consisting of a short periplasmic N-terminus followed by a 




terminus (Lange et al., 2007). Lange et al. (2007) also showed that the amphipathic helix is aligned 
parallel to the membrane. TatE, with its 67 residues (7.0 kDa), is a paralogue protein to TatA with 
42.7 % identity and 57.3 % similarity (Sargent et al., 1998). This protein is 22 residues shorter than 
TatA but still presents a similar membrane conformation (Figure 1-5A). Its function overlaps with 
TatA with some substrates seemingly to require one, the other or both (Sargent et al., 1998). Single 
mutant strains lacking either TatA or TatE are still able to translocate Tat substrates but to a lower 
rate whereas Tat export is inactivated in a double mutant. 
TatB is a 171 amino acid long protein (18.4 kDa) sharing a 23.8 % similarity with TatA and a very 
similar predicted secondary structure (Sargent et al., 1999). TatB possesses two short cytoplasmic α-
helixes on top of the amphipathic and the transmembrane helixes (Figure 1-5A) (Zhang et al., 2014b). 
Despite the resemblance, these proteins have a functionally distinct role. Moreover, the abundance 
of TatA is roughly 20 times higher than TatB in the membrane (Sargent et al., 2001, Jack et al., 2001). 
A TatB-null mutant strain was reported to mislocalise the Tat-dependant trimethylamine N-oxide 
(TMAO) reductase indicating that TatB is essential for a functional Tat pathway (Chanal et al., 1998). 
TatC is a 258 amino acids (28.9 kDa) protein characterised by six transmembrane domains with both 
N- and C-termini located in the cytoplasm (Punginelli et al., 2007). 
The Tat proteins TatA, TatB, TatC and TatD are expressed from the tatABCD operon and TatE 
encoded as a single gene (Figure 1-5B) (Sargent et al., 1998, Weiner et al., 1998). The gene coding 
for TatE locates at about 14 min on the genome while the tatABCD operon locates at about 78 min 
and is thought to be the result of tatA gene duplication (Yen et al., 2002). TatD was identified as a 
cytoplasmic protein with magnesium-dependant DNase activity. This protein was found to be non-
essential for the export of Tat-dependant proteins as a TatD knock-out strain was not impaired for 
Tat translocation (Wexler et al., 2000). Matos et al. (2009) discovered that, even though TatD is not 
essential for Tat substrates export, it is required for the quality control mechanism (discussed in 
section 1.3.2.5). Indeed, Matos et al. (2009) expressed the NrfC, NapG and FhuD Tat substrates which 




these mutants to be stable in the cytoplasm of the TatD-null strain whilst rapidly degraded in the 
wild-type (WT) strain. The latest research on this protein revealed that TatD possesses a 3’-5’ 
exonuclease activity responsible for chromosomal DNA degradation during apoptosis and repair of 
single stranded DNA damage (Chen et al., 2014). The correlation between the DNase activity and the 
role in quality control mechanism of the Tat pathway is still unclear. 
 
 
Figure 1-5: Organisation of the E. coli Tat system 
A. Representation of the integral inner membrane Tat proteins where N and C represent the amino- and 
carboxy-termini of each protein. The cylinders represent α-helixes. B. Arrangement of the tat genes in the 
genome of E. coli K12 W3110 strain: the tatABCD operon and the isolated tatE gene. The minutes are indicated 
on each side of the loci. Adapted from Patel et al. (2014). 
 
1.3.2.4. Tat export mechanism 
The general mechanism by which Tat exports folded proteins across the inner membrane is not fully 
understood. However, the protein structures of some of the Tat components can be used to provide 
insights. The structure of TatA and TatB proteins from E. coli has been solved by NMR in detergent 
solution (Rodriguez et al., 2013, Zhang et al., 2014a, Zhang et al., 2014b) but no structure of the 
other E. coli Tat proteins as isolated components have been published. However, the structure of 




crystallography and found to share 52% similarity with its E. coli homologue (Rollauer et al., 2012, 
Ramasamy et al., 2013). Some structures of complexes have also been published such as TatBC of E. 
coli with and without substrate binding by single-particle electron microscopy (Tarry et al., 2009). 
Using the solved structures, many researchers have attempted to elucidate this mechanism and 
collectively their data has led to the proposal of a mechanism for the recruitment of the Tat complex 
by folded Tat substrates which is generally accepted. However, the actual mechanism for the 
formation of a channel and subsequent translocation is not fully understood. The presence of folded 
Tat substrates with presentation of the N-terminal Tat-specific signal peptide in the cytoplasm 
triggers the translocation event by reversible recruitment of the translocon components (Rose et al., 
2013). The first step of Tat translocation is the association of TatB and TatC proteins as dimers in the 
membrane which act as receptor for the substrates (Alami et al., 2003, McDevitt et al., 2006, Frobel 
et al., 2019). This association is critical to prevent premature release of the substrate. TatC is an 
insertase which alone can recognize Tat substrates through their signal peptide but can prematurely 
trigger their cleavage in the absence of TatB (Frobel et al., 2012). TatB is therefore required for the 
correct initiation of translocation by preventing early cleavage of the Tat signal peptide. Together 
they form a hydrophobic cavity inside the lipid bilayer capable of docking the Tat signal peptides 
(Blummel et al., 2017). The twin-arginine motif is first recognized by the loop located between the 
transmembrane helixes 2 and 3 of TatC (Alami et al., 2003, Gerard and Cline, 2006). The Tat signal 
peptide is then inserted deeply into a cavity formed by the TatBC complex (Figure 1-6) (Blummel et 
al., 2015, Lausberg et al., 2012, Huang et al., 2017). A recent study claims that the early mature part 
of the substrate also plays a role in TatBC binding by having a tighter interaction with the first 






Figure 1-6: The TatA/E-mediated channel model of the Tat pathway of E. coli  
Tat-specific substrates contain a N-terminal signal peptide (SP) with a conserved twin-arginine (RR). They fold 
in the cytoplasm prior to targeting to the membrane TatBC complex. TatA/E proteins are then recruited to the 
TatBC/substrate complex and form a transient pore to accommodate the size of the substrate. Once the 
substrate is translocated across the cytoplasmic membrane, the SP is cleaved by the signal peptidase and the 
mature protein is released in the periplasm while the pore dissociates. Adapted from Lee et al. (2006) and 
Palmer and Berks (2012) 
 
The second step is the recruitment and oligomerization of TatA proteins upon binding of the 
substrate to the TatBC complexes (Alcock et al., 2013). This recruitment is dependent on the proton 
motive force (Patel et al., 2014). TatE was also demonstrated to be recruited along with TatA and 
clustered at the Tat complex proving it plays a part of Tat translocation (Eimer et al., 2015). From 
this point, two models are still being discussed to explain the translocation of the substrate: the TatA-
mediated channel (Figure 1-6) and the transient membrane disruption models (Berks, 2015, Cline, 
2015). The channel hypothesis describes oligomerization of TatA proteins at the TatBC/substrate 
complex to form a size-variable pore adapted for the bound substrate (Lange et al., 2007, Patel et 
al., 2014). In a different way, the latter model suggests that upon oligomerization of TatA proteins, 
the membrane is thinned and destabilized thanks to the N-terminus of these proteins and a transient 
pore into the lipid bilayer is opened, allowing transit of the substrate (Hou et al., 2018). Altogether, 
the Tat translocon is most likely to use both mechanisms to adapt to the various substrates up to 




1.3.2.5. The proofreading mechanism 
All the molybdoenzymes cited in section 1.3.2.1 require their respective cytoplasmic chaperone to 
be exported by the Tat pathway. Without their chaperones, these Tat substrates cannot reach a 
native conformation which is sensed by the translocon thus blocking transport. The ability to sense 
the folded state of Tat-targeted proteins is referred to as the ‘proofreading’ or ‘quality control’ 
mechanism (DeLisa et al., 2003, Sutherland et al., 2018). This unique ability has increased interest to 
exploit the Tat pathway (Waraho-Zhmayev et al., 2013). Rocco et al. (2012) identified suppressors 
mutations on the TatABC proteins which allowed a misfolded model protein to be exported to the 
periplasm. Such a protein was designed for genetic selection as a tripartite fusion containing a test 
protein inserted between the signal peptide of the natural Tat substrate TorA and β-lactamase. The 
test protein itself was designed to be a monomeric, three-helix-bundle protein forming molten 
globules. Moreover, reduced PhoA, another misfolded substrate, fused to the signal peptide of TorA 
was found to reach the Tat translocase but was not exported (Panahandeh et al., 2008, Richter and 
Bruser, 2005). The latter associated with the TatBC complex, but this did not trigger the recruitment 
of the TatA proteins. The degradation of substrates that cannot reach a native conformation is 
triggered by the proofreading system upon interaction with the Tat translocase (Matos et al., 2008). 
Overall, it was concluded that the Tat translocase “senses” the targeted substrate by the so called 
“quality control” system and rejects the incorrectly folded proteins leading to their degradation. 
However, the limit of the folding sensitivity is still unclear. 
Recent studies have shed light on the conformational tolerance of the Tat proofreading mechanism. 
The natural Tat substrate cuprous oxidase (CueO) is exported without its copper cofactor which is 
acquired in the periplasm (Djoko et al., 2010, Roberts et al., 2002). This apo form of the protein is 
exported by Tat in native conditions (Stolle et al., 2016). The apo form is therefore sufficiently folded 
to pass the quality control system but still presents a higher conformational flexibility than the holo-
form. The tolerance of the Tat proofreading mechanism on the substrate flexibility was further 




Tat targeted signal-chain variable fragment (scFv) had about 10-fold enhanced export when the scFv 
was more tightly folded with its two intra-molecular DSB than without them. Moreover, they 
discovered that this scFv was not Tat-translocated when fused to a 26 amino acids unstructured tail. 
The tolerance to a certain conformational flexibility was further demonstrated on another 
recombinant Tat substrate. Using a heme-binding protein known as BT6 maquette, Sutherland et al. 
(2018) observed the correlation between enhancement of Tat export and increase of substrate’s 
rigidity. Indeed, the changes in the folding extent of three variants of BT6 binding to either two, one 
or no heme(s) was demonstrated by circular dichroism and NMR spectroscopy. The three variants 
were then individually fused to the signal peptide of TorA and expressed in E. coli. The rising 
abundance of periplasmic BT6 clearly correlated with the increasing heme-binding capacity 
indicating a link between rigidity status of the substrate and the translocation event. However, it is 
also claimed that the Tat pathway offers a degree of flexibility with respect to surface hydrophobicity 
and net charge. Indeed, mutating surface hydrophobic residues from hydrophilic residues to 
leucines, or the net charge from uncharged residues to lysines and/or glutamines of the scFv were 
shown not to affect Tat export (Jones et al., 2016). 
The proofreading mechanism is still not clear on how it rejects certain proteins. Misfolded proteins 
still interact with the Tat translocon as demonstrated by the co-purification of a mutant PhoA with 
the TatBC complex (Richter and Bruser, 2005). Thus, Tat may not possess an inbuilt proofreading 
mechanism but is rather linked to an efficient degradation system (Frain et al., 2019). This idea is 
supported by the direct interaction of the Tat machinery with the protease WprA which is essential 
for Tat export in Bacillus subtilis (Krishnappa et al., 2012, Monteferrante et al., 2013). 
1.3.2.6. The Tat systems beyond E. coli 
The Tat pathway is an evolutionary conserved mechanism found in 77 % of known bacteria (Simone 
et al., 2013). Not only is it present in Gram-negative bacteria, it is also present in other prokaryotes 
like Gram-positive and Archaea bacteria which both possess a system often considered 




TatAyCy, with specific substrates (Simone et al., 2013). E. coli TatA (89 bp) has 24%, 42% and 35% 
similarity with TatB (171 bp) from E. coli, TatAd (70 bp) and TatAy (57 bp) from Bacillus subtilis 
respectively (Jongbloed et al., 2000). The tatA-like gene tatB is the result of a divergent evolution of 
the tatA gene found in the Proteobacteria Actinobacteria while tatE is the result of a second 
duplication event found only in enterobacteria (Wu et al., 2000). Hence, TatA encoded by one or 
more copy of a tatA-like gene fulfils the function of both TatA and TatB of a TatABC system like E. 
coli (Palmer and Berks, 2012). This was further demonstrated by the successful complementation of 
a Tat-deficient E. coli strain by the TatAdCd system (Barnett et al., 2008, Albiniak et al., 2013). While 
most bacteria have a low abundance of Tat substrates, the predicted Tat substrate within the 
secretome of Archae bacteria such as Natrialba magadii can reach up to 55% (Storf et al., 2010). 
Beyond the prokaryotic organisms, a homologous system has been discovered in plant cells. A Tat 
pathway was identified in the thylakoid membranes of plant chloroplasts (Cline et al., 1992, Henry 
et al., 1994, Hulford et al., 1994). It was first named ΔpH-dependant pathway and was distinguished 
from the Sec-equivalent pathway since the latter requires both energy from ATP and the thylakoidal 
ΔpH whereas the plant Tat pathway only requires the ΔpH (Mori and Cline, 2001). This system uses 
three membrane proteins: thylakoid assembly 4 (Tha4), high chlorophyll 106 (Hcf106) and 
chloroplast TatC (cpTatC) which are the bacterial orthologues of TatA, TatB and TatC respectively 
(Natale et al., 2008). This system is essential for photosynthesis because it is responsible of the 
assembly of photosystem II and cytochrome b6f by inserting the Rieske iron-sulphur complex into 
the thylakoid membrane (Molik et al., 2001). Recent findings suggest that plant mitochondria, which 
possess their own copy of TatB- and TatC-like proteins, use a functional Tat pathway to insert the 
Rieske iron-sulphur complex protein into the membrane (Carrie et al., 2016, Kolli et al., 2018). 
The Tat system is absent from the animal and fungus kingdoms with only two exceptions. The first 
one is the choanoflagellate Monosiga brevicollis (Burger et al., 2003). The second one is the 
homoscleromorph sponges, Oscarellidae (Wang and Lavrov, 2007). In both organisms, only a TatC-




Genes coding for these proteins are located in the mitochondrial DNA and the sponge TatC-like 
protein has been shown to be active in Oscarella carmela for membrane protein insertion (Pett and 
Lavrov, 2013). The authors theorized that, since the sponge Tat system does not have a TatA-like 
protein which is necessary to form the pore even in minimalist systems, the mitochondrial Tat system 
is only able to insert membrane proteins rather than protein translocation.  
1.3.3. The Type I to VI secretion pathways 
The Type I secretion system is a one-step process which translocates unfolded substrates across the 
cell envelope using energy from catalysing ATP (Thomas et al., 2014). Three essential components 
are required for this process: one ABC transporter protein in the inner membrane, one membrane 
fusion protein bridging the inner membrane to the outer membrane and one outer membrane porin-
like protein. Type 1 substrates include proteins that often contribute to bacterial virulence including 
proteases, lipases, adhesins and heme-binding proteins. These substrates bare a C-terminal signal 
sequence specific for Type I secretion which is not cleaved following export. As this system allows 
DSB formation during transport and offers the advantage of protein secretion into the extracellular 
environment, thus simplifying downstream processing, it has been exploited for overexpression of 
recombinant proteins. Indeed, β-galactosidase, prochymosin, chloramphenicol acetyltransferase 
and green fluorescent protein (GFP) were shown to be expressed when fused to the C-terminal 
domain of the Type I natural substrate HlyC, although absolute expression yields have not been 
published (Kenny et al., 1991, Linton et al., 2012). However, to avoid saturation of the ABC 
transporter, overexpression of the translocase components is necessary (Fernandez and de Lorenzo, 
2001). 
The Type II secretion pathway exports proteins from the periplasm into the extracellular media and 
is therefore considered a two-step process (Cianciotto and White, 2017). The first step exports the 
protein into the periplasm using Sec or Tat systems. These substrates contain a N-terminal signal 
peptide for Sec or Tat export (sections 1.3.1.1 and 1.3.2.1) which is cleaved before release of the 




substrate from the periplasm to the extra-cellular medium through a complex channel containing at 
least the 12 “core” proteins named T2S C, D, E, F, G, H, I, J, K, L, M, and O and uses ATP as an energy 
source (Cianciotto and White, 2017). The Type II system is restricted to Proteobacteria and mostly 
contributes to the pathogenic virulence by exporting proteases for example.  
The Type III secretion system secretes proteins across the inner and outer membranes and even 
across a target cell membrane using a syringe-like channel upon contact with the target cell (Buttner, 
2012). The complex secretes unfolded effectors essential for the virulence of many pathogens in an 
ATP-dependent manner. The secretion signals are specific peptides embedded within the N-
terminus of the substrates and are not cleaved through the secretion process.  
The Type IV secretion pathway is also triggered by contact with the target cell and transport 
substrates from the cytoplasm to the extra-cellular medium or to the target cell via a pilus-based 
structure (Cascales and Christie, 2003). The recipient cell can be a bacterium from a different or the 
same species or even a eukaryotic cell. Substrates include single proteins, interacting proteins and 
protein-DNA complexes which serve a variety of roles such as DNA conjugation, DNA uptake and 
release, biofilm formation and effector translocation. 
The Type V secretion system is unique as the substrates do not require a translocation apparatus or 
the assistance of a channel but rather transport themselves (van Ulsen et al., 2014). Three classes of 
substrates have been identified: auto-transporter, two-partner secretion and chaperone-usher 
secretion (Green and Mecsas, 2016). In each class, the substrate is first translocated across the inner 
membrane via the Sec pathway using a N-terminal signal peptide which is cleaved off on entry into 
the periplasm. Then, the β-barrel domain of the substrate protein inserts itself into the outer 
membrane and forms a channel allowing the remainder of the protein or another protein to be 
transported. Most of the substrates are involved in virulence. 
The Type VI secretion pathway is the most recently discovered and therefore, not yet fully 
characterised (Russell et al., 2014). It is however known to have an envelope-spanning complex 




structurally and functionally (Zoued et al., 2014). This system secretes antagonistic and non-
antagonistic effector proteins from one bacterium to another or to a eukaryotic target cell. 
Substrates are linked to interspecies bacterial competition, virulence, bacterial communication and 
interactions in the environment. 
1.3.4. Unknown secretion pathway(s) 
Some recombinant proteins have shown distinct secretion capabilities which are not yet explained. 
For instance, the L-asparaginase, an enzyme used as a therapeutic to treat leukaemia, has been 
produced in E. coli (Khushoo et al., 2004). The protein was expressed in fusion with the signal peptide 
of PelB, a Sec-exported periplasmic protein, and found in high amounts in the extra-cellular medium 
of high-cell density cultures. The reason for the translocation of the recombinant protein across the 
outer membrane is still unclear. Rinas and Hoffmann (2004) published that this phenomenon was 
not specific to the L-asparaginase but was indeed observed when expressing other recombinant 
proteins into the periplasm in high-cell density cultures. They also observed that host periplasmic 
proteins such as DppA and MalE were also found into the cell-free media and in one case, including, 
the cytoplasmic host chaperone DnaK. The localisation of native periplasmic proteins into the extra-
cellular media was not linked to the overexpression of a recombinant protein since they proved that 
non-recombinant strains also show the same “export” pattern in high-cell density cultures. This 
“export” was hypothesized to be the result of the loss of cell envelope integrity (Han et al., 2003, Ni 
and Chen, 2009). Periplasmic leakage has been proposed to be due to a number of reasons including 
cell division prior to formation of the individual outer membranes, accumulation of recombinant 
proteins in the periplasm causing a build-up of osmotic pressure, perturbation of the membrane 
induced by recombinant proteins to cellular lysis as a result of periplasmic secretion (Mergulhao et 
al., 2005). 
The above examples depict an unknown mechanism by which a recombinant protein targeted to the 
periplasm crosses the outer membrane. A recent study describes the secretion of a heterologous 




sequence or dedicated secretion pathway. The superfolder green fluorescent protein (sfGFP) was 
indeed discovered in the cytoplasm, periplasm, outer membrane and extra-cellular compartments 
following expression in E. coli cultures (Zhang et al., 2017). No putative signal peptide within the N-
terminal primary amino acid sequence of sfGFP was identified by prediction software. Deletion of 
the first 10 and 20 residues of the sfGFP sequence did not prevent extra-cellular export, providing 
further support that an N-terminal signal peptide was not involved in this type of autosecretion. The 
authors speculated that sfGFP uses its characteristic β-barrel structure to cross both membranes and 
this was further reinforced by their discovery that the related red fluorescent protein, mCherry which 
also forms a β-barrel, is also autosecreted in a similar fashion. 
Morra et al. (2018) published even more recently, a detailed analysis on unknown secretion events. 
Using enhanced GFP (eGFP) as the overexpressed recombinant protein, they discovered that 
secretion was not due to cell lysis, does not involve outer membrane vesicle budding and was not 
related to cultivation conditions, but rather to high expression levels. The authors further studied 
the stresses related to recombinant protein overexpression and observed that overexpression 
induced greater hypo-osmotic conditions within the cytoplasm resulting in increased membrane 
permeability. They also discovered that the large mechanosensitive channel (MscL) had a direct role 
in this secretion. Finally, translational stress also causes ‘autosecretion’ of cytoplasmic proteins and 
this appears to be mediated by the alternative ribosome rescue factor A (ArfA) (Morra et al., 2018). 
The translational stress was induced by chloramphenicol, an antibiotic known to cause translation 
arrest (Marks et al., 2016). This stress caused several proteins to ‘autosecrete’ including the 
elongation factor Tu 1 and was found to be reproducible even in untransformed WT strain. This 
discovery matched the results from Kapoor et al. (2017) who identified other antibiotics such as 
aminoglycosides, tetracyclines and streptogramins that directly inhibit ribosome translation, which 
can also induce autosecretion to the extra-cellular medium. The conclusions from this study are 




indicated in the previous paragraph. Furthermore, implications of the role that MscL and ArfA play 
with respect to autosecretion of specific proteins also need to be considered. 
 
1.4. Engineering to improve E. coli as an expression host 
Proteins expressed in high organisms have access to different environments, post-translational 
machineries as well as different chaperones. Therefore, when such proteins are produced in simpler 
organism such as E. coli, they may require access to similar conditions to acquire the same biological 
activity. These conditions can be created by refolding or the use of engineered strains for instance. 
The post-translational modifications, codon usage and inclusion body formation are the main 
drawbacks when using E. coli as a host (Rosano and Ceccarelli, 2014, Baeshen et al., 2015). 
Heterologous proteins may require post-translational modifications for their solubility and activity 
such as glycosylation, phosphorylation, acetylation and disulphide bonds (DSB) (Chen, 2012). 
Although E. coli do not possess the same apparatus as eukaryotes for post-translational 
modifications, it still has some features like the disulphide bond formation which naturally takes 
place in the only oxidising environment of the cell: the periplasm. Moreover, the success rate of 
producing soluble proteins in E. coli decreases considerably when the molecular weight is above 60 
kDa (Gräslund et al., 2008). However, E. coli, being a bacterium, has as number of advantages in 
relation to being an expression host (section 1.1) and therefore systems have been developed to 
bypass these bottlenecks.  
1.4.1. Disulphide bond formation 
Many recombinant proteins require the formation of correct DSB to reach their biologically active 
three-dimensional conformation. DSB require an oxidising environment to be formed such as the 
periplasm and cannot form into the cytoplasm of E. coli since it is naturally a reducing environment. 





1.4.1.1. The naturally oxidising periplasmic space 
E. coli possesses an oxidising environment, the periplasm, which hosts DSB formation and 
isomerization catalysts (Mergulhao et al., 2005, de Marco, 2009). This naturally oxidising 
environment hosts the Dsb family proteins which enable DSB formation and are conserved between 
Gram-negative bacteria (Collet and Bardwell, 2002, Messens and Collet, 2006). The soluble 
periplasmic DsbA oxidizes cysteine pairs of substrate proteins to form DSBs and is maintained in an 
oxidizing form by the integral inner membrane DsbB. However, the chance of forming a native DSB 
decreases as the number of cysteine pairs in a protein increases and thus these DSBs are often 
incorrectly paired, trapping the protein in a non-native form. The isomerases DsbC use their quality 
control mechanism to shuffle DSBs into their native conformation. This protein is also known to have 
chaperone activities by which DsbC assists GAPDH reactivation (Chen et al., 1999, Denoncin et al., 
2010). DsbG acts as a chaperone to reduce the amounts of protein aggregates in cells with a 
damaged envelope (Depuydt et al., 2009, Kouidmi et al., 2018). The isomerases are kept in a reducing 
state by the integral inner membrane DsbD.  
1.4.1.2. Disruption of the reducing pathways 
The cytoplasm is maintained as a reducing environment with a negative redox potential by the 
thioredoxin and the glutaredoxin systems which also alleviates damaging oxidising stress (Rosano 
and Ceccarelli, 2014). Thioredoxin 1 (encoded by trxA) reduces substrate proteins and is recycled by 
the thioredoxin reductase (encoded by trxB) (Aberg et al., 1989, Stewart et al., 1998). On the other 
hand, glutathione uses the reducing potential of NADPH via the glutathione oxidoreductase 
(encoded by gor) to reduce the three glutaredoxins (encoded by grxA, grxB, grxC) (Zheng et al., 1998, 
Stewart et al., 1998). The latter three enzymes have DSB reduction activities and therefore 
participate in maintaining the negative redox potential. Therefore, efforts have been made to disrupt 
these pathways to obtain an oxidising cytoplasm enabling DSB formation (Prinz et al., 1997). By 
mutating both the thioredoxin and the glutaredoxin pathways, substantially more DSBs were formed 




mutant was unable to grow aerobically and required the addition of a disulphide reductant to grow 
at a normal rate. Suppressor mutations in the ahpC gene has been shown to solve this problem by 
conferring protein an enhanced activity towards the reduction of glutathionylated glutaredoxins to 
the AhpC (Ritz et al., 2001, Yamamoto et al., 2008). The commercially available strain Origami 
(Novagen) is a double knock-out trxB and gor mutant with the suppressor mutations on ahpC 
allowing cytoplasmic DSB formation without impairing aerobic growth (Bessette et al., 1999). This 
strain has been optimized further onto the commercial strain SHuffle (New England Biolabs) which 
also expresses a chromosomal copy of the periplasmic dsbC without its signal peptide (Lobstein et 
al., 2012). 
1.4.1.3. The CyDisCo technology 
An alternative from disrupting these pathways is to co-express cytoplasmic DSBs catalysts. Indeed, 
Hatahet et al. (2010) expressed cytoplasmic mutants of the periplasmic enzymes PhoA and phytase 
from E. coli which require two and four DSBs respectively for activity. The team demonstrated that 
these enzymes can be produced in an active form in the cytoplasm of a WT E. coli strain by co-
expressing the sulfhydryl oxidase Erv1p. This essential DSB catalyst was isolated from the inner 
membrane space of Saccharomyces cerevisiae (Lee et al., 2000). 
Other DSB-modifying proteins were later co-expressed with Erv1p to improve DSB conformation 
(Nguyen et al., 2011). A fragment of tissue plasminogen activator, bovine pancreatic trypsin inhibitor 
and resistin were all produced with their respective nine, three and six DSBs. When expressing these 
proteins, similar or higher yields were obtained when the catalyst for DSB formation Erv1p was co-
expressed with a disulphide isomerase DsbC compared to expression of Erv1p alone (Nguyen et al., 
2011). Disulphide isomerases enable rearrangement of incorrect DSB. This result supported a 
growing body of evidence highlighting that the production of eukaryotic proteins with multiple DSBs 
in the cytoplasm of E. coli is possible. 
A new system named CyDisCo for cytoplasmic formation of disulphide bonds in E. coli, was hence 




cytoplasmic DSB (Matos et al., 2014). PDI is the human protein disulphide isomerase which has been 
shown to complement a DsbC-dependent phenotype (Stafford and Lund, 2000). This technology was 
used in the cytoplasm with intact reducing pathways to produce antibody fragments scFv and Fab 
presenting specific binding to their ligand proving the correct status of the DSBs (Gaciarz et al., 2016, 
Gaciarz and Ruddock, 2017). CyDisCo was also tested in glucose fed-batch fermentation where hen 
avidin, single chain IgA1 antibody fragment, hGH and interleukin 6 reached around 71 mg/ml, 139 
mg/ml, 1 g/L and 1 g/L respectively (Gaciarz et al., 2017). Although the correct number of DSBs were 
proven on the purified proteins using Ellman’s assay, no activity assays were performed to confirm 
the active state of these proteins. This technology offers an alternative to the gene disruption 
schemes discussed in section 1.4.1.2., where engineered strains are known to have reduced fitness. 
Although, it has been reported that expression appears with the latter system to be variable and the 
activity of expressed recombinant proteins still need to be demonstrated. 
1.4.2. Glycosylation in E. coli 
Glycosylation is the modification of polypeptide chains or lipids through the attachment of 
carbohydrate(s) and are found in eukaryotes as well as archaea and eubacteria (Varki, 2017). The 
nomenclature to identify a glycosylation is based on their linkage type. The most widely distributed 
carbohydrate-peptide bonds are the N- and the O-glycosidic bonds (Spiro, 2002). They can be linked 
to an asparagine or an arginine residue or to a serine, a threonine, a hydroxylysine, a hydroxyproline 
or a tyrosine residue respectively. In eukaryotes, glycosylation is the predominant post-translational 
modification and is difficult to replicate since E. coli does not naturally own a glycosylation pathway. 
Some native glycoproteins can still be expressed without their glycans in an active form in this 
organism such as interleukin-2 (Roifman et al., 1985) while others are unstable and aggregate like 
EPO (Crommelin et al., 2008). When the glycans are mandatory, a couple of solutions can be tested 
including mutagenesis of the residues which are the sites of the modifications (Narhi et al., 2001) or 
by transferring a glycosylation pathway to E. coli (Wacker et al., 2002, Nothaft and Szymanski, 2013, 




glycosylation system from the bacterium Campylobacter jejuni to E. coli allowing N-glycosylation of 
recombinant proteins. Although bacterial N-glycans are different from their eukaryotic counterparts, 
efforts have been made to develop mutant strains allowing eukaryotic glycosylation (Valderrama-
Rincon et al., 2012, Nothaft and Szymanski, 2013). 
1.4.3. Codon usage 
In all living organisms, synonymous codons, with the same encoded amino acid, are not used in equal 
frequencies and this phenomenon is termed codon bias (Zhou et al., 2016). The rarity of a codon can 
impact the expression of a transgene by up to 1000 fold (Gustafsson et al., 2004). Moreover, codon 
usage differs significantly in species across all taxa but seldom between closely related species (Sharp 
et al., 1995, Plotkin and Kudla, 2011). Indeed, some codons from heterologous genes are considered 
rare in E. coli and can therefore, led to translational errors (Kane, 1995).  
Two main options are available to bypass this issue: modifying the rare codons in the target gene to 
reflect the codon usage of E. coli either by directed mutagenesis or by whole gene synthesis or 
increasing the availability of limiting tRNAs using a plasmid or a mutant strain carrying the genes 
coding for the underrepresented tRNAs (Baeshen et al., 2015, Rosano and Ceccarelli, 2014). 
However, a recent study demonstrated that keeping rare codons at the N-terminal can increase 
expression yields by ≈ 14 instead of using common codons (Goodman et al., 2013). 
1.4.4. Stabilization of the recombinant product 
Heterologous proteins can aggregate when their solubility is impaired resulting in the formation of 
inclusion bodies. While solutions are available for the resolubilization of inclusion bodies into soluble 
and active proteins, they remain long, tedious and expensive processes (Singh et al., 2015, He and 
Ohnishi, 2017). Heterologous protein aggregates are mostly due to solubility, cofactors, folding 
mechanisms and osmolarity which differ from the native organism (Rosano and Ceccarelli, 2014). To 
counter these issues, one can enable DSB formation, use an engineered strain permitting bacterial 




expressing chaperones or use of genetic fusions or slow down the production rate (Rosano and 
Ceccarelli, 2014, Baeshen et al., 2015). 
1.4.4.1. Use of protease-deficient strains 
One way to increase the yield of the recombinant protein is by preventing its degradation. For 
instance, the Lon and OmpT proteases were knocked-out in the popular strain BL21 (Daegelen et al., 
2009). Indeed, the cytoplasmic Lon protease has been shown to degrade abnormal proteins and 
many heterologous proteins (Gottesman, 1996). On the other hand, OmpT is a periplasmic protein 
located in the outer membrane and degrades proteins of interest in cell extracts after lysis 
(Gottesman, 1996, Rosano and Ceccarelli, 2014). Another example of protease deficient strain was 
published by Ellis et al. (2017) where the deletion of the Tsp, protease III and DegP proteases were 
assessed on the expression of a Fab’ antibody fragment. The Tsp mutant strain gave the optimum 
yields but required a suppressor mutation on the spr gene to maintain the cell viability. The 
deficiency of the two cell envelope DegP and Tsp proteases were previously shown to be beneficial 
for the growth rate and the production yield (Park et al., 1999, Chen et al., 2004). 
1.4.4.2. Co-expressing chaperones 
Chaperone proteins improve protein solubility by interacting with nascent polypeptide chains during 
synthesis and prevent aggregation or promote refolding and solubilisation of misfolded proteins 
(Carrio and Villaverde, 2003). Co-expressing chaperones have been shown to enhance the solubility 
of the protein of interest and hence, the yields (Rosano and Ceccarelli, 2014). The most popular 
chaperones are GroEL, GroES, DnaK, DnaJ, GrpE and trigger factor which are used individually or in 
sets (Baeshen et al., 2015). For instance, 65 % of a scFv co-expressed with GroEL and GroES were 
found soluble in the cytoplasm against 27 % when expressed without these chaperones (Maeng et 
al., 2011). Another example was the co-expression of Tat-targeted organophosphorus hydrolase with 
the GroEL/GroES combination, allowing 5.5 fold higher activity of the enzyme than without these 




solubility as it may lower the overall protein productivity by causing an extra-metabolic burden to 
the cells (Huang et al., 2012). 
1.4.4.3. Fusion of a soluble partner 
Improving the solubility of a recombinant protein by fusion with a soluble partner is a well-
established concept (Khow and Suntrarachun, 2012). A range of soluble proteins are available from 
the literature such as MBP, GST and SUMO and offer a successful alternative to solubilizing inclusion 
bodies (Peciak et al., 2014, Sorensen and Mortensen, 2005). For instance, MBP (43 kDa) was shown 
to be an excellent solubility enhancer when fused to the N-terminal of the protein of interest (Raran-
Kurussi et al., 2015). Fusion partners are also used to improve folding, production yield, to facilitate 
purification or to prevent degradation of the target protein (Costa et al., 2014). Also, the small 
antigen Fh8 (8 kDa), isolated from the parasite Fasciola hepatica, has a combined feature of 
enhancing the target protein solubility and its purification (Costa et al., 2013a, Costa et al., 2013b). 
1.4.4.4. Improving the process 
The options mentioned earlier in this section require genetic manipulations but optimisation of the 
expression process can also influence the protein yields (Rosano and Ceccarelli, 2014). Indeed, 
slowing the rate of protein production has been demonstrated to allow more time for protein folding 
and reduce the cellular protein concentration which both improves the protein solubility. The most 
common way to achieve this objective is by lowering the incubation temperature during protein 
expression which was shown to also minimize the formation of inclusion bodies (Fahnert et al., 
2004). However, this approach implicates to work with reduced growth and synthesis rates leading 
to lower protein yields. Several other parameters can be optimised such as medium composition, 
plasmid copy number, promoter strength, type of tag or inducer concentration (Baeshen et al., 
2015). 
1.4.5. Other engineered strains 
Over the past decades, more strains have been developed to bypass the bottlenecks of expressing 




mutation on the hns gene allowed greater protein production upon addition of indole (or derivative) 
which stops cell growth but maintain metabolic activity (Chen et al., 2015, Thomson et al., 2018). 
Moreover, a E. coli K12 strain was developed to counter the low abundance of Tat components in 
WT cells in order to achieve higher yields when exporting a recombinant protein via the Tat pathway. 
Indeed, Thomson et al. (2018) engineered a W3110 strain capable of over-expressing the TatABC 
proteins upon induction and obtained a 5-fold higher periplasmic yield of Tat-targeted (hGH) and 
scFv compared to the WT strain. 
 
1.5. Aims and hypothesis 
The cytoplasm of E. coli is a reducing environment hostile for DSB formation, whereas the periplasmic 
space is an oxidising environment where DSBs can naturally be formed by way of the Dsb machinery 
(section 1.3.1.). It also offers the advantages of containing chaperones that can enhance the correct 
folding of recombinant proteins and contains fewer proteases than the cytoplasm enabling a higher 
protein stability (Mergulhao et al., 2005). Overall, the periplasmic space is less crowded, facilitating 
downstream processing (Balasundaram et al., 2009). For these reasons, producing recombinant 
proteins into the periplasm offers an attractive alternative solution to cytoplasmic expression. To 
this aim, proteins of interest have been exported via the Sec mechanism. The more recently 
discovered Tat pathway offers the advantage of translocating folded proteins whereas Sec can only 
handle unfolded polypeptides. Moreover, the proofreading ability of Tat would be a first screening 
step for selecting active proteins easing further the downstream processing. The aim of this study is 
to evaluate the Tat pathway for the production of the recombinant proteins. Such production has 
already been successfully performed in E. coli but only for a limited number of proteins (section 3.1.). 
The approach chosen was to fuse a soluble partner to the proteins of interest to broaden the range 
of recombinant proteins accepted by Tat. The initial hypothesis was to use a natural Tat substrate 
(NTS) as the soluble partner to both improve the solubility of the partner and target the complex to 




First, a robust fractionation method was developed to thoroughly analyse the localisation of proteins 
of interest in the cellular sub-compartments (Chapter 4). Then, a selection of NTS was evaluated for 
their use as soluble partner in the fusion strategy (Chapter 5). In parallel, several reporter proteins 
were assessed to play the role of the protein of interest in the fusion design (Chapter 6). Following 
the failure to identify a suitable soluble partner amongst the E. coli’s NTS, the strategy was adapted 
to use the validated reporter proteins as soluble partner and fuse them to protein of interests 
(Chapter 7). Finally, a feature near the tat operon suggested by the recent development of an 
engineered Tat strain was investigated (Chapter 8). 
 
Materials and methods 
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2. MATERIALS AND METHODS 
2.1. Strains 
The strains used during the course of this project are listed in Table 2-1. Chemically competent cells 
were prepared using the following protocol for all strains except TOP10 (Life Technologies) and 
SHuffle (New England BioLabs) which were bought as ready-to-use aliquots. 
Chemically competent cells were prepared using the TSS method described previously (Chung et al., 
1989). Briefly, 10 ml of LB was inoculated with a single colony from a fresh overnight LB agar plate 
and the culture was incubated for 16 h at 37°C with shaking at 220 rpm. The next day, 100 ml of 2xTY 
media was inoculated with 1 ml of the preculture and incubated at 37°C with shaking at 220 rpm. 
Once the culture reached an OD600 = 0.5, the cells were cooled down on ice for 20 min. The cells 
were harvested by centrifugation for 15 min at 1838 g at 4°C and the resulting cell pellet was 
resuspended in 10 ml of TSS buffer (85 % LB, 10 % PEG 8000, 5 % DMSO, 50 mM MgCl2). Finally, the 
cell suspension was aliquoted in 200 µl volumes and snap frozen in dry ice before storing at -80°C. 
 
Table 2-1: Details of strains used in this project 
Strain Phenotype Genotype Reference 
TOP10   
F-, mcrA, Δ(mrr-hsdRMS-mcrBC), 
Φ80lacZΔM15, ΔlacX74, recA1, araD139, 
Δ(araleu)7697, galU, galK, rpsL, 
(StrR), endA1, nupG 
One Shot™ TOP10 Chemically 
Competent E. coli, Life 
Technologies 
W3110 Wild-type F-, lambda-, IN(rrnD-rrnE)1, rph-1 ATCC 27325 
MC4100 Wild-type 
F-, [araD139]B/r, Del(argF-lac)169, lambda-, 
e14-, flhD5301, Δ(fruK-yeiR)725(fruA25), 




F-, [araD139]B/r, Del(argF-lac)169, lambda-, 
e14-, flhD5301, Δ(fruK-yeiR)725(fruA25), 
relA1, rpsL150(strR), rbsR22, Del(fimB-
fimE)632(::IS1), deoC1, ΔtatABCDE 
(Wexler et al., 2000) 
SHuffle   
F-, lac, pro, lacIq / Δ(ara-leu)7697, araD139, 
fhuA2, lacZ::T7, gene1, Δ(phoA)PvuII, phoR, 
ahpC*, galE, (or U), galK, λatt::pNEB3-r1-
cDsbC(SpecR, lacIq), ΔtrxB, rpsL150(StrR), Δgor, 
Δ(malF)3 
SHuffle® T7 Competent E. 
coli, New England BioLabs 
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2.2. Molecular biology 
2.2.1. Transformation of chemically competent bacteria by heat shock 
Bacteria were transformed using the heat shock method described (Sambrook and Russel, 2001). 
Chemically competent cells were mixed with 100 ng of plasmid DNA and incubated for 10 min on 
ice. After a heat shock of 45 sec at 42°C, the cells were incubated for 5 min on ice. Next, 350 µl of 
recovery SOC medium (Life Technologies) was added to the tube which was then incubated for 1 h 
at 37°C with shaking at 220 rpm. A volume of 100 µl of the suspension was plated on LB agar plates 
supplemented with the appropriate antibiotic and incubated for 16 h at 37°C. 
2.2.2. Plasmid amplification 
Plasmid transformants were grown in 50 ml of LB with appropriate antibiotic for 16 h at 37°C with 
shaking at 220 rpm. Plasmids were purified from the cells using Plasmid Plus Midi kits (QIAGEN) 
according to the manufacturer’s instructions. The DNA was recovered in 100 µl of the supplied EB 
buffer (10 mM Tris-Cl, pH 8.5). DNA concentrations were measured using a NanoDrop™ 2000 (Life 
Technologies) and samples were stored at -20°C. 
2.2.3. Amplification by PCR 
All primers were chemically synthesised by Sigma-Aldrich. Polymerisation chain reactions (PCR) were 
performed by mixing 4 µl of 5X Herculase II reaction buffer (Agilent), 0.2 µl of dNTPs (25 mM mixture 
of dATP, dGTP, dTTP, dCTP) (Life Technologies), 1.25 µl of each primer (10 mM), 100 ng of DNA 
template, 1 % DMSO (final), 0.5 µl of Herculase II (Agilent) and adjusted to 50 µl with UltraPure™ 
water (Ambion). The reactions were carried out in a thermocycler T3000 (Biometra®). An example 
of amplification reaction is given below: 
Initial denaturation 95°C   2 min 
Denaturation  95°C   20 sec 
Annealing  Primer TM minus 5°C 20 sec        35 cycles 
Extension  72°C   30 sec per kbp 
Final extension  72°C   5 min 
Materials and methods 
36 
 
2.2.4. PCR purification 
Amplified DNA fragments from PCR were purified using the QIAquick PCR purification kit (QIAGEN) 
according to the manufacturer’s instructions. The DNA was recovered in 40 µl of supplied EB buffer. 
DNA concentrations were measured using a NanoDrop™ 2000 (Life Technologies) and samples were 
stored at -20°C. 
2.2.5. DNA digestion with restriction enzymes 
Typically, 1 µg of plasmid DNA was digested with 20 units of restriction enzyme (New England 
Biolabs®), 1X CutSmart® buffer (New England Biolabs®) and adjusted to 30 µl with UltraPure™ water 
(Ambion). The reaction was incubated for 1 h at 37°C. The DNA was analysed by agarose gel 
electrophoresis (section 2.2.6). 
2.2.6. Agarose gel electrophoresis 
DNA samples were separated by electrophoresis on agarose gels. Typically, 1 % agarose (w/v) (Life 
Technologies) was added to 100 ml of TAE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8.2) and 
dissolved by heating in a microwave with occasional swirling. The solution was then cooled to ≈ 45-
60oC and ethidium bromide (Sigma-Aldrich) was added to a final concentration of 0.5 µg/ml. The 
solution was poured into a sealed gel tray (Bio-Rad) containing a comb and once set, the seals and 
comb were removed. The gel was submerged in TAE buffer in the electrophoresis tank. The DNA 
sample was mixed with Gel Loading Dye, Purple (6X) (New England Biolabs®) before loading on the 
gel alongside 100 bp and 1 kpb DNA Ladders (Bio-Rad). Electrophoresis was then carried out at 100 
V for 60 min. Gels were visualised and digitalized by the imaging system E-Gel Imager (Life 
Technologies). DNA sizes were estimated by comparison to the 100 bp and 1 kbp DNA Ladders (Bio-
Rad). 
2.2.7. Agarose gel extraction 
To extract DNA fragments from agarose gels, the appropriate bands were first visualised on a UV 
transilluminator (Spectroline) at wavelength 365 nm and the relevant bands were excised from the 
Materials and methods 
37 
 
gel using a scalpel. The DNA was extracted from the gel slices using QIAquick Gel Extraction kits 
(QIAGEN) according to the manufacturer’s instructions. The DNA was recovered in 40 µl of the 
supplied EB buffer. DNA concentrations were measured using a NanoDrop™ 2000 (Life Technologies) 
and samples were stored at -20°C. 
2.2.8. Ligation 
Typically, the restriction-digested backbone vector was mixed with the restriction-digested insert to 
a molar ratio of 1:3 into Quick Ligase Reaction Buffer (New England Biolabs®). After addition of 1 µl 
of Quick Ligase (New England Biolabs®), the solution was incubated at RT for 5 min. A 2 µl volume of 
the mix was then used to transform chemically competent TOP10 cells (section 2.2.1). 
2.2.9. Directed mutagenesis 
The Q5® Site-Directed Mutagenesis kit (New England Biolabs®) was used to introduce nucleotide 
substitutions, deletions or insertions into plasmid DNA according to the manufacturer’s instructions. 
Primers were designed according to the manufacturer’s recommendations and chemically 
synthesised by Sigma-Aldrich. Typically, 25 ng of plasmid DNA was mixed with 0.5 µM of each primer 
and 12.5 µl of Q5® Hot Start High-Fidelity 2X Master Mix. The final volume was adjusted to 25 µl with 
UltraPure™ water (Ambion). The reaction was carried out in a thermocycler T3000 (Biometra) as 
follows: 98°C for 30 sec, 30 cycles of 98°C for 20 sec and 72°C for 20 sec per kbp, 72°C for 2 min. 
Then, 1 µl of the reaction was mixed with 5 µl of KLD reaction buffer and 1 µl of KLD enzyme mix. 
The final volume was adjusted to 10 µl with UltraPure™ water (Ambion). The solution was incubated 
5 min at RT. Chemically competent TOP10 cells were transformed with 5 µl of the reaction mix 
(section 2.2.1). 
2.2.10. Type IIS cloning strategy 
2.2.10.1. Design of backbone vector 
The pTTO expression vector pDPH340 (Ellis et al., 2017) was used to clone all the gene inserts 
expressed in this study unless otherwise stated. This plasmid contains the low copy number origin of 
replication p15A, a tetracycline resistance gene and a lacI gene to repress the tac promoter 
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controlling the expression of the gene(s) of interest. A stuffer fragment containing the lacZα gene, 
flanked by the TypeIIS restriction site BsaI, to enable in-frame gene cloning using Golden Gate 
assembly (Engler et al., 2008), was designed in silico, in the format of [BsaI-lacZ α-Stop codon-BsaI]. 
This cassette was chemically synthesised (ATUM, Inc) and inserted into the MCS, under the control 
of an upstream tac promoter (Malherbe et al., 2019).  
2.2.10.2. Design of inserts 
Typically, the gene of interest, flanked by BsaI restriction sites compatible with the backbone vector 
was designed in silico using E. coli W3110 codon usage (Neidhardt et al., 1996) with a 5’ RBS and 
proprietary spacing before the ATG start site. The inserts were also designed to contain a second 
RBS at the 3’ end with a Type IIS site SapI to enable in-frame insertion of additional downstream 
gene(s) for polycistronic expression, in the format of [BsaI-RBS+spacer1-Gene1-stop codon-
RBS+spacer2-SapI-SapI-BsaI]. All gene inserts were chemically synthesised (ATUM, Inc, section 
2.2.10.1). 
For polycistronic expression, the downstream gene(s) of interest, flanked by SapI sites compatible 
with the upstream gene and vector sites, was designed in silico as [SapI-gene2-stop codon-SapI] and 
chemically synthesised (ATUM, Inc). In the case of cloning multiple downstream genes, an RBS with 
the spacer was introduced upstream of the ATG start site of each additional gene, terminating with 
a 3’ stop codon, as [SapI-gene2-stop codon-RBS+spacer3-gene3-Stop codon-SapI]. 
2.2.10.3. Type IIS cloning reaction 
The TypeIIS cloning reaction was adapted from Golden Gate Assembly (Engler et al., 2008) and 
optimised to give >99 % efficiency in-house (E. Dave, personal communication). Briefly, the 
chemically synthesised gene insert (ATUM, Inc) was received as a lyophilised pellet and re-dissolved 
in 50 µl of UltraPure™ water (Ambion). The first step of assembly consisted of mixing 2 µl of the gene 
insert (about 20 ng) with 20 ng of the TypeIIS-enabled backbone vector, 3 µl of 10X CutSmart® buffer 
(New England Biolabs®), 0.5 mM ATP (Life Technologies), 10 units of BsaI-HF (New England Biolabs®) 
and 200 units of T4 DNA ligase (New England Biolabs®). The solution was adjusted to a final volume 
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of 30 µl with UltraPure™ water (Ambion) and the reaction was thermocycled (thermocycler T3000 
(Biometra®) for 30 cycles of 1 min at 37°C and 1 min at 16°C followed by 20 min at 85°C. The second 
step involved adding 0.5 µl of 10X CutSmart® buffer (New England Biolabs®), 10 units of BsaI-HF 
(New England Biolabs®) and 4 µl of UltraPure™ water (Ambion) to the reaction mix to linearize any 
DNA containing the TypeIIS restriction site including empty vector. The reaction was incubated for 
20 min at 37°C then 20 min at 85°C in a thermocycler T3000 (Biometra®). Chemically competent 
TOP10 cells were transformed with 2 µl of the final reaction (section 2.2.1). 
To clone additional downstream genes for polycistronic expression, the newly constructed plasmid 
as given above was used as the accepting vector. Subsequently, the above reactions were performed 
using SapI (New England Biolabs®) enzyme instead of BsaI-HF. 
2.2.11. Plasmid DNA sequencing 
DNA sequencing was carried out using Sanger sequencing (Sambrook and Russel, 2001) either with 
UCB Celltech’s internal service or externally with Macrogen services using the provided oligos. Oligos 
to span the genes(s) of interest and LacI in the forward and reverse directions were designed in silico 
and chemically synthesized by Sigma-Aldrich. For internal sequencing, 0.5 µg of DNA sample was 
prepared using 1 µl of primers at 3.2 µM and the BigDye® Direct Sanger Sequencing Kit (Life 
Technologies) according the manufacturer’s instructions. The solution was thermocycled in 
(thermocycler T3000 (Biometra®) for 30 sec at 96°C and 35 cycles of 10 sec at 96°C, 5 sec at 50°C 
and 4 min at 60°C. The completed reactions were ethanol precipitated with 1/3 volume of NaOAc 
and 3 volumes of 95 % ethanol and incubated for 30 min at RT. After a 45 min centrifugation at 4186 
g, the supernatant was discarded, and the DNA pellets were washed with 70 % ethanol and air dried. 
DNA was then dissolved in 15 µl of formamide (Life Technologies) and denatured at 95°C for 2 min. 
Samples was sequenced by capillary electrophoresis on an ABI 3130xL sequencer (Life Technologies). 
Sequencing data was obtained by ABI Sequence Analysis 5.2 software (Life Technologies) and 
processed by Sequencher 5.4.5 software (Gene Codes). The sequence-validated plasmids used in this 
study are listed in Table 2-2. 
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Table 2-2: List of plasmids used in this study in order of appearance. 
Name Vector Insert Reference 
pDPH340 pTTO   (Ellis et al., 2017) 
pGM2 pTTO lacZα 
This study, 
(Malherbe et al., 
2019) 
pGM36 pTTO phoA-His This study 
pGM44 pTTO phoA-His + CyDisCo This study 
pGM37 pTTO ompASP-phoA-His This study 
pGM45 pTTO ompASP-phoA-His + CyDisCo This study 
pGM39 pTTO ycbKSP-phoA-His This study 
pGM47 pTTO ycbKSP-phoA-His + CyDisCo This study 
pGM100 pTTO torASP-phoA-His + CyDisCo This study 
pGM74 pTTO Empty vector This study 
pGM88 pTTO paoASP-phoA-His + CyDisCo This study 
pGM13 pTTO amiASP-amiA-His This study 
pGM14 pTTO hyaASP-hyaA-His This study 
pGM15 pTTO paoASP-paoA-His This study 
pGM16 pTTO torASP-torA-His This study 
pGM17 pTTO ycbKSP-ycbK-His This study 
pGM21 pTTO paoA-His This study 
pGM26 pTTO ompASP-paoA-His This study 
pGM101 pTTO torASP-paoA-His This study 
pGM102 pD874 paoB-V5 + paoC-V5 This study 
pGM103 pD874 paoB-V5 + paoC-V5 + paoD-V5 This study 
pGM113 pTTO paoASP-paoA-His + paoB-v5 + paoC-v5 + paoD-HA This study 
pGM29 pTTO lacZ-His This study 
pGM30 pTTO amiASP-lacZ-His This study 
pGM31 pTTO hyaASP-lacZ-His This study 
pGM32 pTTO paoASP-lacZ-His This study 
pGM33 pTTO torASP-lacZ-His This study 
pGM34 pTTO ycbKSP-lacZ-His This study 
pGM35 pTTO ompASP-lacZ-His This study 
pGM73 pTTO CyDisCo This study 
pGM87 pTTO paoASP-phoA-His This study 
pGM99 pTTO torASP-phoA-His This study 
pGM118 pTTO sfGFP-His This study 
pGM119 pTTO ompASP-sfGFP-His This study 
pGM120 pTTO paoASP-sfGFP-His This study 
pGM121 pTTO torASP-sfGFP-His This study 
Materials and methods 
41 
 
Name Vector Insert Reference 
pGM198 pTTO hGH-His This study 
pGM199 pTTO hGH-His + CyDisCo This study 
pGM196 pTTO ompASP-hGH-His This study 
pGM197 pTTO ompASP-hGH-His + CyDisCo This study 
pGM267 pTTO torASP-hGH-His This study 
pGM268 pTTO torASP-hGH-His + CyDisCo This study 
pGM159 pTTO hGH-FLAG-phoA-His This study 
pGM160 pTTO hGH-FLAG-phoA-His + CyDisCo This study 
pGM146 pTTO ompASP-hGH-FLAG-phoA-His This study 
pGM147 pTTO ompASP-hGH-FLAG-phoA-His + CyDisCo This study 
pGM122 pTTO torASP-hGH-FLAG-phoA-His This study 
pGM123 pTTO torASP-hGH-FLAG-phoA-His + CyDisCo This study 
pGM265 pTTO phoA-FLAG-hGH-His This study 
pGM266 pTTO phoA-FLAG-hGH-His + CyDisCo This study 
pGM252 pTTO ompASP-phoA-FLAG-hGH-His This study 
pGM253 pTTO ompASP-phoA-FLAG-hGH-His + CyDisCo This study 
pGM200 pTTO torASP-phoA-FLAG-hGH-His This study 
pGM201 pTTO torASP-phoA-FLAG-hGH-His + CyDisCo This study 
pGM223 pTTO aP2-His This study 
pGM269 pTTO aP2-His + CyDisCo This study 
pGM234 pTTO ompASP-aP2-His This study 
pGM270 pTTO ompASP-aP2-His + CyDisCo This study 
pGM141 pTTO torASP-aP2-His This study 
pGM271 pTTO torASP-aP2-His + CyDisCo This study 
pGM167 pTTO hGH-FLAG-aP2-His This study 
pGM272 pTTO hGH-FLAG-aP2-His + CyDisCo This study 
pGM154 pTTO ompASP-hGH-FLAG-aP2-His This study 
pGM273 pTTO ompASP-hGH-FLAG-aP2-His + CyDisCo This study 
pGM130 pTTO torASP-hGH-FLAG-aP2-His This study 
pGM274 pTTO torASP-hGH-FLAG-aP2-His + CyDisCo This study 
pGM245 pTTO phoA-FLAG-aP2-His This study 
pGM275 pTTO phoA-FLAG-aP2-His + CyDisCo This study 
pGM258 pTTO ompASP-phoA-FLAG-aP2-His This study 
pGM276 pTTO ompASP-phoA-FLAG-aP2-His + CyDisCo This study 
pGM208 pTTO torASP-phoA-FLAG-aP2-His This study 
pGM277 pTTO torASP-phoA-FLAG-aP2-His + CyDisCo This study 
pGM226 pTTO VHH1-His This study 
pGM227 pTTO VHH1-His + CyDisCo This study 
pGM237 pTTO ompASP-VHH1-His This study 
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Name Vector Insert Reference 
pGM238 pTTO ompASP-VHH1-His + CyDisCo This study 
pGM178 pTTO torASP-VHH1-His This study 
pGM179 pTTO torASP-VHH1-His + CyDisCo This study 
pGM190 pTTO hGH-FLAG-VHH1-His This study 
pGM191 pTTO hGH-FLAG-VHH1-His + CyDisCo This study 
pGM184 pTTO ompASP-hGH-FLAG-VHH1-His This study 
pGM185 pTTO ompASP-hGH-FLAG-VHH1-His + CyDisCo This study 
pGM172 pTTO torASP-hGH-FLAG-VHH1-His This study 
pGM173 pTTO torASP-hGH-FLAG-VHH1-His + CyDisCo This study 
pGM248 pTTO phoA-FLAG-VHH1-His This study 
pGM249 pTTO phoA-FLAG-VHH1-His + CyDisCo This study 
pGM261 pTTO ompASP-phoA-FLAG-VHH1-His This study 
pGM262 pTTO ompASP-phoA-FLAG-VHH1-His + CyDisCo This study 
pGM213 pTTO torASP-phoA-FLAG-VHH1-His This study 
pGM214 pTTO torASP-phoA-FLAG-VHH1-His + CyDisCo This study 
pGM228 pTTO VHH2-His This study 
pGM229 pTTO VHH2-His + CyDisCo This study 
pGM239 pTTO ompASP-VHH2-His This study 
pGM240 pTTO ompASP-VHH2-His + CyDisCo This study 
pGM180 pTTO torASP-VHH2-His This study 
pGM181 pTTO torASP-VHH2-His + CyDisCo This study 
pGM192 pTTO hGH-FLAG-VHH2-His This study 
pGM193 pTTO hGH-FLAG-VHH2-His + CyDisCo This study 
pGM186 pTTO ompASP-hGH-FLAG-VHH2-His This study 
pGM187 pTTO ompASP-hGH-FLAG-VHH2-His + CyDisCo This study 
pGM174 pTTO torASP-hGH-FLAG-VHH2-His This study 
pGM175 pTTO torASP-hGH-FLAG-VHH2-His + CyDisCo This study 
pGM250 pTTO phoA-FLAG-VHH2-His This study 
pGM251 pTTO phoA-FLAG-VHH2-His + CyDisCo This study 
pGM263 pTTO ompASP-phoA-FLAG-VHH2-His This study 
pGM264 pTTO ompASP-phoA-FLAG-VHH2-His + CyDisCo This study 
pGM215 pTTO torASP-phoA-FLAG-VHH2-His This study 
pGM216 pTTO torASP-phoA-FLAG-VHH2-His + CyDisCo This study 
 
2.2.12. Genomic DNA extraction 
The extraction of genomic DNA from bacterial strains of interest were achieved using the QIAamp 
DNA Mini kit (QIAGEN) according to the manufacturer’s instructions. Briefly, bacteria were grown 
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for 16 h at 37°C on LB agar. A single colony was used to inoculate 10 ml of LB medium in a 50 ml tube 
which was then incubated for 16 h at 37°C with shaking at 220 rpm. The DNA was then extracted 
using the kit mentioned above and eluted in 100 µl of supplied Buffer AE. DNA concentrations were 
measured using a Qubit 3.0 (Life Technologies) and samples were stored at -20°C. 
2.2.13. Genomic DNA sequencing 
Genomic sequencing was performed externally by GenomeScan using an Illumina HiSeq4000. The 
150 bp paired-end reads obtained were mapped to the reference genome (NCBI, AP009048.1) using 
the Geneious 10.1.3 software. 
2.2.14. Total RNA extraction 
A preculture was set with single colony in 5 ml of LB and incubated overnight at 37°C with shaking at 
220 rpm. A volume of 5 ml of fresh LB was inoculated with 50 µl of the preculture and incubated at 
37°C with shaking at 220 rpm until mid-log phase (OD600 = 0.8). Then, total RNA was extracted from 
0.5 ml of culture using the RNAprotect Bacteria Reagent (QIAGEN) and the RNeasy Protect Bacteria 
mini kit (QIAGEN) according to the manufacturer’s instructions. The RNA was eluted in 40 µl of 
RNase-free water in a fresh 1.5 ml RNase-free tube. RNA concentrations were measured using a 
NanoDrop™ 2000 (Life Technologies) and samples were stored at -20°C. 
2.2.15. Reverse transcription 
The mRNA from the total RNA extracted was reverse-transcribed into cDNA using the SuperScript III 
kit (Life Technologies). In a RNase-free microcentrifuge tube, 200 ng of random primers (Life 
Technologies), 1 µg of total RNA, 1 µl of dNTP mix (at 10 mM each) and RNase-free water up to 13 
µl were mixed. After a 5 min incubation at 65°C, the samples were cooled on ice for at least 1 min 
and the contents were collected by a brief centrifugation. Then, 4 µl of 5X First Strand Buffer (Life 
Technologies), 1 µl of DTT at 0.1 M, 1 µl of RNaseOUT Recombinant RNase Inhibitor (Life 
Technologies) and 1 µl of Superscript III Reverse-Transcriptase were added to the mixture. The 
solutions were mixed by gently pipetting up and down and incubated for 60 min at 55°C. After 
inactivating the enzyme at 70°C for 15 min, the cDNA was used immediately or stored at -20°C. 
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2.3. Protein expression 
2.3.1. Culture media 
Unless indicated, all liquid cultures were grown in Lennox medium (LB) and Lennox agar (LA) was 
used for growth on Petri dishes (Sambrook and Russel, 2001). The 2xTY medium was composed of 
LB medium containing twice as much yeast extract (Sambrook and Russel, 2001). The minimal 
medium M9 was composed of M9 salts (Gibco) supplemented with MgSO4, CaCl2 and glucose to 
working concentrations of 2 mM, 0.1 mM and 20 mM respectively. For protein expression, all media 
were supplemented with MgSO4 (0.5 mM), ZnSO4 (0.5 mM) and appropriate antibiotic: tetracycline 
(10 µg/ml) (FisherScientific) or kanamycin (15 µg/ml) (Sigma-Aldrich). When PaoA was expressed, 
the cofactors FeCl3 (0.5 mM) and Na2MoO4 (1 mM) were also added to the culture media. 
2.3.2. Expression culture 
The culture conditions used are listed in Table 2-3. A preculture was set up by inoculating 15 ml of 
selective media with a single colony from a fresh overnight selective LA plate and incubated for 16 h 
at 37°C with shaking at 220 rpm. The preculture was used to inoculate 25 ml of selective fresh media 
at a starting OD600 = 0.05 in a 125 ml shake flask. The culture was incubated at the appropriate 
temperature as indicated in Table 2-3, with shaking at 220 rpm until the OD600 reached 0.5. Protein 
expression was induced by adding 100 µM IPTG (Sigma Aldrich) and the culture was incubated at the 
relevant temperature for a defined period, as indicated in Table 2-3. The feed, used in condition 7, 
was a 25X solution containing 1 M MOPS pH 7.2, 40 % glycerol, 0.5 % MgSO4 and 0.42 % MgCl2 (C. 
Doyle, personal communication). 
 
2.4. Fractionation methods 
All solutions were freshly supplemented with 100 µM of the capping agent N-ethylmaleimide (NEM) 
to trap the thiol-disulphide status during sample processing due to air oxidization (Matos et al., 2014, 
Hua et al., 2005). Moreover, all buffers were supplemented with one cOmplete™ Protease Inhibitor 
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Cocktail (Roche) tablet per 50 ml to prevent protein degradation by proteases. From harvest 
onwards, the samples and solutions were always kept on ice and all centrifugation steps were carried 
out at 4°C. All liquid removal was carried away by careful pipetting without disturbing the cell pellet. 
At harvest, a volume of 
8
OD600
 of the culture was transferred to a 50 ml tube and centrifuged at 4816 
g for 15 min. Where relevant, the supernatant was recovered in a 2 ml tube and stored at -20°C as 
the media fraction. The cell pellet was washed with 850 ml of PBS, transferred into a fresh 2 ml tube 
and centrifuged at 20,817 g for 3 min. 
 














1 LB LB 30°C 0.5 - 30°C 2 h 
2 LB LB 30°C 0.5 - 30°C 4 h 
3 LB LB 37°C 0.5 - 37°C 2 h 
4 LB LB 30°C 0.5 - 18°C 16 h 
5 2x TY 2x TY 30°C 0.5 - 30°C 2 h 
6 2x TY 2x TY 37°C 3.5 Yes 18°C 16 h 
7 M9 M9 30°C 2 - 18°C 16 h 
 
2.4.1. Periplasmic extraction 
Following periplasmic extraction, the pellet was stored at -20°C prior to further fractionation. 
2.4.1.1. Cold-osmotic shock 
The cold osmotic shock method was adapted from Manoil and Beckwith (1986). The washed cell 
pellet was resuspended in 900 µl of spheroplast buffer (0.1 M Tris pH 8.0, 500 mM sucrose, 0.5 mM 
EDTA pH8.0), incubated for 5 min, centrifuged 3 min at 20,817 g and the supernatant was discarded. 
The pellet was then resuspended in 400 µl of distilled water and incubated 15 sec before adding 20 
µl of MgSO4 at 20 mM. After a 3 min centrifugation at 20,817 g, the supernatant was transferred to 
a 1.5 ml tube and stored at -20°C as the periplasmic fraction. 
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2.4.1.2. Cold-osmotic shock with magnesium 
The washed cell pellet was resuspended in 900 µl spheroplast buffer (0.1 M Tris pH 8.0, 500 mM 
sucrose, 0.5 mM EDTA pH8.0), incubated for 5 min, centrifuged 3 min at 20,817 g and the 
supernatant was discarded. The pellet was then resuspended in 400 µl of distilled water containing 
1 mM of MgCl2 and incubated 1 min. After a 3 min centrifugation at 20,817 g, the supernatant was 
transferred to a 1.5 ml tube and stored at -20°C as the periplasmic fraction. 
2.4.1.3. EDTA/lysozyme/cold-osmotic shock 
The EDTA/lysozyme/cold osmotic shock method was adapted from Jones et al. (2016). The washed 
cell pellet was resuspended in 500 µl Buffer 1 (100 mM Tris-Acetate pH 8.2, 500 mM sucrose, 5 mM 
EDTA pH 8.0). After addition of 500 µl of water then 40 µl of lysozyme at 2 mg/ml, the suspension 
was incubated for 5 min after which 20 µl of MgSO4 at 1 M was added. The sample was centrifuged 
at 20,817 g for 2 min and the supernatant was transferred to a 1.5 ml tube and stored at -20°C as 
the periplasmic fraction. 
2.4.2. Cell disruption 
2.4.2.1. Freeze/thaw cycling 
The method using freeze/thaw cycling was adapted from Manoil and Beckwith (1986). After 
periplasmic extraction, the cell pellet was resuspended in 900 µl of spheroplast buffer followed by 
the addition of 120 µl of fresh lysozyme at 2 mg/ml and 900 µl of water. The suspension was 
incubated for 5 min then centrifuged 30 min at 20,817 g. After discarding the supernatant, the pellet 
was resuspended in 1.2 ml of Tris pH 8.0 at 10 mM. For cell lysis, the suspension was rapidly 
freeze/thaw cycled four times in liquid nitrogen for 2 min and in a 37°C water bath for 3 min. Then 
10 U of benzonase was added to the solution with 20 µl of MgSO4 at 1 M and incubated for 10 min. 
After centrifuging for 20 min at 20,817 g, the supernatant was transferred to a 1.5 ml tube and stored 
at -20°C as the cytoplasmic fraction. The resulting pellet was resuspended with 1 ml of Tris pH 8.0 
and the tube was stored at -20°C as the insoluble fraction. 
2.4.2.2. Ultrasonication 
Materials and methods 
47 
 
The method for fractionation by ultrasonication was adapted from Jones et al. (2016). After 
periplasmic extraction, the cell pellet was resuspended in 1 ml of Buffer 2 (50 mM Tris-acetate pH 
8.2, 250 mM sucrose, 10 mM MgSO4, U/ml benzonase) and centrifuged for 5 min at 20,817 g. The 
supernatant was discarded, and the pellet was then resuspended in 750 µl of Buffer 3 (50 mM Tris- 
acetate pH 8.2, 2.5 mM EDTA pH 8.0). The suspension was sonicated on ice with 5 cycles of 10 sec 
at amplitude 8 µm and 10 sec of incubation (Soniprep 150, MSE) before ultracentrifugation for 30 
min at 186,000 g (Beckman). The supernatant was transferred to a 1.5 ml tube and stored at -20°C 
as the cytoplasmic fraction. The pellet was resuspended in 1 ml of Buffer 3 and stored at -20°C as 
the insoluble fraction. 
 
2.5. Protein analysis 
2.5.1. Western-Blotting 
Protein samples were separated by SDS-PAGE as follows: a Novex™ 4-20 % or 16 % Tris-Glycine Mini 
Gels, WedgeWell™ format, 15-well (Life Technologies) was placed into a gel tank (Life Technologies) 
and the tank was filled with 1X Tris-glycine SDS running buffer (Life Technologies). Loading materials 
were prepared by mixing 10 µl of samples with NuPAGE™ Sample Reducing Agent (10X) (Life 
Technologies) and NuPAGE™ LDS Sample Buffer (4X) (Life Technologies) prior to heating for 5 min at 
98°C in a thermocycler T3000 (Biometra®). The samples, PageRuler Plus Prestained Protein Ladder 
(Life Technologies) and MagicMark™ (Life Technologies) molecular weight markers were loaded onto 
the gel and separated by electrophoresis at 225 V for 35 min. The proteins were dry transferred from 
the gel onto a PVDF membrane (Life Technologies) using an iBlot™ 2 (Life Technologies), according 
to the manufacturer’s instructions. After blocking the membrane in blocking solution (PBS, 0.1 % 
Tween20, 5 % milk powder), the membrane was immunologically detected with a primary antibody 
(Table 2-4) diluted in blocking solution, washed twice with PBST (PBS, 0.1 % Tween20) and revealed 
with appropriate secondary antibody (Table 2-4). The membrane was washed twice in PBST, twice 
in PBS and twice in distilled water for 15 min each. Finally, protein bands were detected with Pierce™ 
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ECL Plus Western Blotting Substrate (Life Technologies) according to the manufacturer’s instructions 
and imaged with the ImageQuant LAS 4000 (GE Healthcare). 
 
Table 2-4: List of antibodies used in this study 
Antibody Target Clonality Species Conjugation Dilution Supplier Reference 












Monoclonal Mouse - 1/1000 Abcam Ab32 
  LacI Monoclonal Mouse - 1/2000 Abcam AB33832 
  G6PD Polyclonal Rabbit - 1/2000 Assaypro 
33115-
05111 
  MBP Polyclonal Rabbit - 1/5000 Abcam AB21144 
  DsbA Monoclonal Mouse - 1/1000 Abcam AB106061 
  V5 tag Monoclonal Mouse - 1/2000 Thermo 
MA5-
15253 



















2.5.2. Protein activity assays 
All samples and standards were measured in triplicate. 
2.5.2.1. β-galactosidase activity assay 
β-galactosidase activity was measured using ONPG substrate (Sigma-Aldrich) as recommended by 
the manufacturer. A titration was prepared in a 96 well plate using concentrations ranging from 1.25 
to 1280 U/L of purified β-galactosidase standard (Sigma-Aldrich). The samples were diluted in PBS in 
the same plate before ONPG substrate (Sigma-Aldrich) was added, then the solutions were 
homogenized by a brief and vigorous shaking. The plate was incubated for 30 min at 37°C and the 
reaction was stopped by the addition of 50 μl Na2CO3 (3 M) to each well followed by brief and 
vigorous shaking. The amount of product formed was measured at A405 on a Synergy 2 plate reader 
(BioTek). A standard curve was fitted from which the activity in each fraction sample was calculated. 
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2.5.2.2. Alkaline phosphatase activity assay 
The activity of PhoA was measured using pNPP substrate (Sigma-Aldrich) as recommended by the 
manufacturer. A titration was prepared in a 96 well plate using purified PhoA (Sigma-Aldrich) at 
concentrations ranging from 1 to 1024 U/L. In the same plate, 10 µl of the fractionated samples were 
diluted in 90 µl PBS before 100 µl of pNPP substrate was added followed by a brief and vigorous 
shaking. The plate was incubated for 30 min at 37°C and the reaction was stopped by the addition 
of 50 μl of 3 M NaOH to each well followed by another brief and vigorous shaking. The activity was 
measured at A405 on a Synergy 2 plate reader (BioTek). A standard curve was fitted from which the 
activity in each fraction sample was calculated. 
2.5.2.3. Green fluorescent protein activity assay 
The activity of sfGFP was estimated by reading the fluorescence on the different sample fractions. In 
a 96 well plate, 50 µl of sample were loaded per well and the relative fluorescence activity was read 
by a Synergy 2 plate reader (BioTek) with λex = 485 nm and λem = 528 nm. 
 
2.6. Microscopic observations 
Bright field observations of bacteria were performed on live cells at the time of harvest. A 5 µl volume 
of culture were mounted between a microscopic slide and a cover slip. The cells were imaged using 
an EVOS™ FL imaging microscope (Invitrogen) with an oil-immersion 100 times objective. 
The fluorescence imaging was made using the same protocol, but a green fluorescence filter was set 
(λex = 470 nm/λem = 525 nm). 
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3. DESIGN STRATEGY TO IMPROVE TAT EXPORT AND ITS ASSESSMENT 
3.1. The limited current use of the Tat pathway 
Export of recombinant proteins through the Tat pathway have been shown successfully over the past 
decade. Indeed, GFP is an interesting example since it was used as a model protein in many studies. 
Sec export of GFP is possible by fusion to the signal peptide of MBP but the recombinant protein was 
not active in the periplasm (Feilmeier et al., 2000). However, GFP was successfully translocated via 
Tat and found to be active in the periplasm (Thomas et al., 2001). The highest export yields of GFP 
through the Tat pathway were obtained in fermenters when co-expressing the TatABC components 
to 1.1 g/L (Matos et al., 2012). These process optimisations have shown that the Tat system can be 
exploited to produce an active recombinant protein to high titres. Fisher et al. (2008) confirmed this 
conclusion by testing the export between Sec and Tat of several recombinant proteins. Comparable 
and improved secretion yields were obtained for MBP, PhoA, GFP and a scFv when transported 
through Tat instead of Sec. The PhoA, phytase AppA, hGH, interferon α2b, a scFv and a VH antibody 
fragments recombinant proteins were also reported to export via Tat in E. coli (Matos et al., 2014, 
Alanen et al., 2015). Overall, Tat can be used to export recombinant proteins in the periplasm of E. 
coli, but, since its discovery, less than a dozen of proteins of interest have been reported. 
Furthermore, the active state of these proteins, to confirm correct folding following export, has only 
been demonstrated for two of these proteins.  
The reason of the low success presented so far may be due to the insolubility of the proteins of 
interest in the cytoplasm resulting in the rejection by the proofreading system. The use of a soluble 
partner to improve protein solubility and hence Tat export, forms the hypothesis of this thesis. 
Indeed, numerous publications justify how the fusion of a soluble partner improved the expression 
of proteins of interest both in the cytoplasm and exported via Sec (section 1.4.4.3.) (Nygren et al., 
1994, Esposito and Chatterjee, 2006, Cheng et al., 2017). 
 
3.2. Design of screening strategy 
Experimental design strategy 
51 
 
Based on the relative success of using a fusion partner strategy for Sec export as discussed in section 
3.1., a similar approach will be used here where a NTS will be used as a ‘carrier’ to export a 
recombinant protein into the periplasm via Tat. A diagrammatic representation of the fusion protein 
is given in Figure 3-1.  
 
 
Figure 3-1: Protein fusion strategy to evaluate Tat export 
The fusion protein consists of a natural Tat substrate baring its N-terminal signal peptide (SP) fused to a His-
tagged protein of interest via a linker consisting of a FLAG tag (FLAG), a TEV cleavage site (TEV) and a flexible 
linker (FL). 
 
A N-terminal NTS bearing a signal peptide is fused to a C-terminally polyhistidine (His)-tagged protein 
of interest via a 34 amino acids long linker region consisting of a FLAG tag, TEV cleavage site and a 
flexible linker. The His (6xHis) tags will be used first to detect the presence of the respective individual 
NTS and protein of interest, and secondly to aid purification if needed.  
Tat export of C-terminally His-tagged proteins has been previously reported, suggesting that the 
flexibility of this unfolded tail does not prevent Tat export (Matos et al., 2014, Alanen et al., 2015, 
Matos et al., 2012). The FLAG tag (DYKDHDGDYKDHDIDYKDDDDK) was also used for detection with 
the final aim to detect the NTS after separation of the two domains. This particularly long version of 
the FLAG tag has been shown to increase the detection sensitivity while still being hydrophilic (Terpe, 
2003). 
A TEV cleavage site was positioned between the two proteins to allow the possibility to remove the 
carrier protein, if necessary, following purification. The TEV cleavage motif (ENLYFQ↓G/S) is 
recognized very specifically by a protease from the Tobacco Etch Virus which cleaves at the position 
denoted by the arrow with high specificity, (Cesaratto et al., 2016). 
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The flexible linker consisting of five amino acid residues of GSSGG and the N-terminal elements of 
the linker were used to allow enough space and flexibility between the two folded protein structures. 
Indeed, the GSSGG linker is known to provide flexibility and maintain solubility through the polarity 
of serine residues (Chen et al., 2013). 
 
3.3. Selection of natural Tat substrates as the carrier partner 
Selecting an NTS as the soluble carrier protein for the fusion construct has dual interest: increasing 
the solubility of the protein of interest hence reducing the risk of forming inclusion bodies and 
improving Tat export. To date, there are 28 known E. coli NTS, of which 19 have been somewhat 
characterized experimentally (such as TorA and DmsA), whereas little is known of the others, apart 
from the signal peptide sequence and its specificity, the molecular weight of NTS and information 
gleaned from analysis of its genetic organization in silico (section 1.3.2.4., Appendix 1) (Tullman-Ercek 
et al., 2007, Mejean et al., 1994, Sambasivarao et al., 1990). The largest Tat-exported complex 
described was the FdnGH subcomplex of the formate dehydrogenase-N which is an NTS of 142 kDa 
(Sargent et al., 2002). Although there is no report defining the maximum protein size limit of the Tat 
translocation capability, the translocon is thought to have an export size limit (Berks et al., 2000). 
Therefore, a small NTS would be preferable as a soluble partner, as this would allow a much larger 
protein of interest to be used. Of the 28 NTS, 12 NTS are within the smallest size range (< 41 kDa), 
therefore NTS larger than this were eliminated from this panel (Appendix 1). 
Another criterium for selection was grounded on whether the NTS with their natural signal peptides 
were obligates for Tat-export. Signal peptide-MBP reporter fusions in a Tat knock-out strain have 
shown that some Tat signal peptides (TatSP) led to promiscuous export into the periplasm via Sec 
(Tullman-Ercek et al., 2007). Subsequently NTS that failed to meet this specificity according to 
available published data, were eliminated. Of the 5 NTS remaining, 2 appear to have partners and 
are therefore not monomeric and the oligomeric state of 2 others are unknown. The potential of 
expressing additional partners is replete with issues such as complicated vector design and larger 
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plasmid size, increased carrier protein size, subsequent overexpression, folding and association of 
the carrier complex, and increased metabolic drain. Ideally the NTS candidate should be monomeric, 
yet of the remaining panel only AmiA (31.4 kDa) is reported to be monomeric (Table1); the oligomeric 
state of YcbK (20.4 kDa) although small, is not known and TorA (94.5 kDa), although monomeric, is 
larger in size. TorA has been used in many published studies and proved to be Tat-specific (Santini et 
al., 1998, Weiner et al., 1998) and its signal peptide (TorASP) is the most widely used in Tat export 
studies (section 3.1.); it may prove to be a useful positive control. To increase the candidate shortlist 
to five, a heterodimer HyaA (40.7 kDa) and a heterotrimer PaoA (24.3 kDa) subunits were selected 
to investigate the potential for Tat export of these proteins (Table 3-1). Initially, these proteins will 
be expressed without their respective partners to gauge whether they alone can be used as a fusion 
partner. 
 
Table 3-1: Selected NTS candidates 
The panel of NTS was selected based on the criteria of small size, monomeric state and specific to Tat export. 
The table indicates the short protein name, molecular weight (kDa), the number of cysteine (#Cys), the number 
of disulphide bond (#DSB), the cofactor(s), the oligomeric state in which the said protein is transported via the 












AmiA 31.4 0 0 Zn GroEL Monomer N/A 
(Ize et al., 
2003) 
YcbK 20.4 0 0 N/D N/D N/D N/D  













PaoA 24.3 9 0 [2Fe-2S]2 PaoD 
Heterotrimer 







AmiA is a periplasmic amidase and functions as a cell wall hydrolase (Ize et al., 2003). This protein is 
non-essential, although the amiA gene deletion results in a morphology defect where cells form 
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growing chains and highlights incomplete septum cleavage during cell division (Heidrich et al., 2001). 
The amiA gene is the first gene of the amiA-hemF operon (Troup et al., 1994). The HemF protein is 
the oxygen-dependent coproporphyrinogen-III oxidase, an enzyme involved in heme biosynthesis in 
aerobic metabolism. The ypeA gene is located upstream from amiA and is transcribed in the opposite 
direction meaning that this operon does not contain more upstream genes. 
YcbK is an uncharacterised protein where the signal peptide has been experimentally tested as an 
MBP fusion for Tat export (Tullman-Ercek et al., 2007). YcbK is encoded as a lone gene and is flanked 
by the downstream gene gloC encoding a cytoplasmic hydroxyacylglutathione hydrolase, 
presumably involved in methyglyoxal detoxification whereas the upstream gene ycbB, encodes for a 
transpeptidase involved in cell wall biosynthesis (Magnet et al., 2008). 
TorA is the trimethylamine N-oxide (TMAO) reductase involved in the electron chain transport in 
anaerobia in E. coli by reducing the TMAO as the terminal electron acceptor (Mejean et al., 1994, 
Jourlin et al., 1996). This periplasmic enzyme receives electron from TorC, a pentahemic c-type 
cytochrome (Gon et al., 2001) and requires the cytoplasmic chaperone TorD for correct maturation 
(Pommier et al., 1998). The TorCAD proteins characterised as the active members of the 
trimethylamine N-oxide reductase system are encoded by the torCAD operon (Mejean et al., 1994). 
The torT and torS genes are located upstream from this operon and their respective proteins are 
responsible for the transcriptional regulation of torCAD (Jourlin et al., 1996). 
HyaA (40.7 kDa) is the small subunit of the hydrogenase 1 complex which also contains the large 
subunit HyaB (66 kDa) (Forzi and Sawers, 2007). HyaA is an inner membrane bound protein facing 
the periplasm (Sawers and Boxer, 1986, Forzi and Sawers, 2007). It therefore contains a TM domain, 
suggesting that expression may lead to incorporation into the inner membrane on the periplasmic 
side. Although no direct evidence has been published, the 102 kDa hydrogenase 1 is believed to be 
Tat exported and uses the TatSP of HyaA to hitchhike the leaderless HyaB (Rodrigue et al., 1999). The 
hyaA gene belongs to the hyaABCDEF operon (Menon et al., 1990). The HyaCDEF proteins encoded 
by the hyaCDEF genes are essential chaperones for HyaAB synthesis and activity (Menon et al., 1991). 
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PaoA is an iron-sulphur binding subunit that forms a heterotrimer with PaoB (34 kDa) and PaoC (78 
kDa) (Lee et al., 2014). The 135 kDa complex functions as a molybdenum-dependent aldehyde 
oxidoreductase and presumably plays a role in detoxification to prevent cell damage (Neumann et 
al., 2009). The subunits PaoB and PaoC are both devoid of export signals and are translocated into 
the periplasm in a piggyback fashion using the TatSP of PaoA (Lee et al., 2014). Both PaoB and PaoC 
partners are thought to be essential for Tat export. A cofactor protein PaoD (35 kDa) is also thought 
to be involved, improving complex stability and a requisite for its activity. The complex is genetically 
encoded by the paoABCD operon (previously known as yagTSRQ) (Neumann et al., 2009).  
 
3.4. Selection of proteins of interest 
To validate the strategy, the selected NTS will initially be fused to reporter protein(s) as the protein 
of interest, as shown in Figure 3-1. An ideal reporter protein would be monomeric to avoid folding 
hindrance, selected with and without DSB(s) for choice flexibility and to test DSB formation in the 
cytoplasm, of small size so that the fusion protein does not breach the size threshold for Tat export, 
and have a rapid and measurable activity assay to quantify whether the reporter is folded correctly. 
The reporter proteins will be initially tested as N-terminal fusions to signal peptides to confirm their 
export via the Tat pathway prior to being used according to the fusion strategy. A valid reporter will 
be a protein that is exclusively exported by Tat and presents activity in the periplasm, thus confirming 
its correct folding (Chapter 6). 
 
3.5. Evaluation of the success of this strategy 
The success of the strategy was estimated by the detection of the cellular localisation of the protein 
of interest and reporter activity assays. The expressing cells were fractionated to separate the 
cellular compartments and the isolated fractions were separated by reducing SDS-PAGE. Gels were 
run in reducing conditions as many of the proteins of interest and reporter proteins possess DSBs. 
Analysis were confirmed by Western-blot and immunological detection of over-expressed proteins 
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via their respective tags using specific antibody reagents. A positive result was expected to be the 
localisation of the protein of interest in the periplasm when fused to a TatSP. In order to confirm the 
Tat specificity of the export, the protein of interest was expected to only localise in the periplasm of 
WT cells and be absent in the periplasm of Tat-null, a strain devoid of an effective Tat pathway 
(section 3.6.).  
The NTSs were first be expressed with their own natural TatSP to select the valid candidates. 
Subsequently, the signal peptides of the latter were planned to be fused to the selected reporter 
proteins to test their export properties via the Tat pathway. However, to mitigate risk that this may 
not be successful, the signal peptide of TorA was also considered. Indeed, this signal peptide has 
been widely and successfully used in the literature for Tat export of recombinant proteins (Thomas 
et al., 2001, Matos et al., 2012, Matos et al., 2014, Alanen et al., 2015, Fisher et al., 2008). This leader 
sequence was proven to allow non-promiscuous export when fused to recombinant proteins 
(Tullman-Ercek et al., 2007, Berks et al., 2000).  
To evaluate whether there is redundancy between the Sec and Tat pathways in relation to export of 
these proteins, a Sec-specific signal peptide was also used to test for Sec export efficiency. The latter 
pathway has the advantages of being a more efficient export pathway with a large capacity for export 
than the Tat pathway and therefore may be preferable. Amongst the discovered Sec substrates, the 
signal peptides of PhoA, pectate lyase B (PelB) or outer membrane protein A (OmpA) are of the most 
commonly used for the secretion of recombinant proteins (Low et al., 2013). In-house, the signal 
peptide of OmpA is preferred for Sec export based on data from periplasmic expression of antibody 
fragments (Ellis et al., 2017). Therefore, OmpASP was selected to direct the proteins of interest into 
the periplasm via Sec. The potential to cytoplasmically express these proteins (without a signal 
peptide) will also be evaluated to understand whether these proteins have the natural ability to fold 
into a native and stable conformation in the cytoplasm, this being a prerequisite for Tat export. 
3.6. Selection of host strain selection 
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The E. coli K12 W3110 (Table 2-1) strain was selected as the WT host, given that it is used routinely 
in-house for periplasmic expression of recombinant proteins. To assess the specificity of Sec and Tat 
export, engineered strains where the Sec or Tat pathway is deleted would be ideal. However, the 
Sec pathway is essential for bacterial growth and the temperature-permissive sec mutant strains 
offer a technically unreliable and conditional alternative (Ito et al., 1989). On the other hand, the Tat 
pathway is non-essential and a knock-out strain (Tat-null) has been successfully developed (Wexler 
et al., 2000). This mutant (Table 2-1) was constructed from E. coli K12 MC4100 by deletion of the 
tatABCD operon and tatE gene (Figure 1-5). Genetically, MC4100 and W3110 appear to have some 
differences, with MC4100 bearing ≈ 2.7 % gene deletions (119 genes) compared to MG1655, a 
W3110-related strain (Peters et al., 2003). From the 8 genetic differences noted between the 
genomes of MG1655 and W3110, only the mutation in rpoS, introducing a stop codon, change the 
gene number in W3110 (Hayashi et al., 2006). Without rpoS, this brings a total expected of 118 genes 
missing in MC4100 compared to W3110. Since W3110 is genetically different from the MC4100 Tat-
null mutant, the MC4100 WT strain (Table 2-1) was also utilized for expression studies. 
As no annotated genomes are available for MC4100 and to confirm authenticity of our strain stocks, 
DNA sequencing of W3110 WT, MC4100 WT and MC4100 Tat-null was conducted as detailed in 
section 2.2.13. The sequencing data was aligned to the theoretical W3110 reference genome 
(AP009048.1, NCBI). The differences highlighted are presented in Appendix 3 and first show no 
variances between the reference and our in-house W3110 WT strain, thereby confirming 
authenticity. Secondly, the sequenced MC4100 WT strain actually lacks 123 genes from seven loci 
compared to W3110 WT, including the lac and paoABCD operons which codes for the Tat substrate 
PaoA. This indicates that this genome is five genes shorter compared to published data by Peters et 
al. (2003). Two of the missing genes yeiW and ykgN (Hayashi et al., 2006) identified in this work were 
referenced after the publication from Peters et al. (2003). The three remaining discrepancies 
identified in this work are the fnr, uspE and ynaJ genes, all from the same genetic locus (Appendix 3, 
locus G). This suggests that these genes were either deleted by spontaneous mutation in our strain 
or the deletions were not detected by Peters and co-workers (2003). The fnr gene is worth 
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mentioning since it encodes for a global transcription factor essential for anaerobic respiratory 
processes (Spiro and Guest, 1990). Hence, the MC4100 WT strain was only used in aerobic 
conditions. Lastly, the MC4100 Tat-null strain is demonstrably identical to MC4100 WT, apart from 
the engineered deletion of the tatABCDE genes. 
The E. coli Tat-null strain was confirmed to have a morphological phenotype as previously reported 
by Caldelari et al. (2008) (Figure 3-2). Cells cultured in LB were visualised with a 1000-fold 
magnification under oil immersion and shown to form long chains. This phenotype is due to the AmiA 
and AmiC Tat-substrates unable to translocate to the periplasm due to the absence of the Tat 
pathway (Bernhardt and De Boer, 2003, Ize et al., 2003). These proteins are cell-wall hydrolases 
involved in septum cleavage during cell division. 
This Tat-null strain has also been reported to have other biological phenotypes including 
hypersensitivity to exogenous drugs and detergents, sensitive to lysis by lysozyme without EDTA, 
sensitive to copper, lower virulence, periplasmic leakiness and resistance to infection by P1 (Caldelari 
et al., 2008). It is thought that the lack of a functional Tat pathway leads to the mis-localisation of its 
substrates, thereby resulting in these phenotypes. 
 
 
Figure 3-2: Morphological differences between E. coli WT and Tat mutant strains. 
The images show bacteria from the strains W3110 WT, MC4100 WT and MC4100 Tat-null from left to right 
taken using an EVO™ FL imaging microscope. The pictures were taken with a 1000-fold magnification and 
under oil immersion. Scale bar is 5 µm. 
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4. DEVELOPMENT OF A ROBUST FRACTIONATION METHOD 
4.1. Available methods to assess protein localisation 
In bacteria, proteins localise at specific sites to form an elaborate subcellular architecture (Rudner 
and Losick, 2010). Gram negative bacteria such as E. coli have four protein locations: the outer 
membrane (OM), the periplasm, the inner membrane (IM) or the cytoplasm (Figure 1-1) (Costerton 
et al., 1974). Fractionation is an experimental process used to isolate proteins from their respective 
sub-cellular compartments. Moreover, the activity of the protein of interest can also be tested in the 
different isolated fractions. The risk with this technique is to have cross-fraction contamination which 
would result in artefactual data. Another method is to fuse GFP to the protein of interest, allowing 
direct observation by microscopy (Arigoni et al., 1995). This approach is limited because fusions may 
influence the localisation of the protein of interest through misfolding, aggregation or the GFP could 
be proteolytically clipped and therefore can no longer identify the localisation of the protein of 
interest. Moreover, the activity of the latter cannot be evaluated in its respective fractions using this 
approach. Hence, the fractionation method was considered for this project with a primary focus on 
fraction purity. 
Although published fractionation protocols are not wholly different from each other, there appears 
to be no standardized method to extract all compartments with due-diligence against cross-
contamination and inconsistency (Balasundaram et al., 2009). Sub-cellular fractionation begins with 
extracting the periplasm through the outer membrane. Then the resulting cells are lysed to release 
the cytoplasm which is separated from the insoluble fraction which includes membranes and 
potentially aggregated proteins by centrifugation. Further preparation to isolate the inner 
membrane from the outer membrane can also be performed (Thein et al., 2010) but this is out of 
the scope of this work. Periplasmic extraction is the most critical step of the process since disruption 
of the inner membrane can result in contamination from cytoplasmic proteins. Common methods to 
extract the periplasm use either an EDTA-lysozyme strategy (Thein et al., 2010, Pierce et al., 1997) 
or cold osmotic shock (Kang et al., 2012, Manoil and Beckwith, 1986), or a combination of both 
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(Alanen et al., 2015) (Figure 4-1). In the former method, EDTA is used to destabilise the outer 
membrane (Clifton et al., 2015), allowing the lysozyme to enter the periplasm and hydrolyse the 
peptidoglycan cell wall. This process subsequently releases the periplasm and leaves the cells as 
spheroplasts (Pierce et al., 1997). The second method generates an osmotic shock induced by 
successively adding a hypertonic solution to weaken the outer membrane, followed by a hypotonic 
solution to partially disrupt the outer membrane without compromising the integrity of the inner 
membrane (Kang et al., 2012). 
 
 
Figure 4-1: Diagram of the action mechanisms of the main periplasmic extraction procedures 
On the left, the EDTA-lysozyme strategy aims to destabilise the outer membrane (OM) by chelating the bivalent 
cations such as Mg2+ and Ca2+. The latter are necessary for the stability of the outer membrane and act as 
cofactors for enzymes involved in cell wall building. Once the outer membrane is fragilized, lysozyme can 
penetrate inside the periplasm and degrade the peptidoglycan. The periplasm is hence released while the inner 
membrane (IM) remains intact. On the right, the cold osmotic shock partially disrupts the outer membrane by 
the successive cell resuspension in hypertonic and hypotonic solutions. 
 
The second and third steps in the fractionation process result in the recovery of the cytoplasmic and 
insoluble fractions simultaneously. This primarily involves cell lysis to disrupt the inner membrane 
and subsequent centrifugation to separate the cytoplasmic and insoluble fractions. The risks are poor 
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soluble protein recovery due to incomplete lysis or the use of harsh conditions resulting in loss of 
soluble protein through aggregation which in turn contaminates the insoluble fraction. The most 
common cell-lysis techniques used in small scale are freeze/thaw cycling and ultrasonication 
(Balasundaram et al., 2009, Thein et al., 2010). Freeze/thaw cycling causes the formation of ice 
crystals ultimately leading to cell disruption. However, loss of enzymatic activity have been reported 
(Lambert et al., 1983) as well as low yields (Stanbury and Whitaker, 1984). Ultrasonication uses the 
cavitation principle to disrupt the membranes by ultrasonic vibration creating local disruption of 
pressure in the form of cavitation bubbles which by collapsing release mechanical energy 
disintegrating the membranes (Harrison, 1991). The risks from this technique are the heat produced 
by the absorption of the acoustic energy which might denature proteins and the ionisation which 
was reported to inactivate enzymes (Lilly and Dunnill, 1969). Moreover, freeze/thaw cycling offers 
the advantage of treating several samples simultaneously whereas ultrasonication can treat only one 
sample at a time. Following cell lysis, the samples are centrifuged to isolate the insoluble debris. The 
pellet contains the membrane fragments and, when present in the cell, protein inclusion bodies. 
To the best of our knowledge, no single study clearly describes in detail, a robust method to obtain 
uncontaminated soluble bacterial fractions. For instance, (Tao, 2008) and Thein et al. (2010) 
compared periplasmic fractions obtained by EDTA/lysozyme and cold osmotic shock and 
demonstrated cross-contamination in each case. Many publications show no due-diligence to 
fraction purity (Pechsrichuang et al., 2016, Alanen et al., 2015, Pierce et al., 1997, Kang et al., 2012, 
Matos et al., 2014). Some do utilize controls in the form of sub-compartment specific host proteins 
as purity markers, but these are incomplete. For instance, Zhang et al. (2017) merely controlled the 
fraction purity in only one of their experiments by Western-blot using an anti-β-lactamase antibody. 
β-lactamase is an E. coli natural periplasmic protein which, in this case, was found contaminating the 
cytoplasmic and outer membrane fractions. In another example, Fisher et al. (2008) used an anti-
GroEL antibody for the same purpose. GroEL being a well-known cytoplasmic protein, was used to 
assess the purity of the periplasmic fractions by the lack of detectable GroEL proteins but in only one 
of their experiments. 




Figure 4-2: Diagram of the action mechanisms of the main cell lysis procedures 
On the left, the freeze/thaw cycling strategy leads to creation of ice crystals which disrupt the cells. On the 
right, the sonication technique applies ultrasonication vibration to the cells creating cavitation bubbles. Their 
collapse releases mechanical energy disintegrating the membranes. OM: outer membrane, IM: inner 
membrane. 
 
4.2. Discovery of cross-contamination issues 
A clean fractionation method is absolutely necessary in order to detect expressed proteins in their 
actual respective subcellular compartments. This method must also be robust enough to handle WT 
strains as well as mutants with envelope debilities such as the control strain MC4100 Tat-null (section 
3.6.). During the preliminary stages of this work, contamination was observed in the form of 
cytoplasmic proteins detected in the periplasmic fraction. His-tagged PhoA (PhoA-His) was expressed 
in W3110 WT and MC4100 Tat-null strains and targeted to either the cytoplasm (no signal peptide) 
or periplasm via Sec and Tat export, the latter with the use of specific signal peptides, OmpASP for 
Sec or the natural signal peptide of the Tat substrate YcbK (Figure 4-3). As PhoA contains two DSBs, 
the CyDisCo components, Erv1p and PDI which enable cytoplasmic DSB formation (section 1.4.1.3) 
were also co-expressed with PhoA as cytoplasmic cMyc-tagged proteins. The cells were grown at 
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37°C and harvested after 16 h at 18°C post-induction (Table 2-3, condition 4). The fractionation 
protocol used was method 1 (Table 4-1) and comprised of cold osmotic shock for periplasm 
extraction and freeze/thaw cycling for cell lysis (Manoil and Beckwith, 1986). Cytoplasmically-
expressed PhoA-His (with no signal peptide) was expected to be confined to the cytoplasm. However, 
as shown in Figure 4-3, significant levels of this protein were detected in both the cytoplasmic and 
periplasmic fractions when co-expressed with CyDisCo. Without CyDisCo, PhoA-His, expressed 
without a signal peptide, was not detected in any fraction, indicating that the CyDisCo components 
are essential for cytoplasmic expression. Similarly, the periplasmic-targeted proteins for either 
export pathway were observed in the periplasm when expressed in W3110 WT as predicted. 
Although the Sec-targeted PhoA-His was observed as expected in the periplasm of the MC4100 Tat-
null strain which lacks the Tat export machinery, the Tat-targeted PhoA-His was unexpectedly 
detected in the periplasmic fraction of this strain. Furthermore, the cytoplasmic CyDisCo 
components, particularly cMyc-tagged PDI was significantly detected in all fractions irrespective of 
the strain. Although Erv1p-cmyc was present at lower levels in the periplasm, cross-contamination 
was still obvious. It is also worthwhile to point out that the CyDisCo proteins were detected in a 
substantial amount in the insoluble fractions irrespective of strain. As the presence of PhoA in the 
insoluble fractions was minimal, this is likely the result of high levels of overexpression of these 
proteins and subsequent formation of insoluble inclusion bodies. Although cross-contamination of 
the insoluble fraction by the presence of un-lysed cells may account for the minimal detection, the 
insoluble preparation could also capture jamming or periplasmic proteins ‘slowly’ translocating 
across the inner membrane. Overall, this experiment confirmed that this fractionation protocol 
needs to be optimised to obtain pure fractions. The contamination of the periplasmic fraction by 
cytoplasmic proteins revealed that the cold osmotic shock compromised the inner membrane 
resulting in cytoplasm leakiness. Also, the large amount of proteins detected in the insoluble 
fractions was a potential risk of artefact from un-lysed cells. Having no cross-contamination and a 
high recovery of soluble proteins are mandatory to drawing reliable conclusions regarding protein 
export.  




Figure 4-3: Cross-contamination issues using cold osmotic shock and freeze/thaw cycling 
His-tagged PhoA (PhoA-His) with no signal peptide (No SP), Sec-targeted signal peptide (OmpASP) or Tat-
targeted signal peptide (YcbKSP) were expressed with (+) and without (-) cytoplasmic cMyc-tagged Erv1p and 
PDI in W3110 WT and MC4100 Tat-null strains. Cells were fractionated using method 1 (cold osmotic shock 
and freeze/thaw cycling) procedure allowing the separation of the cytoplasmic (C), insoluble (I) and periplasmic 
(P) fractions. Proteins were separated by SDS-PAGE and detected following Western-blot by anti-His and anti-
cMyc antibodies where appropriate. Molecular weight markers are indicated in kilodalton (kDa). The figure is 
a composite image where the marker lanes reflects the approximate position of the molecular weights. 
 
4.3. Identification of a robust fractionation method 
As shown in section 4.2, cell fractionation using a published method (Manoil and Beckwith, 1986) 
resulted in fraction cross-contamination which would have inadvertently led to false conclusions. As 
it is critically important for data integrity to identify methodologies that would yield clean fractions, 
several protocols from published literature were compared in parallel (Table 4-1). Method 1, as used 
in section 4.2., comprised of cold osmotic shock for periplasmic extraction and freeze/thaw cycling 
for cell lysis and resulted in cross-contamination. Since cold osmotic shock causes inner membrane 
leakiness, the addition of MgCl2 to the hypotonic solution as suggested by el Yaagoubi et al. (1994) 
was considered (Table 4-1, method 2). MgCl2 is thought to play a major role in maintaining the 
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integrity of the outer membrane (Clifton et al., 2015, Neidhardt et al., 1996). Another popular 
fractionation method utilizes EDTA/lysozyme/cold osmotic shock and ultrasonication for periplasmic 
and cytoplasmic extraction, respectively (Jones et al., 2016). As described in section 4.1., 
ultrasonication is not high-throughput unlike freeze/thaw cycling and therefore EDTA/lysozyme/cold 
osmotic shock was paired with freeze/thaw cycling into method 4 to improve the probability of 
identifying a robust method that is also high-throughput. 
 
Table 4-1: Cell fractionation methods 
Name Periplasmic extraction Cell disruption 
Method 1 Cold osmotic shock Freeze/thaw cycling 
Method 2 Cold osmotic shock with MgCl2 Freeze/thaw cycling 
Method 3 EDTA/lysozyme/cold osmotic shock  Ultrasonication 
Method 4 EDTA/lysozyme/cold osmotic shock  Freeze/thaw cycling 
PureFrac Cold osmotic shock with MgCl2 Ultrasonication 
 
To compare these four methods, cytoplasmically-expressed PhoA-His (without a signal peptide) was 
co-expressed with CyDisCo proteins cMyc-tagged Erv1p and PDI in W3110 WT and MC4100 Tat-null 
strains. Therefore PhoA-His, Erv1p-cMyc, PDI-cMyc as well as the LacI repressor – which is used to 
negatively regulate expression of the latter proteins on the expression plasmid – served as 
cytoplasmic markers. The endogenous cytoplasmic protein, glucose-6-phosphate dehydrogenase 
(G6PD) and periplasmic host proteins, maltose binding protein (MBP) and protein disulphide 
isomerase DsbA were used as native host markers to validate fraction purity (Dalbey and von Heijne, 
2002, Bassford, 1990, Jonda et al., 1999). Protein localisation and cross-contamination was 
monitored by Western blot of overexpressed proteins and selected markers.  
The transformants were grown as outlined in Table 2-3, condition 4 (growth at 37°C and harvest 
after 16h at 18°C post-induction) and the cells were fractionated as outlined in Table 4-1, using 
methods 1 to 4. As shown in Figure 4-4, the periplasmic fraction isolated by cold osmotic shock 
(method 1) presented minor bands with PDI-cMyc and LacI and, to a lesser extent, PhoA-His and 
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G6PD in both strains indicating some cross-contamination from the cytoplasm. The markers MBP 
and DsbA were located in the periplasmic fractions as anticipated, confirming correct localisation of 
the periplasmic proteins. However, the cytoplasmic contamination observed with method 1 was 
completely avoided by the inclusion of MgCl2 during the cold osmotic shock (method 2) while the 
periplasmic markers were still extracted effectively (Figure 4-4) confirming the role of magnesium 
salts in maintaining outer membrane integrity (section 4.1.). Minor bands of periplasmic MBP were 
still detected in the cytoplasmic and insoluble fractions (Figure 4-4) presumably from intact cells 
escaping the periplasmic extraction process and will be addressed later (section 4.5). Despite this 
slight drawback, the periplasmic extraction by cold osmotic shock with MgCl2 resulted in 
reproducible data where each protein was detected in its predicted fraction. 
In contrast, when using EDTA/lysozyme/cold osmotic shock for periplasmic extraction (Table 4-1, 
methods 3 and 4), the periplasmic host proteins were not detected as expected. DsbA was not 
detected at all in any fraction which could be the result of degradation due to instability in the 
cytoplasmic environment (Figure 4-4). The second periplasmic marker protein, MBP, was detected 
in majority in the periplasm of the Tat-null cells with method 4 but more distributed in all fractions 
with method 3 indicating inconsistency of the method. Moreover, this marker was found with a large 
majority in the cytoplasmic fractions of the WT strain suggesting an ineffective periplasmic extraction 
(Figure 4-4). Furthermore, all cytoplasmic markers were unexpectedly detected in the periplasmic 
fractions of the MC4100 Tat-null strain suggesting that this method can be sub-optimal for at least 
this mutant strain. It is likely that the hypotonic conditions of the extraction method in addition to 
the effect of cation chelation by the EDTA on the inner membrane (Clifton et al., 2015), and 
peptidoglycan digestion by the lysozyme all contributed to weakening of the outer and inner 
membranes and subsequent disruption of the latter. Overall, due to cross-contamination, the 
EDTA/lysozyme/cold osmotic shock technique can lead to false-negative and false-positive 
conclusions and therefore is not fit for this purpose. 
 




Figure 4-4: Evaluation of periplasmic and cytoplasmic extraction methods 
Cytoplasmically expressed His-tagged PhoA, cMyc-tagged Erv1p and PDI proteins were co-expressed in W3110 
WT and MC4100 Tat-null strains. The cells were fractionated according to method 1 (cold osmotic shock and 
freeze/thaw cycling), 2 (cold osmotic shock with MgCl2 and freeze/thaw cycling), 3 (EDTA/lysozyme/cold 
osmotic shock and sonication) and 4 (EDTA/lysozyme/cold osmotic shock and freeze/thaw cycling). The 
fractions are represented as cytoplasmic (C), insoluble (I) and periplasmic (P). Western-blots shown (from top 
to bottom) represent the detection of PhoA-His, PDI-cMyc, Erv1p-cMyc, G6PD, LacI, MBP and DsbA proteins 
as detected by anti-His, anti-cMyc, anti-G6PD, anti-LacI, anti-MBP and anti-DsbA antibodies respectively. 
PageRuler Plus Prestained Protein Ladder (Life Technologies) and MagicMark™ (Life Technologies) molecular 
weight markers are indicated in kilodalton (kDa). The figure is a composite image where the marker lanes 
reflects the approximate position of the molecular weights. 
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For the isolation of cytoplasmic fractions, two methodologies, freeze/thaw cycling and 
ultrasonication, were compared. Generally, ultrasonication (method 3) appeared to be superior with 
notably higher recovery of soluble cytoplasmic proteins as indicated by PDI-cMyc, Erv1p-cMyc, G6PD 
and LacI (Figure 4-4). With the freeze/thaw cycling technique (method 1, 2 and 4), most of the 
cytoplasmic proteins except PhoA-His were unexpectedly located in the insoluble fraction 
irrespective of the strain. The inconsistent cytoplasmic proteins recovery from these three methods 
was most likely due to the periplasmic extraction technique used on the previous steps which left 
the cells in different states with inner and outer membrane disruption and variable peptidoglycan 
digestion. The proteins detected in the insoluble fractions likely came from un-lysed cells or 
carryover from the cytoplasmic fraction (unwashed insoluble pellet). The necessity of purity markers 
was highlighted here where LacI and MBP gave clear data whereas G6PD and DsbA were more 
difficult to interpret, if present at all. Hence, the cytoplasmic marker LacI and the periplasmic marker 
MBP will be used throughout the rest of the study. 
In conclusion, cold osmotic shock with MgCl2 appears to be the superior method for periplasmic 
extraction while ultrasonication gave optimal results for cytoplasmic recovery. These two techniques 
were subsequently combined in a single new method. 
 
4.4. Validation of the composite method 
The optimal method, consisting of cold osmotic shock with MgCl2 and sonication, named PureFrac, 
is described in Table 4-1 and Appendix 4 (Malherbe et al., 2019). To assess this extraction procedure, 
the Tat-targeted PhoA-His (fused to a TorA signal peptide, TorASP-PhoA-His) was co-expressed with 
the cytoplasmic CyDisCo proteins, PDI-cMyc and Erv1p-cMyc in W3110 WT and MC4100 Tat-null 
strains. PhoA has previously been shown to export into the periplasm as an active protein via the Tat 
pathway when fused to a TorA signal peptide (Fisher et al., 2008, Matos et al., 2014). Cells were first 
cultivated under varying growth conditions (Table 2-3) commonly used to overexpress proteins in 
order to both determine the optimal conditions for Tat export and evaluate cross-contamination 
Chapter 4 - Fractionation 
69 
 
propensity in relation to the environment (Pierce et al., 1997, Kang et al., 2012, Pechsrichuang et al., 





As shown in Figure 4-5A, periplasmic PhoA-His was only observed in WT cells indicating Tat-exported 
protein as expected (Matos et al., 2014) but to varying degrees, this being dependent on the growth 
Figure 4-5: Evaluation of the composite PureFrac 
method. 
W3110 WT and MC4100 Tat-null strains co-
expressing His-tagged TorASP-PhoA targeted to 
the periplasm, and cMyc-tagged Erv1p and PDI, 
targeted to the cytoplasm, were grown in 
different conditions: induced with 100 µM IPTG 
(1) in LB for 2 h at 30°C, (2) in LB for 4 h at 30°C, 
(3) in LB for 2 h at 37°C, (4) in LB for 16 h at 18°C, 
(6) in 2x TY for 2 h at 30°C, (7) in fed-batch culture 
for 16 h at 18°C or (8) in M9 minimal media for 
16 h at 18°C. The cells were fractionated using 
the PureFrac method into the cytoplasmic (C), 
insoluble (I) and periplasmic (P) fractions. A. 
Western-blots of PhoA-His detected by anti-His 
antibodies. B. Western-blot showing Erv1p, PDI, 
LacI and MBP proteins detected by anti-cMyc, 
anti-cMyc, anti-LacI and anti-MBP antibodies 
respectively. PageRuler Plus Prestained Protein 
Ladder (Life Technologies) and MagicMark™ (Life 
Technologies) molecular weight markers are 
indicated in kilodalton (kDa). The figure is a 
composite image where the marker lanes reflects 
the approximate position of the molecular 
weights. 
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parameters used. Growth condition 2 with a short induction of 4 h at 30°C in LB medium gave the 
optimal level of exported PhoA-His whereas condition 3 gave the lowest level and condition 8 no 
export at all (Table 2-3). The cytoplasmic markers PDI-cMyc, Erv1p-cMyc, LacI, and the periplasmic 
marker MBP were all observed in their predicted fractions of both strains (Figure 4-5B) further 
supporting the robustness of this method. The condition 2 was therefore selected as the expression 
conditions for the following studies. 
 
4.5. Lysozyme addition to PureFrac is not a solution 
The PureFrac process appeared to be superior to published methods as all control proteins were 
detected in their predicted fractions. However, this method could potentially be improved using 
lysozyme to enhance soluble protein recovery. Degrading the peptidoglycan using lysozyme could 
expand the release of the periplasmic proteins whilst the added magnesium could stabilize the outer 
membrane disrupted by the osmotic shock. Therefore, a comparison between the use of PureFrac 
with and without lysozyme was undertaken whilst exploring the Tat-mediated export of PhoA using 
the signal peptide of another Tat-specific substrate, aldehyde oxidoreductase iron-sulphur-binding 
subunit A (PaoASP). 
PaoASP-PhoA-His was co-expressed with CyDisCo in W3110 WT and MC4100 Tat-null strains and 
fractionated using PureFrac with and without lysozyme in the hypotonic solution (100 µg/ml). Minor 
bands of PhoA-His were detected in the periplasmic fractions of the PureFrac method whereas a 
significant amount of the protein was located in the periplasm when using the lysozyme-
complemented PureFrac method (Figure 4-6A). Without lysozyme treatment, the cytoplasmic 
marker proteins Erv1p-cMyc and LacI were exclusively observed in the cytoplasm whereas a small 
portion of PDI-cMyc was also found in the periplasm of WT cells. Conversely, significant levels of all 
these proteins were detected in the periplasm when extracted with lysozyme. This indicated that 
lysozyme addition to the periplasmic extraction buffer increased cross-contamination risk and the 
high level of PaoASP-PhoA-His observed in the periplasmic fraction with lysozyme was most likely a 
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cross-contamination artefact. The detection of this protein in the periplasm of the Tat-null strain 
further supported the artefactual data. In terms of PhoA activity, this protein appeared to be active 
in all fractions with close correlation with levels of PhoA found in each fraction (Figure 4-6B). In 
conclusion, presence of lysozyme appears to cause further cross-contamination and therefore 
should be avoided. 
 
4.6. The importance of NEM to analyse the disulphide bond status 
Some proteins need their DSBs to be formed to reach a native conformation and thus be active. 
However, the DSB status within a protein can change during sample processing because of air 
oxidation leading to artefacts and loss of activity (Elena et al., 1998). The use of very weakly alkaline 
solutions and the multiple pipetting/resuspension steps as required in the PureFrac protocol are 
optimal conditions for this process to occur. Therefore, preserving the DSB linkages of a protein is of 
paramount importance. 
N-ethylmaleimide (NEM) is a capping agent used to block the free thiol groups of cysteine residues 
in proteins by reacting with sulfhydryl groups to form alkyl derivatives and thus preventing artefacts 
(Matos et al., 2014). To test the impact of NEM on DSB formation during extraction procedures, PhoA 
was expressed in MC4100 WT in fusion with OmpASP. The protein was expressed in LB at 30°C against 
an empty vector as a control and harvested 2 h after induction as outlined in Table 2-3, method 1. 
The culture was split into equal volumes and the resulting cell samples after harvest were 
fractionated using the PureFrac method where 100 µM NEM was added to all the buffers used for 
one sample. For the other sample, NEM was added at the same concentration to all buffers except 
to the PBS used to wash the cells in the very first step of the method. 
 





Figure 4-6: Effect of lysozyme treatment on fractionation purity with PureFrac 
W3110 WT and MC4100 Tat-null strains consisting of the empty vector (1) as a control or co-expressing Tat-
targeted His-tagged PaoASP-PhoA with cytoplasmic CyDisCo (PDI-cMyc and Erv1p-cMyc) were cultured in LB at 
30°C and induced with IPTG for 2 h. The cultures were split into two samples and recovered cells were 
fractionated using the PureFrac method (-) or treated by the addition of 100 µg/ml of lysozyme to the 
hypotonic solution (+). Fractions include cytoplasmic (C), insoluble (I) and periplasmic (P) fractions. A. Western-
blots representing PhoA-His, PDI-cMyc, Erv1p-cMyc, LacI and MBP proteins were detected by anti-His, anti-
cMyc, anti-LacI and anti-MBP antibodies respectively. Molecular weight markers are indicated in kilodalton 
(kDa) on the right of each blot. The figure is a composite image where the marker lanes reflects the 
approximate position of the molecular weights. B. PhoA activity was determined using a titration curve of a 
commercial, purified PhoA and normalized against the empty vector. The bars indicate the cytoplasmic (white), 
insoluble (grey) and periplasmic (black) fractions. n=3.  
 




Figure 4-7: Relevance of NEM to assess the propensity of disulphide bond status 
W3110 WT strain expressing sec-targeted His-tagged OmpASP-PhoA or only containing an empty vector were 
incubated for 2 h at 30°C post-induction. The cells were split in two samples and fractionated using PureFrac 
method into the cytoplasmic (C), insoluble (I) and periplasmic (P) fractions. One sample was washed in PBS 
with (+ NEM) and without NEM (-NEM) while all other solutions used contained NEM for both samples. A. 
Western-blots showing PhoA-His, LacI and MBP proteins detected by anti-His, anti-LacI and anti-MBP 
antibodies respectively. Molecular weight markers are indicated in kilodalton (kDa) on the right of each blot. 
The figure is a composite image where the marker lanes reflects the approximate position of the molecular 
weights. B. PhoA activity was determined using a titration curve of a commercial, purified PhoA. The bars 
indicate the cytoplasmic (white), insoluble (grey) and periplasmic (black) fractions. n=3 
 
Figure 4-7A shows high expression of PhoA, albeit clipped products were detected in all fractions 
including the expected periplasmic fraction indicating export through the Sec pathway, irrespective 
of NEM addition to PBS. The respective cytoplasmic and periplasmic control markers LacI and MBP 
indicate no cross-contamination between the soluble compartments further supporting the 
robustness of the fractionation method. Appreciable levels of PhoA-His and associated clipped 
product was also detected in the insoluble fractions and likely to be derived from inclusion bodies as 
a result of high levels of overexpression in rich media. 
The activity assays however, revealed a significant difference between the periplasmic fractions 
(Figure 4-7B). Indeed, without NEM, a 28 % increase in PhoA activity was observed when compared 
to the condition with NEM. Since PhoA is only active when the DSBs are formed, this strongly 
supports disulphide shuffling, enabled by air oxidation has taken place. This has resulted in more 
than 25 % of the extracted periplasmic PhoA-His gaining activity through correct DSB formation in 
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the absence of NEM. Consequently, the addition of NEM from the very first step of the sample 
processing, is critical to assess the activity of secreted proteins that contain DSB(s). 
 
4.7. Conclusion 
A fractionation protocol was needed for this study, giving pure sub-cellular compartments to reflect 
the precise localisation of expressed proteins within a cell. From the literature, cold osmotic shock 
and EDTA/lysozyme/cold osmotic shock are two common methods for periplasmic extraction. In this 
work, both presented cross-contamination between their soluble fractions. However, when MgCl2 
was added to the hypotonic solution of the cold/osmotic shock procedure, uncontaminated 
periplasmic fractions were obtained. The next step in cell fractionation is to isolate the cytoplasmic 
preparation. Comparison of ultrasonication and freeze/thaw cycling used to lyse the cell 
demonstrated that ultrasonication gives superior recovery of soluble proteins. Thus, the optimized 
cell fractionation method PureFrac, combines both the cold osmotic shock with MgCl2 and 
ultrasonication procedures and was demonstrated to be a robust technique to isolate proteins with 
respect to their sub-cellular compartments. This was accomplished without cross-contamination and 
with superior recovery of soluble proteins. Minor contamination with respect to the periplasmic host 
marker MBP was observed in the cytoplasmic and insoluble fractions of some cases indicating that 
no method would give 100 % clean fractions and it is unrealistic to believe so. As the cross-
contamination levels are so low in these experiments, very little room is left to misinterpret these 
observations as false-positives. Conversely, if the cross-contamination was significant, then this 
would be a major risk. Moreover, adding lysozyme was attempted to enhance soluble periplasmic 
recovery but led to major cross-contamination and is best avoided for this type of study. 
To improve the process, wash steps could be added before the solubilization of the insoluble pellet 
after ultracentrifugation which should minimize contamination by carryover. If more persists, a slow 
speed centrifugation step could be added after solubilization of the insoluble materials to separate 
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the potential un-lysed cells or the ultrasonication step could be further optimized to increase cell 
lysis.  
Since the purpose of this PhD is to investigate Tat export of expressed proteins, only the soluble 
cytoplasmic and periplasmic compartments are of interest. Therefore, the method to isolate further 
pools of different protein structures from the insoluble preparation was not optimized. 
PureFrac was proven to be robust with both the WT strain and the Tat-null strain which has a 
compromised envelope. This process was also adequate in all the rich media conditions tested and 
the isolated proteins were demonstrated to be active. Moreover, the necessity for NEM was 
demonstrated to cap the free thiol groups and thus, prevent the formation of DSBs by air oxidation 
during sample processing. 
The development of PureFrac has highlighted the need for specific localisation markers, particularly 
the selection of appropriate and consistent protein markers to monitor cross-contamination events. 
Hence, through the whole project, Western-Blots against LacI and MBP were performed to justify of 
fractions purity for every single experiment. 
Overall, PureFrac presents several advantages over the compared methods from literature. It allows 
extraction of the periplasmic fraction without contamination by cytoplasmic endogenous (G6PD) or 
recombinant (PhoA-His, PDI-cMyc, Erv1p-cMyc and LacI) whereas EDTA/lysozyme and cold osmotic 
shock procedures led to such contamination. Moreover, PureFrac enable a higher recovery of soluble 
cytoplasmic proteins by sonication than by using freeze/thaw cycling. Such improvements are not 
only valid for WT E. coli strain but also for a mutant strain with impaired cell wall demonstrating the 
robustness of the method. Furthermore, the addition of NEM in PureFrac allow extraction of proteins 
which DSB status is unaltered during sample processing. The purity of the soluble fractions could be 
further demonstrated by running proteomics analysis on the samples from the different 
fractionation techniques. Finally, quantitative measurement of the benefit of PureFrac over other 
techniques can be achieved via such proteomics study but also via peptide mapping, His-tag 
purification followed by size exclusion chromatography and mass spectrometry on the fractions. 
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5. EVALUATION OF NATURAL TAT SUBSTRATES AS SOLUBLE PARTNER 
5.1. Initial expression of the five selected candidates 
The suitability of the selected five NTS as outlined in section 3.3. as an export and soluble partner in 
the fusion design was tested. To this aim, all five His-tagged candidates (AmiA, HyaA, PaoA, TorA and 
YcbK) were expressed in W3110 WT, MC4100 WT and MC4100 Tat-null strains in LB at 30°C induced 
for 2 h at 30°C (Table 2-3, condition 1). The cells were fractionated according to the PureFrac method 
(section 4.4, Appendix 4) and the expression and export profiles analysed by SDS-PAGE and Western 
blot. As shown in Figure 5-1A, the expression of the 5 NTS was measured through various degrees of 
success. YcbK was not expressed even though the plasmid sequence was confirmed before and after 
the experiment to rule out nucleic acid mutations. The growth profile of YcbK was similar to those of 
the other NTS in the WT strains with respect to that during the induction phase (Appendix 5), a lower 
OD600 was reached compared to the control strain (empty vector). This suggests that YcbK was 
expressed but bearing in mind the results on analysis, was instable in the cytoplasm and so was 
degraded. YcbK is currently of unknown function, is not in an operon structure with other genes 
which could highlight its role or the necessity of partners or chaperones essential for expression, 
folding and stability (section 3.3.). Computational analysis using Virtual Footprint of the region 
upstream of the open reading frame of ycbK within the chromosome revealed a conserved -10 and 
-35 promoter region as well as RpoD, CRP, ArgR and Sigma70 binding sites, which strongly support 
that this gene is at least transcribed (Munch et al., 2005, Solovyev, 2011). The absence of YcbK 
expression in this study could be due to several reasons: (i) requirement of unknown chaperones 
and/or partners, (ii) requirement of an unknown metal ion which was not found in the supplied LB, 
(iii) instability brought by the aerobic conditions as some Tat substrates are involved in anaerobic 
growth. Furthermore, AmiA, HyaA and PaoA were expressed but most of the proteins were detected 
in the insoluble fractions demonstrating their instability irrespective of the strain. TorA was the only 
candidate to express in a significant amount and showed partial stability as demonstrated by the 
intensity of the detected bands in the soluble fractions (Figure 5-1A). 
Chapter 5 - NTS 
77 
 
Regarding export, the three highly unstable candidates AmiA, HyaA and PaoA showed no sign of 
crossing the inner membrane. AmiA has been overexpressed previously but no evidence of the 
subcellular localisation have been sought using isolated fractions (Ize et al., 2003, Bernhardt and De 
Boer, 2003). HyaA is known to form a dimer with HyaB and this complex is believed to be Tat 
exported using the signal peptide of HyaA (Rodrigue et al., 1999), although no direct evidence have 
been published. Moreover, evidence of the chaperone HyaE binding the HyaA signal peptide have 
been highlighted by Dubini and Sargent (2003). However, no evidence of HyaE being required for 
HyaA export has been presented. It is plausible that the chaperone HyaE and/or the partner HyaB 
may need to be co-expressed in order for the complex to be exported by the Tat mechanism.  
In relation To PaoA, a more complex story has emerged from other authors. A cytoplasmic variant of 
PaoA has been expressed in the cytoplasm where it was found to interact with the PaoB and PaoC 
partners to form the PaoABC complex (section 3.3.) (Neumann et al., 2009, Correia et al., 2016). Lee 
et al. (2014) confirmed the formation of this complex but also proved that both partners are required 
for Tat export of the complex as “hitchhikers” thanks to the signal peptide of PaoA. The team also 
demonstrated the implication of the PaoD chaperone in improving the complex stability and its 
requirement to gain activity. In this case, PaoA would require co-expression of the partners PaoB and 
PaoC as well as potentially, the chaperone PaoD for Tat export. Due to the success of export reported 
by Lee et al. (2014), this highlighted that the PaoA experiment needed further optimization which 
was performed and reported in section 5.2. 
The only successful candidate, with regards to export in the first experiment, was TorA, as a 
significant amount of proteins was detected in the periplasmic fraction of the WT strains. Conversely, 
no proteins were detected in the periplasm of the Tat-null strain (Figure 5-1A). Since the control 
markers LacI and MBP were both detected in their respective fractions, this confirms TorA was 
specifically exported by Tat and supports previous published data (Weiner et al., 1998, Jack et al., 
2004). TorA, even without its chaperone TorD, is known to fold to a near native conformation 
although at a slower rate (Pommier et al., 1998, Ilbert et al., 2003). 
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The fractionation controls represented in Figure 5-1B indicate the purity of the isolated fractions, as 
confirmed by the absence of LacI and MBP contaminating proteins in the respective periplasmic and 
cytoplasmic fractions. Overall, only TorA was exported by Tat without any further optimization. 
However, the DNA sequence coding for this protein rendered the plasmid unstable which made TorA 
technically impractical. Therefore, none of the five selected candidates were fit to use as soluble 
partner as such and would require optimization. 
 
5.2. Optimization of PaoA for Tat export 
5.2.1. PaoA stability assessment 
In section 5.1., PaoA was shown to not export via Tat and revealed a relatively low stability when 
expressed while bearing its own signal peptide. Expression of PaoA alone has never been published 
hence the following experiment was designed to assess the cytoplasmic expression and periplasmic 
export of PaoA alone and with its partners and /or chaperone. PaoA was expressed with no signal 
peptide to assess the stability in the cytoplasm, with OmpASP to test the suitability for Sec export, 
with its own signal peptide as a reference and with the TorASP to test the improvement of the stability 
or export. These proteins were expressed in the W3110 WT strain and the cells were grown in LB at 
30°C and induced for 2 h (Table 2-3, condition 2) before fractionation using the PureFrac method 
(Appendix 4). 
 





Figure 5-1: Initial screen of the selected natural Tat substrates for suitability as a soluble partner 
The His-tagged natural Tat substrates AmiA, HyaA, PaoA, TorA and YcbK with their own signal peptides and an 
empty vector as a control, were expressed in the W3110 WT, MC4100 WT and MC4100 Tat-null strains. The 
cells were grown at 30°C and induced for 2 h prior to cell fractionation using the PureFrac method, into the 
cytoplasmic (C), insoluble (I) and periplasmic (P) fractions. A. The western-blots represent AmiA, HyaA, PaoA, 
TorA, YcbK and an empty vector detected by an anti-His antibody. The molecular weights of proteins 
before/after theoretical cleavage of their respective signal peptide are indicated in kDa on the left. B. The 
western-blots represent the LacI (38.7 kDa) and MBP (43.4/40.7 kDa) detected on the same samples by anti-
LacI and anti-MBP antibodies respectively. Molecular weight markers are indicated in kilodalton on the right 
(kDa). The figure is a composite image where the marker lanes reflects the approximate position of the 
molecular weights. 
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In Figure 5-2, PaoA was revealed to be unstable when expressed in the cytoplasm without a signal 
peptide. This further supports the conclusion from Neumann et al. (2009) and Correia et al. (2016) 
stating that cytoplasmic PaoA is unstable without its partners PaoBC (section 3.3.). Further evidence 
of instability is demonstrated with its own signal peptide (25.3 kDa) and TorASP (24.2 kDa), where no 
export was detected, and both presented expressed material in the insoluble fraction. The secondary 
bands observed in these insoluble fractions have an apparent larger size than the mature protein 
(see No SP lane) and hence, are likely to be degradation products. All the bands correlated to PaoA 
appeared to have migrated around 5 kDa higher than their expected sizes. This discrepancy was not 
observed in the work of Neumann et al. (2009) and Lee et al. (2014) but was consistently present in 
this work (Figure 5-1, Figure 5-2, Figure 5-3, Figure 5-4, Figure 5-5, Figure 5-7 and Figure 5-8). 
With OmpASP, the premature protein (22.1 kDa) is present in the periplasm which suggest 
cytoplasmic contamination. Indeed, Sec-exported proteins are released in the periplasm upon 
cleavage of their signal peptide by the LepB peptidase (section 1.3.1.). The protein may be targeted 
to the Sec pathway but cannot be fully processed, hence the signal peptide still present. This idea is 
supported by the presence of presence of mature protein in the insoluble fraction which could come 
from PaoA jammed into Sec. The wedging of Sec would compromise the cells which is supported by 
the two species of the periplasmic marker MBP found in all three fractions. Furthermore, the 
insoluble fraction also contains mature proteins (20.0 kDa) which were properly exported via Sec but 
were unstable in the periplasm due to the absence of its partners and therefore, formed inclusion 
bodies. Overall, the data suggests that the expression of PaoA in the cytoplasm or targeted to the 
periplasm via Sec or Tat, resulted in protein aggregation and therefore confirms that PaoA is not 
stable on its own. 
5.2.2. Co-expression of the partners and chaperone of PaoA 
Since the instability of PaoA alone was confirmed in the section 5.2.1., co-expressing the chaperone 
and its partners was tested to replicate the data of Neumann et al. (2009), Lee et al. (2014) and 
Correia et al. (2016) as validation. According to Lee et al. (2014), PaoA only requires its partners PaoB 
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and PaoC to form the PaoABC complex and export via Tat into the periplasm of E. coli. But according 
to Neumann et al. (2009), the cytoplasmic chaperone PaoD improves the complex stability and is 
required for its activity. Therefore, two new plasmids were created for polycistronic expression of 
PaoB and PaoC and of PaoB, PaoC and PaoD (Table 2-2). All three proteins were C-terminally V5-
tagged. These plasmids were designed to enable co-transformation with the pTTO plasmid 
expressing PaoA, and therefore, needed to have compatible origins of replication. Hence, the pBR 
replication origin was selected since it offers a copy number of 15-20 close to the 18-22 copies for 
p15A, the origin of replication of pTTO (Chang and Cohen, 1978). Additionally, the new plasmids 
contained an ampicillin resistance gene for specific selection.  
 
 
Figure 5-2: Assessing the stability of PaoA 
An empty vector ant the natural Tat substrate PaoA-His fused with no signal peptide (No SP), the signal peptide 
of OmpA (OmpASP), PaoA (PaoASP) or TorA (TorASP) were expressed in the W3110 WT strain. The cytoplasmic 
(C), insoluble (I) and periplasmic (P) fractions were obtained using the PureFrac method. The Western-blots 
represent the detection of PaoA-His, LacI and MBP using an anti-His, anti-LacI and anti-MBP antibodies 
respectively. The bands matching the sizes of the premature and mature proteins are indicated by orange and 
blue arrows respectively on the right side of the relevant blots. Molecular weight markers are indicated in 
kilodalton (kDa). The figure is a composite image where the marker lanes reflects the approximate position of 
the molecular weights. 
 
Due to their relatively similar sizes, PaoB-V5 (35.3 kDa) and PaoD-V5 (36.4 kDa) could not be 
distinguished on anti-V5 Western-blots and have therefore been annotated as PaoB-V5/PaoD-V5 
whilst PaoC-V5 (79.5 kDa) was well separated. PaoA-His, with and without its own signal peptide or 
an empty vector, was co-expressed with PaoBC or PaoBCD from two different plasmids to replicate 
the export reported by Lee et al. (2014). The W3110 strain were used and the cells were fractionated 
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according to the PureFrac method (Appendix 4) into the cytoplasmic, insoluble and periplasmic 
fractions.  
The results, represented in Figure 5-3, showed no significant improvement of PaoA-His export with 
or without PaoBC nor PaoBCD. PaoA still remained largely in the insoluble fraction with a small 
portion located soluble in the periplasm. However, PaoA was also detected in a similar amount in 
the periplasm when expressed without a signal peptide indicating that the periplasmic localisation 
of this proteins is not the result of translocation by Tat. Moreover, PaoC-V5 and PaoB-V5/PaoD-V5 
were detected in the periplasm when co-expressed with PaoA-His (no signal peptide) which was 
unexpected since neither of these proteins bear a signal peptide. Moreover, PaoB-V5/PaoD-V5 were 
again detected in the periplasm when co-expressed with the empty vector. No proteins are 
significantly detected in the periplasm without PaoD-V5, and the marker proteins are present in their 
respective fractions demonstrating the absence of cross-contamination (Figure 5-3). Therefore, 
PaoD-V5 somehow enabled export of PaoB-V5/PaoD-V5 and PaoC-V5 (only when co-expressed with 
PaoA-His) most likely through its chaperone activity. Furthermore, soluble cytoplasmic PaoC-V5 
appeared to be more stable when co-expressed with PaoD-V5 as published by Neumann et al. (2009). 
Altogether, PaoD-V5 is needed to increase the stability of PaoC-V5 and export of PaoC-V5 and PaoB-
V5/PaoD-V5 but its expression was still not enough to obtain export of the complex. 
5.2.3. Effect of the molybdenum cofactor on export of PaoABC 
In the section 5.2.2., PaoABCD were co-expressed in LB as described by Lee et al. (2014) but PaoA 
was not significantly exported. Otrelo-Cardoso et al. (2014) published that in the PaoABC complex, 
the PaoA subunit binds to two iron-sulphur clusters and the PaoC subunit binds to a molybdenum 
cofactor as identified by small-angle X-ray scattering. This data was later confirmed by Correia et al. 
(2016) by crystallography. Therefore, a new attempt to export PaoA was performed using the same 
conditions as the section 5.2.2. except that sodium molybdate and iron chloride were added to the 
culture medium to a final concentration of 1 mM (Neumann et al., 2009) and 0.5 mM respectively 
(section 2.3.1.). 




Figure 5-3: Co-expression of PaoA with its partners PaoBC(D) 
An empty vector as control (1), PaoA-His without a signal peptide (2) or PaoASP-PaoA-His (3) were expressed 
alone (Ø) or co-expressed with the partners PaoB-V5 and PaoC-V5 (PaoBC) or with the partners and the 
chaperone PaoD-V5 (PaoBCD) in the W3110 WT strain. The cells were grown on LB at 30°C, induced for 2 h at 
30°C and fractionated using the PureFrac method into the cytoplasmic (C), insoluble (I) and periplasmic (P) 
fractions. The Western-blots represents the detection of the PaoA-His, PaoC-V5 and PaoB-V5/PaoD-V5 using 
anti-His and anti-V5 antibodies respectively. Molecular weight markers are indicated in kilodalton on the right. 
The figure is a composite image where the marker lanes reflects the approximate position of the molecular 
weights. 
 
No significant improvement was observed on the export status of the PaoABCD proteins compared 
with the expression without the cofactors (Figure 5-4). The cofactors were thought to improve the 
stability of the complex but surprisingly, cytoplasmic PaoABCD were detected in a lower amount. 
The LacI and MBP purity control markers, however, indicated extraction of nearly all periplasmic 
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proteins, no contamination by cytoplasmic proteins and a high recovery of soluble cytoplasmic 
proteins.  
 
Figure 5-4: Effect of the molybdenum cofactor on export of PaoABC 
An empty vector as control (1), PaoA-His without a signal peptide (2) or PaoASP-PaoA-His (3) were expressed 
alone (Ø) or co-expressed with the partners PaoB-V5 and PaoC-V5 (PaoBC) or with the partners and the 
chaperone PaoD-V5 (PaoBCD) in the W3110 WT strain. The cells were grown on LB supplemented with FeCl3 
(0.5 mM) and Na2MoO4 (1 mM) at 30°C, induced for 2 h at 30°C and fractionated using the PureFrac method 
into the cytoplasmic (C), insoluble (I) and periplasmic (P) fractions. The Western-blots represents the detection 
of the PaoA-His, PaoC-V5, PaoB-V5/PaoD-V5, LacI and MBP using anti-His, anti-V5, anti-LacI an anti-MBP 
antibodies respectively. Molecular weight markers are indicated in kilodalton on the right. The figure is a 
composite image where the marker lanes reflects the approximate position of the molecular weights. 
 
5.2.4. Culture conditions and strains assessment for export of PaoABC 
In the next attempt to reproduce the data obtained by Lee et al. (2014), the divergence of strains 
and culture conditions were considered. The MC4100 WT strain was used by the Lee team while 
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W3110 WT was used in these experiments and even if no difference were observed in terms of 
protein localisation when studying the NTS between the two strains, they were compared to test 
whether the strain mattered. It is interesting to note here that the paoABCD operon is present in 
W3110 WT strain whereas it has been deleted in the MC4100 WT strain (section 3.3.). With respect 
to experimental methodology, very little information regarding the particular expression conditions 
used have been stated by Lee et al. (2014), and despite efforts to discern this information from 
attempted communication with the authors. However, experimental methods for the cytoplasmic 
expression of PaoABC have been provided by Neumann et al. (2009) and cited since by other authors. 
Therefore, the culture conditions referenced from the latter publication and subsequent citations 
thereof, are hence believed to be a 16 h induction at 22°C with 100 rpm agitation or a 2 h induction 
at 30°C with 220 rpm. Consequently, W3110 WT and MC4100 WT were compared for Tat export of 
PaoABC in three culture conditions: 2 and 4 h induction at 30°C with 220 rpm agitation (Table 2-3, 
condition 1 and 2) and 16 h incubation at 22°C with 100 rpm agitation. 
Figure 5-5 indicated no export of PaoA-His in the tested conditions meaning that the genetic 
differences between the strains have no impact on localisation of the protein of interest but also 
that these culture conditions do not influence protein localisation. Figure 5-6 revealed export of 
PaoC-V5 and PaoB-V5/PaoD-V5 after 2 h post-induction in W3110 WT but could be due to 
fractionation artefacts since LacI was observed contaminating the periplasmic fraction in this 
condition. Similarly, the large periplasmic band observed 16 h post-induction in the same strain with 
PaoABCD and signal peptide is non-conclusive because of the presence of contaminating LacI in the 
periplasm. With the other conditions, PaoC-V5 was detected in the cytoplasm only when co-
expressed with PaoD-V5 in the MC4100 WT strain whereas it was observed in the cytoplasm of 
W3110 WT in all conditions. This difference indicated that PaoD improved the solubility of PaoC 
through its chaperoning effect. The expression of endogenous PaoD might be the reason why this 
protein is not required in W3110 to solubilize PaoC-V5. The localisation of LacI in the other conditions 
than cited above and MBP validated the fractionation robustness. The upper and lower bands 
present in the insoluble fractions when expressing PaoASP-PaoA-His matched the premature and 
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mature proteins respectively and could be the results of signal peptide cleavage in inclusion bodies. 
Overall it seems that the PaoABC subunits are more stable in solution when PaoD was co-expressed 
but none of the growth conditions tested allowed export of PaoABC complex. 
 
 
Figure 5-5: Culture condition and strain screen to achieve export of PaoABC – Part I 
PaoA-His without a signal peptide or PaoASP-PaoA-His were co-expressed with the partners PaoB-V5 and PaoC-
V5 (PaoBC) or with the partners and the chaperone PaoD-V5 (PaoBCD) in the W3110 WT and MC4100 strains. 
The cells were grown on LB supplemented with FeCl3 (0.5 mM) and Na2MoO4 (1 mM) at 30°C, induced for 2 h 
or 4 h at 30°C or for 16 h at 22°C and fractionated using the PureFrac method into the cytoplasmic (C), insoluble 
(I) and periplasmic (P) fractions. The Western-blots represents the detection of PaoA-His using anti-His 
antibody. Molecular weight markers are indicated in kilodalton. The figure is a composite image where the 
marker lanes reflects the approximate position of the molecular weights. 
 




Figure 5-6: Culture condition and strain screen to achieve export of PaoABC – Part II 
The samples used in this figure are the same as the ones used in Figure 5-5. PaoA-His without a signal peptide 
or PaoASP-PaoA-His were co-expressed with the partners PaoB-V5 and PaoC-V5 (PaoBC) or with the partners 
and the chaperone PaoD-V5 (PaoBCD) in the W3110 WT and MC4100 strains. The cells were grown on LB 
supplemented with FeCl3 (0.5 mM) and Na2MoO4 (1 mM) at 30°C, induced for 2 h or 4 h at 30°C or for 16 h 
at 22°C and fractionated using the PureFrac method into the cytoplasmic (C), insoluble (I) and periplasmic (P) 
fractions. The Western-blots represents the detection of PaoC-V5, PaoB-V5/PaoD-V5, LacI and MBP using anti-
V5, anti-LacI and anti-MBP antibodies respectively. PageRuler Plus Prestained Protein Ladder (Life 
Technologies) and MagicMark™ (Life Technologies) molecular weight markers are indicated in kilodalton (kDa). 
The figure is a composite image where the marker lanes reflects the approximate position of the molecular 
weights. 
 
5.2.5. Single plasmid expression of PaoABCD in several growth conditions 
The strain and the tested growth conditions made no difference in terms of export of PaoA-His. 
Therefore, more culture conditions were evaluated with the objective of reproducing the data 
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published by Lee et al. (2014). Another difference from their work to this tentative remained in their 
expressions of the PaoABC proteins from a single plasmid whereas two plasmids were used here so 
far. Two plasmids induce more stresses upon the cell than a single plasmid due to the presence of 
two antibiotics to maintain the selection. Also, the copy numbers were slightly different from one 
plasmid to the other which might have led to differential expression of the PaoABC complex proteins 
creating an unbalanced ratio. Therefore, two new pTTO-based vectors were designed to co-express 
the PaoABC or the PaoABCD proteins from a single vector (Table 2-2). This modification was used as 
an opportunity to change the detection tag on PaoD for the HA tag to be able to distinguish it from 
the similar sized protein PaoB. To remain as close as possible from Lee et al. (2014) conditions, the 
culture media were supplemented with FeCl3 (0.5 mM) and Na2MoO4 (1 mM) in the growth 
conditions described in Table 2-3. 
Unfortunately, no export of PaoA-His was observed in the conditions tested which seem to have no 
impact on the protein localisation (Figure 5-7A). The same observations were made on PaoB-V5 
(Figure 5-7B) and PaoC-V5 showed signs of periplasmic export but no localisation difference between 
the conditions. PaoD-HA appears to be exported to the periplasm as well but at very low and 
fluctuating levels. The Figure 5-7C proves the robustness of the fractionation by the absence of LacI 
contaminating the periplasm and the full extraction of MBP into the periplasmic fraction. The only 
growth condition where changes observed in terms of protein localisation was the condition 7 with 
minimal media. This condition is shown once again to lead to poor recovery of soluble materials and 
a less robust fractionation purity. 
 





Figure 5-7: Expression of the PaoABCD proteins from a single plasmid in different growth conditions 
PaoASP-PaoA-His, PaoB-V5, PaoC-V5 and PaoD-HA were co-expressed in the MC4100 WT and Tat-null strain. 
The cells were grown in different conditions: induced (1) in LB for 2 h at 30°C, (2) in LB for 4 h at 30°C, (3) in LB 
for 2 h at 37°C, (4) in LB for 16 h at 18°C, (5) in 2x TY for 2 h at 30°C, (6) in fed-batch culture for 16 h at 18°C or 
(7) in minimal media for 16 h at 18°C. Each media was supplemented with FeCl3 (0.5 mM) and Na2MoO4 (1 
mM) and the cells were fractionated using the PureFrac method into the cytoplasmic (C), insoluble (I) and 
periplasmic (P) fractions. The Western-blots (WB) represent the detection of the PaoA-His (A), PaoC-V5, PaoB-
V5 and PaoD-V5 (B) and LacI and MBP (C) using anti-His, anti-V5, anti-HA, anti-LacI and anti-MBP antibodies 
respectively. PageRuler Plus Prestained Protein Ladder (Life Technologies) and MagicMark™ (Life 
Technologies) molecular weight markers are indicated in kilodalton (kDa). The figure is a composite image 
where the marker lanes reflects the approximate position of the molecular weights. 
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5.2.6. Influence of the induction level with IPTG on PaoA export 
The partners, chaperone, cofactors, strain, vector and growth condition were optimized for the 
export of PaoA but the results from Lee et al. (2014) are still not reproducible. The last parameter 
which wasn’t optimized is the induction level by ITPG. Indeed, the article specifies that IPTG was 
added at the time of induction to a working concentration of 100-500 µM. To appreciate the impact 
of IPTG level on the export of PaoA-His, a titration was performed using 0, 10, 100 and 500 µM of 
IPTG. The closest expression conditions were selected: in MC4100 WT, in LB supplemented with 
FeCl3 (0.5 mM) and Na2MoO4 (1 mM) at 30°C, induced for 16 h at 22°C, with the partners PaoB-V5 
and PaoC-V5, with the chaperone PaoD-HA and in a single vector. 
 
 
Figure 5-8: IPTG titration to export PaoA 
PaoASP-PaoA-His (1) or an empty vector (2) were co-expressed with the partners PaoB-V5 and PaoC-V5 and the 
chaperone PaoD-V5 in the MC4100 WT strain. The cells were grown on LB supplemented with FeCl3 (0.5 mM) 
and Na2MoO4 (1 mM) at 30°C, induced for 16 h at 22°C with 0, 10, 100 or 500 µM of IPTG and fractionated 
using the PureFrac method into the cytoplasmic (C), insoluble (I) and periplasmic (P) fractions. The Western-
blots represents the detection of the PaoA-His, PaoB-V5, PaoC-V5, PaoD-HA, LacI and MBP using anti-His, anti-
V5, anti-HA, anti-LacI and anti-MBP antibodies respectively. PageRuler Plus Prestained Protein Ladder (Life 
Technologies) and MagicMark™ (Life Technologies) molecular weight markers are indicated in kilodalton (kDa). 
The figure is a composite image where the marker lanes reflects the approximate position of the molecular 
weights. 
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The absence of PaoA-His in the periplasmic fractions (Figure 5-8) indicated that none of the IPTG 
levels tested influenced its export. PaoB-V5 and PaoD-HA were found only in the insoluble fractions 
whereas PaoC-V5 was found soluble in both the cytoplasm and the periplasm even if the majority 
was detected in the insoluble fraction irrespective of the level of induction. The large bands of 
PaoABCD proteins with 0 µM of IPTG were the results of the leakiness of the tac promoter controlling 
their expression (section 2.2.10.1.). 
 
5.3. Conclusion on the use of a natural Tat substrate as a soluble partner 
To use as a soluble partner enhancing both the folding of the protein of interest and the targeting to 
the Tat pathway, an NTS was initially considered to fuse to the recombinant protein. To identify 
suitable applicants, five NTS were selected using criteria such as size and oligomeric status. From the 
initial screen of these five proteins, only TorASP-TorA-His showed Tat export. The translocation failure 
from the other candidates could be due to missing partner(s) or chaperone(s) or yet unknown 
specific conditions. However, TorA is a large protein (94.5kDa) and only small size proteins could be 
fused to it for Tat export since protein with a maximum known of 70 Å can be processed by this 
pathway (Palmer and Berks, 2012). 
The NTS PaoA was investigated more thoroughly since its successful Tat export was reported (Lee et 
al., 2014). The authors demonstrated the requirement of the partners PaoB and PaoC to form the 
pre-export complex PaoABC. Also, Neumann et al. (2009) established the need to co-express the 
chaperone PaoD to stabilize PaoC and confer activity to the PaoABC complex. However, Lee et al. 
(2014) published export of PaoABC without co-expressing this chaperone.  
Here, the candidate was observed in its premature and mature forms in the insoluble fractions 
suggesting that the signal peptide can be cleaved off in inclusion bodies. Interestingly, with the dual 
plasmid expression, PaoB-V5/PaoD-V5 were observed in the periplasm when co-expressed with the 
empty vector or the leaderless PaoA-His controls while the fractionation purity was proven via the 
LacI and MBP blots (sections 5.2.2., 5.2.3. and 5.2.4.). Since this event was not reported using the 
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MC4100 strain (Figure 5-6), the export could be the result of association of plasmid-encoded PaoBC 
with endogenous PaoA in the W3110 strain since the MC4100 does not possess the pao operon 
(section 3.6.). In the end, efforts to replicate the exact conditions used to express periplasmic PaoABC 
were unsuccessful and thus the export data remains unreproducible. 
Overall, the initial candidates tested proved to be unsuitable to use as a soluble carrier protein in the 
fusion design. Optimisation of the expression conditions might lead to their export but the story of 
PaoA troubleshooting indicated no guaranteed success. Going back to the list of NTS (Appendix 1) 
could be an option but based on this work, it would likely be laborious, difficult to interpret data and 
very time consuming as little is known about these proteins. Therefore, it was a better use of time 
to look for a carrier from an alternative source. 
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6. EVALUATION OF REPORTER PROTEIN CANDIDATES 
6.1. Introduction to reporter proteins 
Many proteins are used as reporter for gene expression and regulation studies (Tsien, 1998, Thorne 
et al., 2010, Juers et al., 2012). Applications are wide and cover transcriptional control element 
testing, identification of interacting proteins, monitoring transfection efficiency, viral assays and 
mechanism of action, promotor region identification as well as many other processes (Schenborn 
and Groskreutz, 1999). Because the results are observed through the reporter protein’s activity, they 
need to provide a measurable readout which are available with different properties: enzymatic 
activity (e.g. β-galactosidase, PhoA, chloramphenicol acetyltransferase), fluorescence (e.g. GFP), 
luminescence (e.g. luciferase) (Miraglia et al., 2011, Juers et al., 2012).  
The experiment helps determinate the most qualified reporter protein for the desired task. β-
galactosidase is easy to assay, widely used for in-situ staining but is a large protein due to its 
homotetrameric form (465 kDa) and there can be endogenous activity (Schenborn and Groskreutz, 
1999). PhoA is a naturally exported enzyme in E. coli and its activity can be assessed with an easy 
and sensitive assay but potential endogenous background activity need to be subtracted (Schenborn 
and Groskreutz, 1999). GFP was derived in various colours which can report of several activities in a 
single assay. It is a highly stable protein and require no substrate (Schenborn and Groskreutz, 1999, 
Day and Davidson, 2009). Luciferases are enzymes capable of luminescence which can be measured 
through a fast and easy assay with a high sensitivity and a wide linear range but it requires a special 
equipment (luminometer) and the protein is labile (Schenborn and Groskreutz, 1999). 
Here, proteins of interest were thought to be first replaced by a reporter protein to validate the 
fusion design as describe in section 3.4. By selecting suitable NTS and reporter protein which both 
export specifically through the Tat pathway, the fusion of these two proteins should also lead to 
translocation. Here, the objective of the reporter protein was to inform onto the export of the fusion 
protein and its native folding through its activity. Selecting such reporter proteins is not trivial for E. 
coli due to their limited amount and to their lack of validity in different cellular compartments. 
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Nevertheless, β-galactosidase, PhoA, sfGFP and hGH were selected and their evaluation for Tat 
export and periplasmic activity are described in this chapter. 
 
6.2. β-galactosidase 
β-galactosidase is a natural cytoplasmic enzyme of E. coli, composed of 116 kDa monomers which 
form a 465 kDa homotetramer. It is encoded by the lacZ gene from the lacZYA operon (Juers et al., 
2012). A simple and quick activity assay is available whereby the amount of o-nitrophenol (yellow) 
released from the hydrolysis of o-nitrophenyl-β-D-galactopyranoside (ONPG) by β-galactosidase, can 
be measured. It does not possess any DSBs and therefore, does not require the use of a DSB enabling 
technology (section 1.4.1.). With respect to export in E. coli, β-galactosidase was reported to not 
export via Sec because of multiple regions within the amino acid sequences as well as N-terminal 
positively charged amino acids (Lee et al., 1989). Furthermore, Tat export has not been reported to 
date in E. coli. However, successful translocation of β-galactosidase through the Tat pathway has 
been demonstrated in Bacillus subtilis using the signal peptide of alkaline phosphatase D (Xia et al., 
2010, Ren et al., 2016). Due to the large size of the complex, it was believed that the monomeric 
components are primarily exported prior to assembly into active complexes after crossing the 
membrane. It is important to note here that the reason why this enzyme was secreted by Xia et al. 
(2010) and Ren et al. (2016) might lie in the different Tat mechanism of Bacillus subtilis as detailed 
in section 1.3.2.6., the different sequence of their engineered β-galactosidase, the use of the signal 
peptide from PhoD, the requirement of TatAd-Cd co-expression and that the alkaline phosphatase D 
is not found in Gram-negative bacteria. Thus, it is plausible to speculate that β-galactosidase at least 
in monomeric form, can be exported by the Tat machinery of E. coli and therefore would make it a 
suitable reporter partner to test.  
A preliminary experiment was performed to confirm the absence of β-galactosidase export via the 
Sec pathway. To this end, the E. coli lacZ gene was fused to a C-terminal His tag for detection (coding 
for LacZ-His) and fused to the N-terminal OmpASP for export. A cytoplasmic control with no signal 
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peptide was also used. During this experiment, Tat export was also investigated by N-terminal fusion 
of the five selected NTS signal peptides (AmiA, HyaA, PaoA, TorA and YcbK) described in Chapter 5. 
All proteins were expressed in the MC4100 WT and Tat-null strains in LB at 30°C with induction of 2 
h at 30°C (Table 2-3, condition 1) and fractionated using the PureFrac method (Appendix 4). As 
expected, cytoplasmic LacZ-His expressed well and was localised in the cytoplasm and insoluble 
fraction, presumably as inclusion bodies (Figure 6-1A). Moreover, the insoluble materials showed 
greater activity than the cytoplasmic proteins (Figure 6-1B). But, the latter observation is most likely 
to be the result of a higher concentration of enzyme in the insoluble fraction than in the cytoplasmic 
fraction as the activity presented is not specific to the amount of protein. The activity in the insoluble 
fraction is suspected to come from the inclusion bodies as they have been shown to be capable of 
retaining the proteins activities (García-Fruitós et al., 2005, de Groot and Ventura, 2006). 
Nevertheless, the fact that the enzyme is active reflected the stability of the monomers and the 
correct assembly into an active tetrameric form. 
Similarly, when fused to OmpASP and in support of published data (Lee et al., 1989), LacZ-His did not 
export via the Sec pathway. Surprisingly, no export via Tat was evident with respect to the five NTS 
signal peptides tested, in terms of periplasmic localisation or periplasmic activity. However, 
cytoplasmic stability appears to be signal peptide dependent where AmiASP, PaoASP and YcbKSP enable 
polypeptides to form stable β-galactosidase complexes in the cytoplasm whereas HyaASP and TorASP 
do not, irrespectively of the strain (Figure 6-1B). This difference showed that signal peptides do not 
perform in the same way and can lead to various extent of instability of the recombinant protein. 
The differences highlighted in the set of signal peptides in terms of net charge, hydrophobicity or 
length (Appendix 2), do not correlate to any behaviour given to β-galactosidase. The Western-blots 
revealed no signs of double bands which is a usual indication of signal peptide cleavage. But the 
western-blot resolution prevents from identifying them as premature or mature proteins. Since β-
galactosidase presented activity in the cytoplasm, N-terminal signal peptides do not interfere with 
the folding of the monomers nor with the assembly of the active tetramers. With the signal peptides, 
activity was also demonstrated in the insoluble fractions (Figure 6-1B). Since a similar activity of 
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about 50 kU/L was observed in the absence of a signal peptide, it is suspected to come from inclusion 




Figure 6-1: Cellular localisation and activity profiles of β-galactosidase expressed in E. coli 
His-tagged LacZ with no signal peptide (No SP) or fused with OmpASP, AmiASP, HyaASP, PaoASP, TorASP or YcbKSP 
were expressed in the MC4100 WT and Tat-null strains. The cells were harvested after 2h induction at 30°C 
and fractionated using the PureFrac method into the cytoplasmic (C), insoluble (I) and periplasmic (P) fractions. 
A. Western-blots represent the detection of LacZ-His, LacI and MBP using anti-His, anti-LacI and anti-MBP 
antibodies respectively. Molecular weight markers are indicated in kilodalton (kDa). The figure is a composite 
image where the marker lanes reflects the approximate position of the molecular weights. B. β-galactosidase 
activity assays were performed in triplicate and measured against a titration curve of a commercially available 
β-galactosidase as a standard. The background signals were eliminated by subtracting the activity value from 
the empty vector’s fractions to each corresponding fraction. The bars indicate the cytoplasmic (white), 
insoluble (grey) and periplasmic (black) fractions. 
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The localisation results are strengthened by the LacI and MBP controls which proved the purity of 
the periplasmic fraction while the periplasmic proteins are still extracted (Figure 6-1A). Overall, β-
galactosidase was not a suitable reporter protein because it showed no translocation via Tat likely 
because it folded into its tetrameric structure in the cytoplasm before reaching the Tat translocon 
preventing export. To better understand the expression, secretion and stability behaviours of β-
galactosidase with the different signal peptides, analysing the specific activity of the sample would 
have been more informative. However, since the reporter protein is only a tool in this study and β-
galactosidase presented no sign of Tat export, no further work was performed on this recombinant 
protein. 
 
6.3. Alkaline phosphatase 
PhoA is a zinc homodimeric enzyme (99 kDa) formed by two non-covalently linked subunits (49 kDa) 
(Fisher et al., 2008). This protein is naturally located in the periplasm of E. coli thanks to its Sec signal 
peptide (Michaelis et al., 1983). PhoA requires two DSB on each subunit to be correctly folded and 
active which explains its natural need for periplasmic export (Derman and Beckwith, 1991). These 
DSB were found to be required for Tat export and could be cytoplasmically formed by CyDisCo 
(Hatahet et al., 2010, Matos et al., 2014). In these cases, the signal peptide of TorA was used to direct 
the disulphide bonded PhoA to the periplasm via Tat making this protein a potential candidate as 
reporter protein. 
6.3.1. Evaluation of alkaline phosphatase as a reporter protein 
During the optimisation of the fractionation method (Chapter 4), TorASP-PhoA-His was shown to 
successfully export into the periplasm via the Tat pathway when co-expressed with CyDisCo. This 
experiment highlighted condition 4 (Table 2-3) as the culture parameters required for optimal Tat 
export: growth at 30°C and 4 h induction at 30°C. Following on from this discovery, the export of 
PhoA was tested with a restricted set of signal peptides in the presence or absence of CyDisCo for 
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DSB formation. The β-galactosidase case (section 6.2.) demonstrated that the use of signal peptides 
is not straight forward. It was therefore decided that selecting the signal peptides which have been 
already proven successful was a better approach. Hence, the signal peptide of TorA and PaoA were 
selected based on previous publications detailed in section 3.4. and 5.2. Additionally, TorASP-PhoA-
His and PaoASP-PhoA-His, PhoA-His with no signal peptide and the Sec signal peptide OmpASP 
completed the set.  
Expectedly, PhoA-His was Tat-dependently exported and active in the periplasmic fraction when 
fused to TorASP and co-expressed with CyDisCo (Figure 6-2, Figure 6-3). In this condition, proteins 
were also detected in the cytoplasm and insoluble fractions, the latter presumably from inclusion 
bodies or membrane-associated proteins. The activity assays indicated that the material in the 
insoluble fraction is indeed inactive and therefore not folded correctly, but also surprisingly, the 
proteins in the cytoplasmic fraction did not show activity (Figure 6-3). Although, a higher quantity of 
cytoplasmic proteins was detected with CyDisCo suggesting that this technology improved protein 
stability supposedly through its DSB formation activity. This indicated that although PhoA-His was 
expressed and stable in the cytoplasm via CyDisCo, it was not correctly folded presumably due to 
inability to form native DSBs or to form DSBs in the first place. This implied that PhoA was exported 
in an inactive state by Tat and gained its activity in the periplasm likely due to the action of the natural 
Dsb pathway (section 1.4.1.1.). 
Without CyDisCo, more soluble material was observed in the cytoplasm with PaoASP than with TorASP 
demonstrating that signal peptides can influence specifically the expression of recombinant proteins. 
With PaoASP, PhoA-His was exported to the periplasm via Tat but a small amount was observed in 
the periplasmic fraction of the Tat-null strain (Figure 6-2). This indicates that this export is not wholly 
Tat specific and correlates with data observed previously (Figure 4-6). It appears that two forms of 
periplasmic PhoA-His are present in the WT strain compared to Tat-null, which correlate with the 
molecular weights of the premature (PaoASP-PhoA-His, 53.7 kDa) and mature (PhoA-His, 48.0 kDa) 
proteins. Since a similar profile was observed with OmpASP and TorASP, it was evident that the lack of 
signal peptide cleavage by the signal peptidase (section 1.3.) was not related to the secretion 
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pathway. The cause may come from the accessibility and number of the signal peptidase not being 
optimal leading to the partial export of recombinant proteins by an unknown mechanism (discussed 
in section 1.3.4.). PhoA is a natural Sec substrate and when fused to the non-natural Sec signal 
peptide OmpASP was observed to give the highest export yield of active proteins as anticipated 
(Figure 6-2, Figure 6-3). Export was observed in both WT and Tat-null strains confirming translocation 
via the general and Tat-independent Sec pathway. Unexpectedly though, in the presence of CyDisCo, 
increased protein levels were detected in the cytoplasmic and insoluble fractions reinforcing the 
theory that this technology improves protein expression. However, cytoplasmic activity was not 
detected consistent with the hypothesis that DSBs may be shuffled into non-native states (Figure 
6-3). The exported PhoA was observed to be active in the WT strain, presumably due to post-
translocation modifications as discussed previously. 
In the absence of a signal peptide and CyDisCo, PhoA-His was only recovered in the insoluble fraction 
in a very faint band (Figure 6-2). This result was expected as PhoA expressed without signal peptide 
was reported to be inactive in the cytoplasm and to quickly degrade (Michaelis et al., 1983, Manoil 
and Beckwith, 1985, Hoffman and Wright, 1985). With CyDisCo, however, the recombinant protein 
appeared more stable in solution and remained in the cytoplasm as anticipated. Here again, no 
activity was observed from the cytoplasmic proteins. 
PhoA-His was exported specifically by the Tat pathway when fused to TorASP and co-expressed with 
CyDisCo and was active in the periplasm as published (Matos et al., 2014). However, a significant 
amount of proteins was found in the cytoplasm which were inactive (Figure 6-3). Unfortunately, 
Matos et al. (2014) did not analyse the cytoplasmic activity. This suggest that the Tat exported PhoA-
His became active in the periplasm after translocation. In this case, PhoA-His became sufficiently 
folded by the help of CyDisCo to be accepted by Tat but was still in a non-native conformation 
indicating a failure from the proofreading mechanism as discussed in section 1.3.2.5. Although 
CyDisCo worked partially, it provided the proteins to acquire a more stable conformation to be 
accepted by the proofreading system of Tat. 
 




Figure 6-2: Cellular localisation of PhoA expressed in E. coli 
An empty vector (1) or His-tagged PhoA with no signal peptide (2) or fused to OmpASP (3), TorASP (4) or PaoASP 
(5) were expressed without (-) or with CyDisCo (+) in the MC4100 WT and Tat-null strains. The cells were 
harvested after 4 h induction at 30°C and fractionated using the PureFrac method into the cytoplasmic (C), 
insoluble (I) and periplasmic (P) fractions. A. Western-blots of PhoA-His, Erv1p-cMyc, PDI-cMyc, LacI and MBP 
detected by anti-His, anti-cMyc, anti-LacI and anti-MBP antibodies respectively. PageRuler Plus Prestained 
Protein Ladder (Life Technologies) and MagicMark™ (Life Technologies) molecular weight markers are 
indicated in kilodalton (kDa). The figure is a composite image where the marker lanes reflects the approximate 
position of the molecular weights. 
 
Chapter 6 – Reporter proteins 
101 
 
Hatahet et al. (2010) found that purified PhoA was active in the cytoplasm of BL21(DE3) strain when 
co-expressed with Erv1p only. The difference with the present study could come from the co-
expression of isomerase PDI which could theoretically shuffle the DSB into a non-native 
conformation explaining the absence of activity from the cytoplasmic PhoA-His. Moreover, when co-
expressing TorASP-PhoA-His with Erv1p and DsbC, Matos et al. (2014) obtained active protein but did 
not specifically looked at the cytoplasmic activity. DsbC is an isomerase from E. coli (section 1.4.1.1.) 
whereas PDI is a human isomerase. The different origin between these enzymes could explain the 
still hypothetic shuffling issue. To test this hypothesis, the strain SHuffle was used since it expresses 
cytoplasmic DsbC (section 1.4.1.2. and Table 2-1). 
 
 
Figure 6-3: Activity of PhoA expressed in E. coli 
The samples collected in Figure 6-2 were also used to determinate the activity of PhoA. Briefly, an empty vector 
(1) or His-tagged PhoA with no signal peptide (2) or fused to OmpASP (3), TorASP (4) or PaoASP (5) were expressed 
without (-) or with CyDisCo (+) in the MC4100 WT and Tat-null strains. The cells were harvested after 4 h 
induction at 30°C and fractionated using the PureFrac method into the cytoplasmic (C), insoluble (I) and 
periplasmic (P) fractions. The PhoA activity assays were performed in triplicate and measured against a titration 
curve using a commercially available E. coli-derived PhoA as a standard. The background signals were 
eliminated by subtracting the activity value from the empty vector’s fractions to each corresponding fraction. 
The bars indicate the cytoplasmic (white), insoluble (grey) and periplasmic (black) fractions. 
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6.3.2. The impact of CyDisCo on the disulphide bonds of alkaline phosphatase 
In section 6.3.1., the Tat export of PhoA-His was observed with the Tat signal peptide TorASP and in 
the presence of the CyDisCo components Erv1p and PDI. However, disparities in PhoA activity 
demonstrated in the cytoplasmic and periplasmic fractions (Hatahet et al., 2010, Matos et al., 2014) 
suggest that CyDisCo is not responsible for the active state of these proteins. To test the origin of 
the cytoplasmic activity of PhoA-His, the strain SHuffle was used since it expresses cytoplasmic DsbC 
(section 1.4.1.2. and Table 2-3). The proteins locations were validated with the LacI and MBP controls 
as well as PDI-cMyc and Erv1p-cMyc located in their respective fractions (Figure 6-4). 
Effective expression of cytoplasmically targeted PhoA-His (no signal peptide) required co-expression 
of either cytoplasmic Erv1p and PDI (CyDisCo) or DsbC (SHuffle, Figure 6-4). The WT MC4100 strain 
showed no soluble cytoplasmic PhoA-his and only traces of insoluble protein. In all situations, no 
meaningful PhoA activity was detected (Figure 6-5). Hence, neither CyDisCo nor cytoplasmic DsbC 
appear to achieve the properties claimed for them. 
The Sec signal peptide of OmpA directs expressed PhoA-His to the periplasm and the periplasmic 
material has high levels (3.8-7.3 kU/L) of enzymatic activity (Figure 6-4, Figure 6-5). These results 
were expected since PhoA is a natural Sec substrate of E. coli. Moreover, the lower bands present 
on anti-His do not correlate to the mature protein since OmpASP weights 2.1 kDa, but are likely to be 
truncation products. 
With TorASP, no periplasmic export of PhoA-His was achieved in the WT cells without CyDisCo (Figure 
6-4). However, co-expression of cytoplasmic DsbC or CyDisCo or DsbC and CyDisCo resulted in 
detectable periplasmic PhoA-His, with activity being seen in all three situations. For the first time, 
soluble cytoplasmic enzyme activity was detected in the SHuffle cells (Figure 6-5), but it was not 
established whether this was related to the premature or the mature forms of the protein. This 
suggest that conferring activity in the cytoplasm is signal peptide dependent. To understand how the 
presence of TorASP led to PhoA-His activity in the SHuffle strain without CyDisCo, a screen of signal 
peptides and TorASP mutants might shed light on the impact of the signal peptide on DsbC’s activity. 
 




Figure 6-4: Effect of the cytoplasmically expressed disulphide isomerase DsbC on the localisation of PhoA 
An empty vector (1) or His-tagged PhoA with no signal peptide (2) or fused to OmpASP (3) or TorASP (4) were 
expressed without (-) or with CyDisCo (+) in the MC4100 WT and SHuffle strains. The cells were harvested after 
4 h induction at 30°C and fractionated using the PureFrac method into the cytoplasmic (C), insoluble (I) and 
periplasmic (P) fractions. A. Western-blots of PhoA-His, PDI-cMyc, Erv1p-cMyc, LacI and MBP were detected 
by anti-His, anti-cMyc, anti-LacI and anti-MBP antibodies respectively. Molecular weight markers are indicated 
in kilodalton (kDa). The figure is a composite image where the marker lanes reflects the approximate position 
of the molecular weights. 
 




Figure 6-5: Effect of the cytoplasmically expressed disulphide isomerase DsbC on the activity of PhoA 
The samples collected in Figure 6-4 were also used to determinate the activity of PhoA. Briefly, an empty vector 
(1) or His-tagged PhoA with no signal peptide (2) or fused to OmpASP (3) or TorASP (4) were expressed without 
(-) or with CyDisCo (+) in the MC4100 WT and SHuffle strains. The cells were harvested after 4 h induction at 
30°C and fractionated using the PureFrac method into the cytoplasmic (C), insoluble (I) and periplasmic (P) 
fractions. The PhoA activity assays were performed in triplicate and measured against a titration curve using a 
commercially available E. coli-derived PhoA as a standard. The background signals were eliminated by 
subtracting the activity value from the empty vector’s fractions to each corresponding fraction. The bars 
indicate the cytoplasmic (white), insoluble (grey) and periplasmic (black) fractions. 
 
6.4. Superfolder green fluorescent protein 
GFP is a widely used reporter protein due to its fluorescence activity which can be observed in living 
cells for gene expression (Chalfie et al., 1994) and protein localisation studies (Feilmeier et al., 2000). 
GFP was first identified from the jellyfish Aequorea Victoria and its exceptional properties quickly 
raised interest (Prasher et al., 1992). This protein has a unique β-barrel structure which allows it to 
emit a green light when excited at the appropriate wavelength (section 2.5.2.3.). It has no DSB, is 
monomeric and has a size of 26.9 kDa. In E. coli, GFP was reported to export via the Sec pathway but 
remained inactive in the periplasm whereas the cytoplasmic protein was active (Feilmeier et al., 
2000). However, successful Tat export leading to active periplasmic GFP has been reported in E. coli 
and optimized to up to 1.1 g/L of active protein purified from the periplasm after fermentation 
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(Matos et al., 2012). Furthermore, a GFP variant was created, named superfolder green fluorescent 
protein (sfGFP), to improve the solubility of the recombinant partner in reporter fusions thanks to 
six mutations (Pedelacq et al., 2006). This sfGFP mutant was exported to the periplasm via the Sec 
pathway (Aronson et al., 2011, Dinh and Bernhardt, 2011) but no report of Tat translocation has 
been published. However, Zhang et al. (2017) described the “auto-secretion” phenomenon of sfGFP 
where the protein localised in the cytoplasm, periplasm, outer membrane and extracellular medium 
without a signal peptide in E. coli (detailed in section 1.3.4.). The experiment was pursued here to 
establish the reproducibility of the data and the suitability of the sfGFP as a reporter protein. 
In a preliminary experiment to investigate whether sfGFP can be stably produced in our expression 
system, His-tagged sfGFP were built with no signal peptide or in fusion with OmpASP, PaoASP or TorASP. 
They were expressed in the MC4100 WT and Tat-null strains at 30°C, induced for 2 or 4 h at 30°C. 
They were immediately observed under a fluorescence microscope (section 2.6.) and these cells 
were fractionated using the PureFrac method including the media fraction. 
sfGFP-His with no signal peptide, was observed in all cellular fractions including the periplasm 
irrespective of strain, in support of published data (Figure 6-6) (Zhang et al., 2017). The exported 
protein was found to be active whereas the cytoplasmic fraction was surprisingly not active for 
reasons unknown (Figure 6-7). Fluorescence microscopy of induced cells at 2 h and 4 h showed no 
distinctive features to differentiate between cytoplasmic and exported sfGFP (Figure 6-8). The only 
difference observed was morphological in relation to WT and Tat-null strains where Tat-null was 
observed in chains consistent with published data (section 3.6.). When the signal peptides OmpASP 
or PaoASP targeting the respective Sec and Tat export pathways was fused at the N-termini of sfGFP-
His, a similar result to sfGFP-His with no signal peptide was observed with respect to protein 
localisation, activity and fluorescence as expected for OmpASP-sfGFP-His (Dinh and Bernhardt, 2011, 
Aronson et al., 2011). The exception is with OmpASP, where sfGFP-His was also found active in the 
media fraction after 4h. However, LacI, a cytoplasmic host marker was also present in the periplasmic 
and media fractions indicating cellular lysis. With PaoASP, the bands corresponding to the mature size 
of sfGFP-His in the periplasmic fractions are significantly less intense in the Tat-null than in the WT 
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strains. This suggests that these proteins were exported by Tat which allowed the signal peptides to 
be processed. The bands corresponding to the premature size in the periplasmic fractions were most 
likely exported by the same unknown mechanism which treated the signal peptide-less version of 
sfGFP-His. The same observation goes with OmpASP where a band matching the size of the premature 
proteins were located in the periplasmic fractions. 
 
 
Figure 6-6: Western-blot analysis for the evaluation o sfGFP as a reporter 
An empty vector (1) or His-tagged sfGFP with no signal peptide (No SP) (2) or fused to OmpASP (3), PaoASP (4) 
or TorASP (5) were expressed in the MC4100 WT and Tat-null strains. The cells were harvested after 2 and 4 h 
induction at 30°C and fractionated using the PureFrac method into the cytoplasmic (C), insoluble (I), 
periplasmic (P) and media (M) fractions. Western-blots represent the detection of PhoA-His, LacI and MBP 
using anti-His, anti-LacI and anti-MBP antibodies respectively. The arrows on the right indicate the mature 
(black) and premature (grey) forms of the proteins. Molecular weight markers are indicated in kilodalton (kDa). 
The figure is a composite image where the marker lanes reflects the approximate position of the molecular 
weights. 
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Conversely with TorASP, a different behaviour was observed. sfGFP-His was not exported by the 
unknown mechanism when fused to TorASP since no band matching the premature size was detected 
in the periplasmic fractions (Figure 6-6, Table 6-1). However, regarding the mature size bands, active 
sfGFP-His was found in the periplasmic fraction of the WT cells and a considerably lower amount of 
protein was detected in the Tat-null strain but appeared to be active (Figure 6-6, Figure 6-7). These 
observations revealed that most of the periplasmic proteins were exported via the Tat pathway but 
the remaining exported proteins most likely came as cytoplasmic mature proteins through the 
unknown mechanism. Moreover, the fluorescence was localised as discrete bodies around the 
cellular periphery and in particular, at the poles (Figure 6-8). Polar localisation of other Tat-targeted 
GFP variants were reported before with a periplasmic distribution of the fluorescence but a stronger 
signal at the poles (Santini et al., 2001, Ize et al., 2002). The localisation of Tat substrates at the pole 
of E. coli was speculated to be due to the thicker periplasmic space at the cell poles (Bernhardt and 
De Boer, 2003) or due to the polar localisation of the majority of the Tat translocase components 
(Berthelmann and Bruser, 2004, Ray et al., 2005). 
 
Table 6-1: sfGFP protein sizes 
Sizes before (premature) and after (mature) signal peptide cleavage of the sfGFP proteins expressed in Figure 
6-6, Figure 6-7 and Figure 6-8. 
Number 
Construct Size (kDa) 
Signal peptide Gene Premature Mature 
2 No SP sfGFP-His N/A 27.5 
3 OmpASP sfGFP-His 29.6 27.5 
4 PaoASP sfGFP-His 33.2 27.5 
5 TorASP sfGFP-His 32.2 27.5 
 
Pedelacq et al. (2006) observed a loss of GFP fluorescence due to the sonication used to lyse the 
whole cells which could explain the absence of activity in the cytoplasmic and insoluble fractions in 
the present study since the fractionation method employed on the periplasmic-extracted cells 
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involved sonication (Appendix 4). Overall, sfGFP is not a valid candidate to use as a reporter protein 
as it was confirmed to export via an unknown mechanism which did not appear to involve Tat. 
 
Figure 6-7: Activity analysis for the evaluation of sfGFP as a reporter 
The activity assays were performed on the samples obtained as detailed in Figure 6-6 were in triplicate and 
represented the relative fluorescence compared to the empty vector. The bars indicate the cytoplasmic 
(white), insoluble (light grey), periplasmic (dark grey) and media (black) fractions. 
 
6.5. Human growth hormone 
hGH is a 24.9 kDa secreted protein possessing two DSB and is monomeric in solution but dimerizes 
upon binding to its receptor (Li, 1982, Walsh et al., 2003). This protein was historically produced in 
the cytoplasm of E. coli. However, this method was limited by the accumulation of the difficult to 
resolubilise inclusion bodies, a refolding step necessary to form the DSB and the remaining N-
terminal methionine increased immunogenicity in patients treated with this hormone (Becker and 
Hsiung, 1986, Glasbrenner, 1986, Soares et al., 2003). To counter these issues, hGH was produced 
in the periplasm of the bacteria where the DSB formed thanks to the Dsb pathway (section 1.4.1.1.) 
and hence, less inclusion bodies were observed (Gray et al., 1985). Sec export of hGH was reported 
with OmpASP to 10-15 mg/L (Becker and Hsiung, 1986). More recently, translocation of this protein 
was published via the Tat pathway in E. coli when fused to TorASP (Alanen et al., 2015). Interestingly, 
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the authors demonstrated that hGH was translocated even without its DSB suggesting that the apo-
protein adopted a near-native conformation accepted by the Tat proofreading mechanism (Bewley 
et al., 1969, Youngman et al., 1995). Alanen et al. (2015) also demonstrated that hGH acquired its 
DSB in the periplasm after translocation but that the Tat transport event was not impaired if the DSB 
were cytoplasmically formed. This protein is therefore an interesting candidate as a reporter protein 
for Tat expression. 
 
 
Figure 6-8: Microscopic observations of E. coli expressing sfGFP 
An empty vector (1) or His-tagged sfGFP with no signal peptide (2) or fused to OmpASP (3), PaoASP (4) or TorASP 
(5) were expressed in the MC4100 WT and Tat-null strains. The cells were harvested after 2 and 4 h induction 
at 30°C and immediately observed under a fluorescence microscope with a 1000-fold magnification. The scale 
bar is 4 µm. 
 
To test its suitability, the gene coding for the hGH protein (gh1) was cloned into pTTO without its 
natural 26 bp mammalian signal peptide and with a C-terminal His tag (Table 2-2). Variants were 
then built to bear the N-terminal signal peptides OmpASP or TorASP. These three plasmids including 
an empty vector as the negative control were expressed in MC4100 WT and Tat-null strains, with 
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and without CyDisCo. After 2 h induction at 30°C (Table 2-3, condition 1), the cells were fractionated 
according to the PureFrac protocol into the cytoplasmic, insoluble and periplasmic fractions (Figure 
6-9). Surprisingly, hGH-His with no signal peptide was detected in the periplasm of all conditions with 
an apparent higher amount with CyDisCo. This suggested the involvement of an unknown transport 
mechanism since no N-terminal export signal peptide was identified with the prediction software 
SignalP (Nielsen, 2017a). No previous report of this hGH “auto-export” was found and this 
phenomenon was not artefactual since the localisation of the Erv1p, PDI, LacI and MBP controls 
indicated correct fractionation. A parallel can be made with the “auto-secretion” of sfGFP (section 
6.4.) but no evidence so far suggested that both proteins were transported via the same mechanism. 
This discovery is worth investigating further to see if a protein of interest can be piggybacked into 
the periplasm when fused to hGH-His but was outside the scope of this project. Furthermore, the 
candidate protein appeared in the periplasmic fractions in all tested conditions with OmpASP 
indicating Sec export was not influenced by CyDisCo. But with this signal peptide, fraction impurities 
were observed where the periplasm was contaminated by the cytoplasmic PDI, Erv1p and LacI 
proteins. The fact that such cross-contamination was not observed in any other condition led to the 
conclusion that the expression of hGH-His with OmpASP compromised the cell envelope which was 
consequently more sensitive to the fractionation. The periplasmic hGH-His could hence come from 
a compromised envelope, the unknown mechanism observed with the no signal peptide variant or 
Sec export. With TorASP, hGH-His were detected in the periplasmic fractions of the WT but not the 
Tat-null strains irrespective of CyDisCo confirming that hGH-His can be Tat-dependently exported 
even when the DSB are not formed prior to translocation Overall, Tat-specific export was proven 
thanks to TorASP making this protein a suitable reporter protein for Tat export and promising 
transport alternative to control with no signal peptide. 
 




Figure 6-9: Tat-independent and dependent exports of human growth hormone 
An empty vector (1) or His-tagged hGH with no signal peptide (2) or fused to OmpASP (3) or TorASP (4) were 
expressed in the MC4100 WT and Tat-null strains. The cells were harvested after 2 h induction at 30°C and 
fractionated using the PureFrac method into the cytoplasmic (C), insoluble (I), periplasmic (P) and media (M) 
fractions. The Western-blots represents the detection of hGH-His, LacI and MBP using anti-His, anti-LacI and 
anti-MBP antibodies respectively. PageRuler Plus Prestained Protein Ladder (Life Technologies) and 
MagicMark™ (Life Technologies) molecular weight markers are indicated in kilodalton (kDa). The figure is a 
composite image where the marker lanes reflects the approximate position of the molecular weights. 
 
6.6. Conclusion on valid reporter proteins 
Out of the four proteins tested, only two came out as valid reporter proteins. PhoA was exported 
specifically via Tat using when fused to the signal peptide of TorA and found active in the periplasm 
but only when co-expressed with CyDisCo. It appeared that the homodimer form of PhoA was not 
an issue for translocation and PhoA was considered to be exported via Tat as a monomer since all 
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periplasmic PhoA appeared to be leaderless. The second valid candidate was hGH which has shown 
Tat-dependant export with TorASP. Interest was also raised from a different feature: hGH was 
observed to export without the need for a signal peptide. Both characteristics made this protein an 
interesting candidate for periplasmic secretion. On the other hand, β-galactosidase and sfGFP were 
also considered but not selected. The former showed no evidence of export with any of the tested 
signal peptides. In the case of the Tat pathway, β-galactosidase was believed to assemble into a 
multimeric structure prior to reaching the translocase. However, including the signal peptide of 
alkaline phosphatase D from Bacillus subtilis in this screen would have led to a more complete set of 
data since it was reported to allow export of β-galactosidase in this strain by Xia et al. (2010) and Ren 
et al. (2016). The sfGFP protein demonstrated a Tat-specific export profile with the TorASP but only 
at a specific harvest time. This protein, similarly to hGH, presented periplasmic export even without 
a signal peptide and evidence suggested that sfGFP fused to OmpASP and PaoASP was partially 
exported independently to the Sec and Tat pathway respectively. Moreover, this protein has already 
been assessed to carry proteins of interest across the inner membrane of E. coli (Zhang et al., 2017). 
To summarize, PhoA and hGH were selected to use as reporter protein in the fusion strategy. 
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7. EVALUATION OF NON-NTS PROTEINS AS CARRIER TO FACILITATE 
TAT EXPORT 
7.1. Modifying the strategy by using PhoA and hGH as soluble carrier 
proteins 
The original hypothesis was to investigate whether an NTS could be used as a fusion partner to 
facilitate the correct folding and subsequent export of a C-terminally linked reporter or recombinant 
protein into the periplasm via the Tat pathway (Chapter 3). As described in Chapter 5, the five initial 
NTS candidates selected for study were either poorly expressed and/or could not be exported into 
the periplasm via Tat when linked to their own signal. Furthermore, strain selection, optimisation of 
growth conditions, cofactors addition, co-expression of partners/chaperone, expression vector and 
induction level did not improve export efficiency of the NTS in the case of PaoA (section 5.2.) and 
thereby highlighted that this process is low throughput, time consuming and does not guarantee 
success. Successful Tat export of PaoA was reported (Hatahet et al., 2010, Matos et al., 2014) but 
this published data was found to be not reproducible in the present study despite exploring several 
avenues for optimisation. The remaining NTS of E. coli mentioned in Appendix 1, did not pass the 
selection criteria. Gathering the fundamental information necessary to export these NTS via Tat via 
informative deductions and technical evidence would require more time than allocated for this 
project.  
On the other hand, experiments to select potential reporter proteins identified two proteins, PhoA 
and hGH that both presented properties that would inadvertently be considered as good 
characteristics of a potential soluble partner (Chapter 6). Thus, the initial hypothesis was modified 
to utilize these reporter proteins as the soluble partner instead of an NTS. Both PhoA and hGH 
proteins are relatively small (49.4 and 24.9 kDa respectively), allowing the fusion of a broad range of 
recombinant protein of varying size with limits for export. Moreover, both were specifically exported 
as soluble proteins via Tat thanks to the TorASP and in the case of PhoA, also as active proteins. 
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Indeed, PhoA and hGH were detected in uncontaminated periplasmic fractions in WT strain when 
fused to TorASP while no export was observed in the Tat-null strain (section 6.3. and 6.5.).  
Thus, design strategy was revised to export proteins of interest in fusion with PhoA or hGH as the 
soluble partner bearing the signal peptide of TorA. First, the validated soluble partners were fused 
to one another (hGH-PhoA and PhoA-hGH) as positive controls to test whether the independently-
exported proteins can be translocated as a fusion as well as the fusion design itself. Then, relevant 
proteins of interest from UCB Celltech were applied: the human fatty acid binding protein 4 (FABP4) 
and two camelid-derived single domain VHH antibodies. 
 
7.2. Evaluation of the fusion strategy 
7.2.1. Design of the fusion proteins 
The ability of PhoA (with CyDisCo) and hGH to be exported by Tat, as revealed by the lack of export 
with the Tat-null strain, indicated their capability to fold in the cytoplasm in a state accepted by the 
Tat proofreading mechanism (Chapter 6). Preliminary experiments were performed to evaluate 
whether these proteins could be exported when fused to one another as a control for the new fusion 
strategy. However, although PhoA was found to strictly require a signal peptide for export, hGH 
export is complicated by the observation that it was also translocated without a leader sequence by 
an unknown mechanism. Selected recombinant proteins were then used with hGH and PhoA as the 
soluble carrier to test Tat export of these fusions. The design of the fusion constructs can be found 
in Figure 7-1. 
7.2.2. Export capability of PhoA using hGH as a soluble partner 
The first fusion construct expressed was PhoA fused to hGH as the carrier protein as described in 
Figure 7-1, part 1. Ideally, the PhoA-hGH fusion (Figure 7-1, part 2) would also be expressed in parallel 
along with hGH-His and PhoA-His alone to validate export of the fusion partners individually. 
Unfortunately, the number of samples exceeded the maximum which can be handled in one run. 
Therefore, the fusions were expressed in separate experiments with their respective C-terminal 
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protein as export control. In this section, hGH-PhoA and PhoA-His with no signal peptide or fused 
with OmpASP or TorASP were expressed in MC4100 WT, with and without CyDisCo, at 30°C and 
induced for 2 h at the same temperature (Table 2-3, condition 1). The harvested cells were 
fractionated using the PureFrac method into cytoplasmic, insoluble and periplasmic fractions and 
analysed by reducing SDS-PAGE and immunological detected with relevant antibodies. The shifts in 
the band sizes between in conditions 2, 3 and 4 (Figure 7-2) are due to the theorical molecular weight 
sizes of the protein with no signal peptide, OmpASP (2.1 kDa) and TorASP (4.2 kDa) respectively 
(Appendix 7). With respect to detection of the exported proteins with anti-His and anti-FLAG, the 
pre-mature and mature proteins are indicated where possible. The latter indicates cleavage of the 
signal peptide by presumably the inner-membrane located signal peptidase, LepB. The presence of 
truncated species with both signal peptides in the cytoplasmic and periplasmic fractions is also 
notable in this data and will be discussed in section 7.5. 
 
 
Figure 7-1: Design of the fusion constructs following the new hypothesis 
The constructs were designed from N-terminal to C-terminal as follows: signal peptide (SP), either hGH or PhoA 
as soluble carrier protein, FLAG tag, TEV cleavage site, short flexible linker (FL), recombinant protein and His 
tag. The recombinant proteins tested were either PhoA, hGH, FABP4, VHH1 or VHH2. 
 
The localisation (Figure 7-2, panel A) and activity of PhoA-His (Figure 7-3, panel A) were consistent 
with previous PhoA-His data as reported in section 6.3.1. Briefly, PhoA-His with no signal peptide was 
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degraded without CyDisCo whereas it was stabilized in the presence of CyDisCo (Figure 7-2, panel A, 
His, 2) although inactive (Figure 7-3, panel A), presumably through incorrect DSB formation. The 
protein localisation was validated since the Erv1p, PDI, LacI and MBP control proteins were all 
detected in their respective fractions (Appendix 6). 
Effective expression and translocation of PhoA-His was achieved in fusion to OmpASP (Figure 7-2, 
panel A, 3) suggesting that the signal peptide improved the expression of this protein. Indeed, Singh 
et al. (2013) demonstrated that signal peptides modulate the stability of recombinant proteins in a 
sequence-dependent manner. Moreover, the SecB chaperone binds to the signal peptide and the 
emerging polypeptide from the ribosome (section 1.3.1.2.). Thus, this chaperone prevents 
conformational changes through its antifolding activity (Huang et al., 2016) and ultimately leads to 
its rapid export via Sec. In addition, chaperones such as GroEL, DnaK and trigger factor (TF), were 
reported to be recruited by SecB and involved in OmpA preprotein processing by direct interaction, 
thus contributing to the antifolding activity and targeting of the preprotein to the inner membrane 
(Castanie-Cornet et al., 2014). OmpASP-PhoA-His was exported irrespective of CyDisCo and was active 
in the periplasm (Figure 7-2, panel A, 3; Figure 7-3, 3). As PhoA is a natural Sec substrate of E. coli, 
all soluble proteins were expected to be exported and here, the presence of cytoplasmic proteins 
suggests that the Sec pathway is saturated presumably due to overexpression of this protein. PhoA 
activity was only detected in the periplasmic fractions, indicating correct folding of the protein 
exported via the Sec pathway (Figure 7-3, panel B, 3). 
With TorASP, PhoA-His was exported only when co-expressed with CyDisCo and was also active in the 
periplasm (Figure 7-2, panel A, His, 4 and Figure 7-3, panel A, 4). However, this protein was not active 
in the cytoplasmic fraction and suggests that PhoA was exported via Tat in a folded but non-native 
state and acquired its native conformation in the periplasm (detailed in section 6.3.). This strongly 
suggests that CyDisCo did not form cytoplasmic DSBs or that they were in a non-native state. 
With respect to the hGH-PhoA fusion protein, without a signal peptide, this protein was detected in 
the periplasm by both anti-His and anti-FLAG (Figure 7-2, panel B, His and FLAG, 2). This was not 
wholly unexpected as previously it was shown that without a signal peptide, hGH was carried across 
Chapter 7 – Fusions 
117 
 
the inner membrane by an unknown mechanism (section 6.5.). The protein was translocated into 
the periplasm irrespective of CyDisCo, although CyDisCo did improve overall expression and amplify 
export (Figure 7-2, panel B, His, 2). The marker proteins LacI and MBP were detected in their 
respective fractions validating fraction purity (Appendix 6). Moreover, PhoA, in the C-terminal region 
of the fusion, presented no activity in any fraction (Figure 7-3, panel B). This suggests that although 
the full-length fusion protein adopted a stable conformation, this was not native for PhoA. 
 
 
Figure 7-2: Localisation of hGH fusions with PhoA as the protein of interest 
His-tagged PhoA or the fusion hGH-PhoA with no signal peptide (2) or fused with OmpASP (3) or TorASP (4) as 
well as an empty vector (1) were expressed with (+) and without (-) CyDisCo in the MC4100 WT strain. The cells 
were harvested after 2h induction at 30°C and fractionated using the PureFrac method into the cytoplasmic 
(C), insoluble (I) and periplasmic (P) fractions. The Western-blots represent the detection of His-tagged and 
FLAG-tagged proteins using anti-His and anti-FLAG antibodies respectively. Arrows indicate the bands of 
premature (orange) and mature proteins (blue) when corresponding to the theoretical molecular weight size 
(Appendix 7). Green arrows indicate full-length protein where the presence of the absence of the signal 
peptide is not discernible. PageRuler Plus Prestained Protein Ladder (Life Technologies) and MagicMark™ (Life 
Technologies) molecular weight markers are indicated in kilodalton (kDa). The figure is a composite image 
where the marker lanes reflects the approximate position of the molecular weights. 
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With fusion to the Sec signal peptide of OmpA, hGH-PhoA was detected in all fractions with both 
anti-His and anti-FLAG, indicating export irrespective of CyDisCo (Figure 7-2, panel B, 3). Though as 
the leaderless variant of this protein was shown to export via an unknown mechanism, it is difficult 
to confirm whether export was solely via Sec. Indeed, identifying exported premature and mature 
proteins is challenging due to the presence of truncated species and the large size of the fusion 
(Figure 7-2, panel B, 3; Appendix 7). Interestingly, the periplasmic proteins showed some PhoA 
activity (Figure 7-3, panel B, 3) although the levels were significantly lower (> 5-10 fold) compared 
to the corresponding independently expressed PhoA-His controls. However, due to a range of 
truncated species detected by anti-FLAG in the periplasmic fraction, it is difficult to confirm whether 
PhoA activity can be attributed to correctly folded, full-length proteins, or to truncated species that 
contain an intact PhoA (Figure 7-2, panel B, 3). The presence of periplasmic preproteins suggest 
cytoplasmic cross-contamination, however this is unlikely as the control proteins LacI and MBP were 
only found in their natural locations, although Erv1p and PDI were not (Appendix 6). The periplasmic 
localisation of the CyDisCo components when co-expressed with an OmpASP-recombinant protein 
has been a recurring and consistent observation throughout this study and will be discussed further 
in section 9.4. (Appendix 6). 
In contrast, expression of this fusion with TorASP led to the periplasmic localisation of full-length 
protein when co-expressed with CyDisCo (Figure 7-2, panel B, 4; Appendix 7). Due to the close 
molecular weights of pre-(87.9 kDa) and mature (84.7 kDa) proteins, it is difficult to ascertain the 
quality of the periplasmic bands (Appendix 7). Whilst in the cytoplasm, the truncated products are 
indicative of a lower stability, and only the full-length protein is exported. However, although the 
latter appears to be stable and fully intact, it is completely inactive, indicating a non-native 
conformation (Figure 7-3, panel B, 4). Without CyDisCo, the full-length protein was detected in the 
periplasmic and, interestingly, also in the cytoplasmic fraction (Figure 7-2, panel B, 4). The absence 
of truncated species in the cytoplasm contrasts starkly with co-expression of this fusion with CyDisCo. 
This suggests that the presence of these chaperones resulted in the reiteration of many and often 
unstable conformations, destined presumably for proteolytic cleavage. However, all proteins were 
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also inactive and point to non-native conformations (Figure 7-4, panel B, 4). To confirm whether the 
pathway used during this translocation event was Tat or the same unknown pathway as with the 
leader-less version, a test could be conducted comparing export in the WT versus the Tat-null strains. 
The amount of periplasmic proteins was higher with OmpASP compared to no signal peptide or with 




Figure 7-3: PhoA activity of hGH fusions with PhoA as the protein of interest 
The PhoA activity assays were performed in triplicate and measured against a titration curve using a 
commercial enzyme. The background signals were eliminated by subtracting the activity value from the empty 
vector’s fractions to each corresponding fraction. PhoA (panel A) and hGH-PhoA fusions (panel B) are 
represented as no signal peptide (2), fused with OmpASP (3) or with TorASP (4), and with (+) and without (-) 
CyDisCo. The bars indicate the cytoplasmic (white), insoluble (grey) and periplasmic (black) fractions. 
 
7.2.3. Export capability of hGH using PhoA as a soluble partner 
A similar set of constructs were built and expressed using hGH as the protein of interest and PhoA 
as the soluble partner (Figure 7-1, part 2). In this case, the aim was to test the export of hGH carried 
by PhoA. The localisation and PhoA activity results are represented in Figure 7-4 and Figure 7-5 
respectively. The localisation profile of hGH-His which was used as a control (Figure 7-4, Panel A, 
His), was identical to previous data obtained in section 6.5. Briefly, hGH-His showed minimal traces 
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of the “auto-export” feature with no signal peptide and exported at a higher yield with OmpASP and 
TorASP in what appears to be the premature form (Appendix 7). The marker proteins were all located 
in their expected fractions justifying the purity of the isolated compartments except for the 
periplasmic-localised CyDisCo proteins which has been observed previously. 
 
 
Figure 7-4: Localisation of PhoA fusions with hGH as the protein of interest 
His-tagged hGH or the fusion PhoA-hGH with no signal peptide (2) or fused with OmpASP (3) or TorASP (4) as 
well as an empty vector (1) were expressed with (+) and without (-) CyDisCo in the MC4100 WT strain. The cells 
were harvested after 2h induction at 30°C and fractionated using the PureFrac method into the cytoplasmic 
(C), insoluble (I) and periplasmic (P) fractions. The Western-blots represent the detection of His-tagged and 
FLAG-tagged proteins using anti-His and anti-FLAG antibodies respectively. Arrows indicate the bands of 
premature (orange) and mature proteins (blue) when corresponding to the theoretical molecular weight size 
(Appendix 7). Green arrows indicate full-length protein where the presence of the absence of the signal 
peptide is not discernible. PageRuler Plus Prestained Protein Ladder (Life Technologies) and MagicMark™ (Life 
Technologies) molecular weight markers are indicated in kilodalton (kDa). The figure is a composite image 
where the marker lanes reflects the approximate position of the molecular weights. 
 
With respect to the PhoA-hGH fusion, with no signal peptide, no export was detected, and soluble 
proteins were only detected in the cytoplasm with anti-His and anti-FLAG (Figure 7-4, Panel B, 3). 
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The PhoA component of these fusions was found to be inactive irrespective of CyDisCo (Figure 7-5, 
panel B, 2). 
With fusion to OmpASP, the full-length fusion protein was found in the cytoplasm and periplasm 
(Figure 7-4, panel 2, His, 3) irrespective of CyDisCo. This was detected by anti-His and anti-FLAG, 
although detection by anti-FLAG, highlights major truncated species and therefore fusion instability 
(Figure 7-4, panel B, 3). As full-length protein (Appendix 7) was observed with anti-His (Figure 7-4, 
Panel B, His, 3), it appears that the fusion was truncated at multiple positions after the FLAG tag. In 
terms of activity, the protein was active in the periplasmic but not in the cytoplasmic fractions (Figure 
7-5, panel B, 3). This indicates that a native conformation was achieved in the periplasm, presumably 
thanks to the Dsb pathway (section 1.3.1.), but in the cytoplasm, most of the hGH-PhoA conforms to 
a stable but non-native conformation facilitated by the co-expression of CyDisCo. However, since 
PhoA-containing truncated products are present in the periplasm, it is not possible at this stage to 
determine whether the activity originates from full-length protein. Similar to exported hGH-PhoA 
(section 7.2.2.), it was difficult to confirm whether the periplasmic fraction contained premature 
and/or mature protein due to a size difference of only 2.1 kDa (Appendix 7). PDI, a member of 
CyDisCo, was also detected in the periplasmic fraction (Appendix 8) as observed previously with 
OmpASP-hGH and OmpASP-hGH-PhoA (section 7.2.2.). Cell lysis was ruled out since LacI was not 
detected in the periplasm. This support the idea that the combination of OmpASP fusions with 
CyDisCo correlates with specific export of at least one of the CyDisCo components by a means yet 
unknown. 
In contrast, TorASP did not allow export of the PhoA-hGH fusion (Appendix 7) irrespective of CyDisCo 
(Figure 7-4, panel B, His, 4). The cytoplasmic proteins were both detected as full-length and also 
truncated downstream of the FLAG-tag but were found to be inactive (Figure 7-5, panel B, 4). This 
indicates that although these fusions have achieved a stable conformation in the cytoplasm, they are 
not native for activity nor can bypass the proofreading ability of Tat. Furthermore, this suggests that 
either PhoA, hGH or both are not folded to the same conformation as their independently expressed 
counterparts (section 6.3. and 6.5.). 





Figure 7-5: PhoA activity of fusions with hGH as the protein of interest 
The PhoA activity assays were performed in triplicate and measured against a titration curve using a 
commercial enzyme. The background signals were eliminated by subtracting the activity value from the empty 
vector’s fractions to each corresponding fraction. PhoA-hGH fusions are represented as no signal peptide (2), 
fused with OmpASP (3) or with TorASP (4), and with (+) and without (-) CyDisCo. The bars indicate the cytoplasmic 
(white), insoluble (grey) and periplasmic (black) fractions. 
 
7.3. Fusions with the fatty acid binding protein 4 
The fatty acid binding protein 4 (FABP4), also known as aP2 and A-FABP, is a human protein localised 
in the nucleus (Cao et al., 2013). It possesses no DSBs, has a native size of 14.7 kDa and is monomeric. 
This protein is a chaperone involved in many immunometabolic diseases by reversibly binding to 
specific lipids and thus is a therapeutic target (Burak et al., 2015, Miao et al., 2015, González and 
Fisher, 2015). Soluble FABP4 was successfully expressed in-house in the cytoplasm of E. coli to the 
decent yields of ≈ 50-100 mg/L in shake flasks (D. McMillan, unpublished data). This protein is 
therefore not in need for an alternative way of production but was selected to evaluate Tat export 
as it readily folds correctly in the cytoplasm. FABP4 alone as well as fusions with hGH (hGH-FLAG-
FABP4-His) or PhoA (PhoA-FLAG-FABP4-His) were cloned with no signal peptide, OmpASP and TorASP 
(Table 2-2). The plasmids containing these genes were transformed, along with an empty vector, into 
the MC4100 WT strain and protein expressed following a 2 h induction at 30°C (Table 2-3, condition 
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1). The harvested cells were fractionated into the cytoplasmic, insoluble and periplasmic fractions 
according to the PureFrac method. The localisation and PhoA activity results are represented in 
Figure 7-6/Appendix 9 and Figure 7-7 respectively. 
When FABP4 was expressed alone and without a signal peptide, stable FABP4-His was detected in 
the cytoplasmic and, unexpectedly, in the periplasmic fractions irrespective of CyDisCo (Figure 7-6, 
panel A, 2). Similar to sfGFP and hGH (sections 6.4. and 6.5.), this indicates export via an unknown 
mechanism(s). The reliability of this data can be justified by the PDI-cMyc, Erv1p-cMyc, LacI and MBP 
controls which confirmed the fractions purity (Appendix 9). Analysis of the N-terminal protein 
sequence of FABP4 by the prediction software SignalP failed to identify a conserved Sec-like signal 
peptide motif (Nielsen, 2017a), although it is naturally secreted by adipocytes to control liver glucose 
metabolism via a non-classical pathway (Cao et al., 2013). FABP4 shares a β-barrel structure with 
sfGFP (Appendix 10) which could be linked to a common unknown transport mechanism. However, 
hGH, which also presented evidence of non-classical export (sections 6.5. and 7.2.3.), has a helix 
bundle structure (Figure 9-1), suggesting that there might be more than one unknown pathway. It 
would be interesting to investigate whether the tertiary structure of the substrate plays a role in 
determining export by this unknown pathway, as eluded to by Zhang et al. (2017). Lastly, CyDisCo 
had no effect on protein localisation of the leaderless FABP4, but this is not unexpected since FABP4-
His does not contain any DSBs, although improved expression was evident. 
FABP4 is exported without a signal peptide and therefore, subsequent interpretation of the data 
when this protein is fused to a signal peptide might be challenging. Indeed, with OmpASP and without 
CyDisCo, this protein was present in the periplasm but in the premature form (Figure 7-6, panel A, 
His, 3, orange arrow, Appendix 7). The fractionation controls confirm that this result is not due to 
cross contamination artefacts (Appendix 9). A prerequisite for Sec export of periplasmic proteins is 
the cleavage of the signal peptide by LepB prior to release into the periplasm (section 1.3.1.). LepB 
is an essential endopeptidase and therefore reports of a non-functional or attenuated enzyme has 
never been published. It can be argued that those polypeptides that exit the Sec translocon pore, 
but bear uncleaved signal peptides, will presumably remain tethered to the plasma membrane and 
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consequently be detected in the insoluble fraction. Therefore, this data suggests that the export 
occurred via an unknown mechanism where the premature protein does not interact with LepB nor 
is the result of the Sec pathway. It is not known if this is the same pathway used by OmpASP-hGH-
PhoA (Figure 7-2, panel A, 3), although there is strong correlation with the latter which was also 
exported and released into the periplasm with an intact leader sequence. Indeed, the lower band 
detected in the periplasm does not correspond to the theoretical molecular weight size of the 
mature protein but is rather considered a proteolytically-cleaved product (Appendix 7). 
With CyDisCo however, the absence of export of OmpASP-FABP4 (Figure 7-6, panel A, 3) was 
unexpected with respect to export profiles of leaderless FABP4 which was exported irrespective of 
CyDisCo. Although FABP4 does not possess any DSBs, it does have two free cysteine residues 
(González and Fisher, 2015) as indicated in magenta in Appendix 10. These residues are internally 
located within the β-barrel structure of FABP4 and presumably are inaccessible to CyDisCo once 
FABP4 is correctly folded. As FABP4 was exported without a leader, and with TorASP in the presence 
of CyDisCo (Figure 7-6, panel A, 4), it is clear that a unique interaction between CyDisCo and the Sec-
targeted FABP4 has occurred. It is therefore possible that SecB recruitment by OmpASP delays folding 
of the nascent polypeptide and this allows CyDisCo to force a DSB bond. The resulting, presumably 
unstable and non-natively folded proteins are subsequently unsuitable for either export pathway 
and are either degraded or aggregated. The lack of any stable protein in the cytoplasmic fraction and 
presence of less aggregate in the insoluble preparation compared to the profile without CyDisCo, 
lends support to this possibility. Further confirmation with cysteine mutants of FABP4 may elucidate 
the validity of this theory. 
Lastly, with TorASP, export of FABP4 was comparable irrespective of CyDisCo (Figure 7-6, panel A, His, 
4) and suggests that TorASP nor the nascent polypeptide interacts with CyDisCo. It is possible that 
these polypeptides fold rapidly similar to FABP4 expressed without a signal peptide, and before 
CyDisCo can interact. The exported proteins correlate to the theoretical molecular weight size of the 
mature form (Appendix 7) thereby suggesting that this is specifically Tat export. It is less likely that 
export is due to the unknown mechanism utilised by the leaderless FABP4 since it is suspected to not 
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trigger signal peptide cleavage. However, to prove that this is exclusively Tat-specific export, further 
confirmation is needed using the Tat-null strain. 
 
 
Figure 7-6: Localisation of fusions with FABP4 as protein of interest 
His-tagged FABP4-His, the fusion hGH-FABP4-His or the fusion PhoA-FABP4-His with no signal peptide (2) or 
fused with OmpASP (3) or TorASP (4) as well as an empty vector (1) were expressed with (+) and without (-) 
CyDisCo in the MC4100 WT strain. The cells were harvested after 2h induction at 30°C and fractionated using 
the PureFrac method into the cytoplasmic (C), insoluble (I) and periplasmic (P) fractions. The Western-blots 
represent the detection of His-tagged and FLAG-tagged proteins using anti-His and anti-FLAG antibodies 
respectively. Arrows indicate the bands of premature (orange) and mature proteins (blue) when corresponding 
to the theoretical molecular weight size (Appendix 7). Green arrows indicate full-length protein where the 
presence of the absence of the signal peptide is not discernible. PageRuler Plus Prestained Protein Ladder (Life 
Technologies) and MagicMark™ (Life Technologies) molecular weight markers are indicated in kilodalton (kDa). 
The figure is a composite image where the marker lanes reflects the approximate position of the molecular 
weights. 
 
With regards to the FABP4-His fused to hGH as the soluble partner, the fusion protein was observed 
in all periplasmic fractions irrespective of a signal peptide or CyDisCo. hGH was able to carry C-
terminally-fused FABP4 across the inner membrane without any signal peptide (Figure 7-6, panel 2, 
His and FLAG, 2) similar to the hGH-PhoA fusion (Figure 7-2, panel B, 2). It is also clear that whist 
proteolytically-cleaved species were detected in both the cytoplasmic and the insoluble fractions 
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(Figure 6, panel B, 2), only full-length protein was exported (Appendix 7). However, due to this 
undefined export, the interpretation of data when the fusion is expressed with a signal peptide, is 
challenging. 
Indeed, the export mechanism of the translocated proteins observed with OmpASP cannot be easily 
deduced (Figure 7-6, panel B, 3). This protein appears to be pre-mature, though it is difficult to assign 
a mature form due to the presence of proteolytically cleaved products (Figure 7-6, panel B, 3). This 
further suggests that the fusion with OmpASP is unstable. However, as the localisation profiles are 
similar irrespective of CyDisCo, this suggests that fusion of FABP4 to hGH prevents an interaction 
with CyDisCo as observed previously with OmpASP-FABP4 (Figure 7-6, panel A, 3). 
 
 
Figure 7-7: PhoA activity of fusions with FABP4 as protein of interest 
PhoA activity assays were performed in triplicate and measured against a titration curve using a commercial 
PhoA enzyme. The background signals were eliminated by subtracting the activity value from the empty 
vector’s fractions to each corresponding fraction. PhoA-FABP4 fusions are represented as no signal peptide 
(2), fused with OmpASP (3) or with TorASP (4), and with (+) and without (-) CyDisCo. The bars indicate the 
cytoplasmic (white), insoluble (grey) and periplasmic (black) fractions. 
 
With TorASP, the exported proteins are mostly full-length proteins and correspond to the theoretical 
molecular size of the mature proteins (Figure 7-6, panel B, 4; Appendix 7). However, proteins 
corresponding to the both premature and mature forms were detected in the cytoplasm. It is unclear 
if these are proteolytically-cleaved products by a non-specific protease(s) or specifically cleaved at 
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the signal peptide, a reaction that can be driven by TatC in the absence of TatB (section 1.3.2.4.). It 
is therefore difficult to understand the role of the Tat pathway in relation to export of this fusion. 
Conversely, when FABP4 is fused to PhoA, this product behaved in a specific way towards the export 
pathways compared to the hGH-FABP4 fusion. With regards to the leaderless and OmpASP-fused 
proteins, the export and activity profiles correlate with to the corresponding fusion where hGH was 
used as the protein of interest (Figure 7-4 and Figure 7-5, panel B, 2 and 3). Export of FABP4 with the 
natural Sec substrate PhoA at the N-terminus was not detected without a signal peptide, as expected 
(Figure 7-6, panel C, 2). Conversely, with OmpASP, the fusion was comparably exported, irrespective 
of CyDisCo, and demonstrably active in terms of PhoA activity (Figure 7-6, panel C, 3 and Figure 7-7, 
3). It is not clear whether this protein is the mature or premature form due to their similarity in 
molecular weight size. Interestingly without CyDisCo, activity of soluble PhoA was only detected in 
the periplasmic fractions, presumably from translocated proteins via the Sec pathway and their 
subsequent native folding in the periplasm. In contrast with CyDisCo, activity was also detected in 
the cytoplasmic fraction, suggesting that a portion of the preprotein is folded in the cytoplasm with 
correct DSB formation within the PhoA portion, presumably via CyDisCo. It is also notable that the 
fusion is significantly truncated (Figure 7-6, FLAG, 4), and therefore the activity could be attributed 
to a proportion of proteolytically cleaved products that bear an intact PhoA as well as the full-length 
fusion. 
With the Tat leader TorASP, the fusion protein showed export albeit minor, only with CyDisCo (Figure 
7-6, panel C, 4). It is not known whether this form is the premature or mature due to their similar 
predicted molecular weight sizes (Appendix 7). The periplasmic proteins presented insignificant 
PhoA activity (Figure 7-7, 4) but is not unexpected based on the poor level of export. PhoA, the N-
terminal soluble carrier of the fusion, was confirmed to be active mostly in the cytoplasmic and 
insoluble fractions and only with CyDisCo (Figure 7-7, 3). This suggests that when the correct DSBs 
of the carrier PhoA are formed, the fusion protein is accepted by the proofreading of Tat and 
translocated. With CyDisCo, however, the cytoplasmic proteins showed similar PhoA activity with 
the corresponding OmpASP cytoplasmic fusion, supporting the idea that, in this case, CyDisCo 
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enabled correct DSB formation. A test comparing export in WT and Tat-null strains would conclude 
on Tat contribution to this export. 
In conclusion, FABP4 was shown to export without a leader sequence similar to hGH (section 7.2.1.) 
and sfGFP (section 6.4.). FABP4 and sfGFP share a β-barrel structure but it is not known whether 
these proteins are exported by the same unknown mechanism. sfGFP was demonstrably active as 
indicated by its fluorescence (section 6.4.) so it would be interesting to determine if exported FABP4 
is also correctly folded. However, this is not possible in this present work due to the complicated 
nature of these binding assays and the necessity for purified protein ((González and Fisher, 2015)). 
Furthermore, due to this ‘auto-export’ nature, it is difficult to attribute a pathway(s) responsible for 
export when fused to hGH. There is strong correlation that exported proteins are premature in that 
they still retain their signal peptides upon exit into the periplasm, particularly with OmpASP. Whether 
this is a phenotype of the unknown export mechanism is unclear. 
Conversely, with PhoA at the N-terminus, export of the fusion is signal peptide dependent. PhoA 
being a Sec substrate, is not exported without a Sec signal peptide. However, although export was 
demonstrated with a signal peptide, the fusion was also deemed unstable or poorly exported with 
the respective OmpA and TorA signal peptides. However, given that FABP4 auto-exports as an intact 
protein into the periplasm and providing that it is correctly folded, the auto-export also raises the 
question of redundancy with respect to the fusion strategy. 
 
7.4. Fusions with single variable domain of camelid heavy chain antibodies 
As well as the conventional immunoglobulin (IgG1 subclass) antibody shared with humans, camelids 
and sharks possess another unique type of antibody which is characterised by only a heavy chain and 
no light chain (Bever et al., 2016) (Figure 7-8A). These heavy-chain only antibodies (HcAb) are 
homodimers of the heavy chain and consist of a variable heavy domain linked directly to the Fc 
region. The fragment crystallizable (Fc) region itself is classified as either a gamma 2 or gamma 3 
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subclass and therefore these HcAbs are known as IgG2 or 3 (IgG2/3), as illustrated in Figure 7-8A. 
Hence, they do not contain the CH1 constant region present in a human classical IgG antibody. The 
complementary domain region 3 (CDR3) of the variable heavy is also typically longer than the 
corresponding region of a conventional IgG antibody (Bever et al., 2016). The variable domain itself 
can be expressed independently and, in this case, is known as a VHH or Nanobody® (Steeland et al., 
2016). Since their discovery in 1991, interest in VHHs has increased due to several features: their 
obvious small size enabling access to hidden viral epitopes, their stability, efficient production in E. 
coli or yeast, tissue penetration competency, rapid elimination by the kidneys and the possibility to 
create bivalent antibodies or add an effector domain by fusion (Harmsen and De Haard, 2007, 
Wesolowski et al., 2009, de Marco, 2011, Muyldermans, 2013). VHHs possess one canonical DSB 
linking framework (FW) 1 to FW3 which stabilizes the structure and is represented as S-S1 in Figure 
7-8B. But some llama germlines possess additional cysteines in the CDRs that are involved in non-
canonical DSB formation. Indeed, a DSB between CDR1 and CDR3 (S-S2) or between two cysteine 
residues in CDR3 (S-S3, Figure 7-8B) have been identified (Nguyen et al., 2011, Iezzi et al., 2018). 
These non-canonical DSBs are known to confer a higher thermal stability (Akazawa-Ogawa et al., 
2016). VHHs are often expressed in the periplasm of E. coli through Sec since the canonical DSB is 
necessary for the stability and activity of the antibody fragment (Yau et al., 2003, Akazawa-Ogawa et 
al., 2016, de Marco, 2015). Moreover, another type of antibody fragment, scFv (Figure 7-8A), has 
been reported to be exported by Tat when co-expressed with CyDisCo (Alanen et al., 2015). Here, a 
variable heavy and a variable light domain derived from an IgG antibody are connected via a linker. 
Since a VHH is a smaller but a similar class of antibody to a scFv, it raises the question whether this 
molecule could also be exported via the Tat pathway. Furthermore, Tat export of VHH antibody 
fragments has never been reported. Therefore, testing Tat export of VHHs is attractive due to the 
interest of these molecules in the biopharmaceuticals industry (Maffey et al., 2016, Wang et al., 
2018, Iezzi et al., 2018). 
 




Figure 7-8: Origin and details of VHH antibody fragment 
A. A typical representation of an immunoglobulin G (IgG) antibody (IgG1 subclass) and a camelid heavy chain 
only antibody (HcAb) of the subclass IgG2 or IgG3 (IgG2/3) is presented. The IgG1 is composed of two light and 
two heavy chains. The light chain consists of a variable light (VL) region and a constant light (CL) region. The 
heavy chain is composed of a variable heavy (VH), constant heavy (CH1) domains and a fragment crystallizable 
(Fc) region. The Fc consists of a CH2 and CH3 domain. The camelid IgG2/3 is composed of 2 heavy chains 
consisting of a VHH domain and an Fc region of subclass 2 or 3. The following antibody fragments can be 
engineered from their respective parental IgGs: Fab antibody fragment (Fab), scFv and VHH. The variable 
domain of the camelid antibody is called VHH single domain also known as Nanobody®. Disulphide bonds are 
represented in orange. The approximate molecular weights are indicated underneath the corresponding 
molecules in kilodalton (kDa). B. Schematic of a “conventional” VHH from llamas is indicated with frameworks 
(FW), complementary domain regions (CDR) and disulphide bonds (S-S). The canonical and non-canonical DSBs 
are represented by the respective plain and dashed lines. The Figure was adapted from Muyldermans (2001) 
and Iezzi et al. (2018). 
 
Two VHHs were selected for assessment based on the specific properties of the molecule. These 
antibody fragments were originally selected by phage display panning where the VHHs are displayed 
on the surface of the phage as N-terminal fusions to the coat protein pIII (Ledsgaard et al., 2018). 
The Sec pathway of E. coli is utilised to enable DSB formation of the VHH by fusing the post-
translational Sec signal peptide of Erwinia carotovora pectate lyase B (PelBSP) (Solforosi et al., 2012). 
Thus, this ensures that only those VHHs that are correctly folded with DSB(s) and displayed in an 
active conformation albeit in a fusion context, can be selected for binding to an antigen via panning. 
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Table 7-1: Biochemical characteristics of the two VHHs 
VHH Length Size (kDa) DSB Charge at pH 7.0 Library of origin 
VHH1 116 12.7 1 1.1 Naïve 
VHH2 119 12.9 2 -0.1 Immune 
 
Two VHHs were selected from UCB Celltech’s in-house screening platforms (A. Scott-Tucker, 
personal communication), based on specific features integral to each molecule as summarized in 
Table 7-1. Although both VHHs have very similar molecular weight size, VHH1 possesses one DSB 
whilst VHH2 possesses two DSBs. The additional DSB of VHH2 is represented as S-S3 in Figure 7-8B 
and is known to increase the rigidity and thus the stability of the protein (Akazawa-Ogawa et al., 
2016). The alignment of primary sequences of these VHHs reveals a 75 % similarity between the two 
antibody fragments (Appendix 11). Regarding the net charge, decreasing the surface charge to a 
negative value was demonstrated to improve protein solubility (Kramer et al., 2012, Chan et al., 
2013). Therefore, VHH2 was predicted to be more stable than VHH1. Other discrepancies beyond 
this feature were investigated in terms of hydropathy and secondary structures to predict any 
potential differences with regards to export. Figure 7-9A revealed a globally similar hydropathy with 
the highest discrepancies located around positions 25 and 55. Furthermore, the secondary structure 
predictions indicate potential variances notably in the number and length of β-sheets which may 
result in different spatial conformations (Figure 7-9B). Overall, the two VHHs would be ideal test 
cases to investigate Tat export and the effect of CyDisCo. 
To evaluate Tat export of these proteins and whether translocation can be improved by fusion, 
expression vectors were designed to produce the His-tagged VHHs alone as well as C-terminal fusions 
to PhoA and hGH as depicted in Figure 7-1. Constructs were cloned with either no signal peptide or 
fused to OmpASP or TorASP, and with or without CyDisCo (Table 2-2). These plasmids were 
transformed into MC4100 WT, cultured at 30°C and expression was induced for 2 h at 30°C (Table 
2-3, condition 1). The harvested cells were treated according to the PureFrac method to isolate the 
cytoplasmic insoluble and periplasmic subcellular compartments. Subsequently, the proteins were 
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separated by reducing SDS-PAGE and detected by Western-blot. The localisation results of both 
VHHs as well as the activity assays of PhoA are described in sections 7.4.1. and 7.4.2. 
 
 
Figure 7-9: Hydropathy scale and predicted secondary structures for both VHH amino acid sequences 
A. The graph represented the hydropathy scale of the VHH1 (blue) and VHH2 (orange) sequences using 
ProtScale online analysis tool with the Kyte and Doolittle package (Kyte and Doolittle, 1982). B. Alignment of 
the secondary structure of the VHH1 and VHH2 predicted using the online tool CFSSP (Ashok Kuma, 2013). The 
α-helixes are represented in orange, the β-sheets in green and the coil in grey. 
7.4.1. Expression of fusions with VHH1 
When VHH1-His was expressed without a signal peptide, no detectable protein was observed as 
represented in Figure 7-10 (panel A, His, 2). This demonstrated that the protein was either not 
expressed, expressed then degraded or expressed but the His tag was cleaved. Fusion to OmpASP, 
enabled comparable Sec export with respect to CyDisCo, where most of the preprotein was 
presumably translocated and processed to the mature form (Appendix 7). However, a protein 
corresponding to the predicted molecular weight of the mature protein was also observed in the 
cytoplasm, irrespective of CyDisCo. Cross-contamination was ruled out, as the periplasmic marker 
MBP was not detected in any other fraction, although an insignificant amount of LacI was found in 
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the periplasmic fraction of the sample without CyDisCo (Appendix 12). However, this does not 
account for level of VHH1 shown in the cytoplasmic fraction and is presumably proteolytic cleavage. 
As VHH1 was not detected when expressed without a leader, the nature of this protein is unclear. It 
is possible that through the recruitment of Sec specific chaperones, the protein was able to fold and 
stabilise (Figure 7-10, panel A, His, 3). It is apparent that CyDisCo has no effect on this localisation. 
 
 
Figure 7-10: Localisation of fusions with VHH1 as protein of interest 
His-tagged VHH1, the fusion hGH-VHH-His or the fusion PhoA-VHH1-His with no signal peptide (2) or fused 
with OmpASP (3) or TorASP (4) as well as an empty vector (1) were expressed with (+) and without (-) CyDisCo 
in the MC4100 WT strain. The cells were harvested after 2h induction at 30°C and fractionated using the 
PureFrac method into the cytoplasmic (C), insoluble (I) and periplasmic (P) fractions. The Western-blots 
represent the detection of His-tagged and FLAG-tagged proteins using anti-His and anti-FLAG antibodies 
respectively. Arrows indicate the bands of premature (orange) and mature proteins (blue) when corresponding 
to the theoretical molecular weight size (Appendix 7). Green arrows indicate full-length protein where the 
presence of the absence of the signal peptide is not discernible. PageRuler Plus Prestained Protein Ladder (Life 
Technologies) and MagicMark™ (Life Technologies) molecular weight markers are indicated in kilodalton (kDa). 
The figure is a composite image where the marker lanes reflects the approximate position of the molecular 
weights. 
 
With TorASP, poor expression and export of VHH1 was observed irrespective of CyDisCo (Figure 7-10, 
panel A, 4). This suggests that the protein cannot fold into a native conformation in the cytoplasm 
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despite CyDisCo. (Figure 7-10, panel A, His, 4). Indeed, VHH1 instability is apparent as demonstrated 
by the overall reduced level of expressed protein but also by the presence of a similarly 
proteolytically cleaved species in the cytoplasm when compared to OmpASP. No cross-contamination 
was detected to indicate artefactual data, although interestingly, both CyDisCo proteins Erv1p-cMyc 
and PDI-cMyc, were detected in the periplasm with OmpASP and TorASP fusions (Appendix 12) These 
unexpected sub-cellular localisations will be further discussed in section 9.4. 
With regards to the hGH fusion (Appendix 7) with no signal peptide, VHH1 was stable in the 
cytoplasm and presented minimal export with some improvement when co-expressed with CyDisCo 
(Figure 7-10, panel B, 2). This indicates that hGH, by way of its ‘auto export’ mechanism, can not only 
lead PhoA and FABP4 but also, minimally, VHH1 into the periplasm. It appears as though CyDisCo 
enhances expression of VHH1 including minimal export improvement. However, the exported 
protein status, folded or unfolded, is still unknown. The localisation data was supported by the 
absence of cross-contamination (Appendix 12). However, neither OmpASP nor TorASP allowed export 
of the full-length fusion protein irrespective of CyDisCo, although the fusion with TorASP appeared to 
be more unstable compared to OmpASP (Figure 7-10, panel B, 3 and 4). Proteolytically cleaved species 
were detected in all relevant fractions where the fusion was expressed with anti-FLAG but not with 
the anti-His antibody. This indicates that the cleavage point(s) is within the C-terminal region 
downstream from the FLAG tag (Figure 7-1) and that the resulting products will likely bear an intact 
hGH and signal peptide. The cytoplasmic profiles correlate with the corresponding periplasmic 
profiles, and further support that the truncated fusion proteins that still bear a signal peptide, are 
exported thereafter. This highlights a weakness in the fusion design which is further discussed in 
section 9.7.1. 
On the other hand, when using PhoA as the soluble partner (Appendix 7), the fusion was highly 
unstable when expressed without a signal peptide and degraded or proteolytically cleaved as 
observed with anti-FLAG (Figure 7-10, panel C, 2). However, the protein was stabilised with OmpASP 
and poor export was observed with slight improvement with CyDisCo (Figure 7-10, panel C, 3). Similar 
to the hGH fusion, anti-FLAG detection revealed export of truncated species irrespective of CyDisCo 
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which suggest that this is Sec export as well as highlighting fusion instability (Figure 7-10, panel C, 
FLAG 2). Significant PhoA activity (> 3kU/L) was detected in the periplasmic fractions (Figure 7-11, 
3). However, due to the poor export of the full-length fusion and the presence of proteolytically 
cleaved species which likely contains an intact PhoA (Figure 7-10, panel C, 3 and Figure 7-11, 3), it is 
not clear if activity comes from the exported full-length fusion. 
With regards to TorASp, no export of the full-length fusion was noted but CyDisCo significantly 
increased the expression of the full-length and clipped products in the cytoplasm (Figure 7-10, panel 
C, 4). Poor export of a proteolytically cleaved species was detected only with anti-FLAG and with 
CyDisCo, suggesting that this likely contains an intact PhoA. PhoA was previously shown to export via 
Tat (section 7.2.2.). Lack of PhoA activity in any fraction indicates that targeting the fusion to the Tat 
pathway does not confer a native folding (Figure 7-11, 4). 
 
 
Figure 7-11: PhoA activity of fusions with VHH1 as protein of interest 
The PhoA activity assays were performed in triplicate and measured against a titration curve using a 
commercial enzyme. The background signals were eliminated by subtracting the activity value from the empty 
vector’s fractions to each corresponding fraction. PhoA-VHH1 fusions are represented as no signal peptide (2), 
fused with OmpASP (3) or with TorASP (4), and with (+) and without (-) CyDisCo. The bars indicate the cytoplasmic 
(white), insoluble (grey) and periplasmic (black) fractions. 
 
To sum up, expression of VHH1 without a signal peptide was unstable in the cytoplasm of E. coli but 
fusing a signal peptide or a carrier protein to the N-terminus of the VHH improved stability. Export 
of the full-length protein was only observed with the signal peptide of OmpA, but this was poor. Due 
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to the export of proteolytically cleaved species which likely contain an intact PhoA, it is unclear if the 
exported full-length fusion is active. The presence of extensive truncated species indicates that the 
fusion design may need further optimisation. 
7.4.2. Expression of fusions with VHH2 
The export profile of the second antibody fragment, VHH2 (section 7.4.), revealed similarities but 
also discrepancies compared to VHH1 (Table 7-1 and Figure 7-9). Indeed, the lack of detected 
proteins for VHH2-His with no signal peptide irrespective of CyDisCo indicates that this VHH has 
expression and/or degradation issue(s) in E. coli just like VHH1 (Figure 7-12, panel A, His, 2). With the 
post-translational Sec signal peptide of OmpA and without CyDisCo, VHH2 was mostly located in the 
insoluble fraction in a mature form, although proteolytic cleavage is also detected (Figure 7-12, panel 
A, His, 3; Appendix 7). This suggests that the preprotein was exported by Sec and processed by LepB, 
but the mature form folded incorrectly in the periplasm resulting in the formation of periplasmic 
inclusion bodies. This indicates that this VHH is unstable whilst VHH1 was stable in similar settings. 
With CyDisCo however, the localisation and cleavage status of VHH2 appeared different from the no 
CyDisCo profile, implying that these chaperones improved VHH2 expression (Figure 7-12, panel A, 
His, 3). Very poor export was observed, though this was mostly premature whereas most of the 
mature form was found in the insoluble fraction. As the CyDisCo chaperones enable folding which is 
incompatible with Sec export, the insoluble mature proteins are likely to originate from Sec exported 
protein which aggregate in the periplasm due to incorrect folding. However, the mature form was 
also discovered in the periplasm along with the cytoplasmic markers, PDI, Erv1p and LacI, suggesting 
cytoplasmic contamination (Appendix 13). But, inner membrane permeability was ruled out since 
the periplasmic marker, MBP was not detected in the cytoplasm. This is, therefore, unclear if VHH2 
exhibited Sec targeted export or employed a similar export mechanism to PDI, Erv1p and LacI. 
Periplasmic presence of PDI and Erv1p when expressing a protein fused to OmpASP was observed in 
other cases and is further discussed in section 9.4 and 9.7.1. 
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The data with TorASP and without CyDisCo further confirm the instability of VHH2 but also indicates 
that the stability conferred by OmpASP is signal peptide dependent. CyDisCo marginally improved the 
expression of the protein as premature and a protein corresponding to the predicted molecular 
weight size of the mature form were observed in both the cytoplasm and insoluble fractions (Figure 
7-12, panel A, 4). Cross contamination was not detected (Appendix 13) indicating that proteolysis is 
responsible for the cytoplasmic cleaved product. Mature protein was present in the periplasmic 
fraction though this indicates very poor export. Thus, VHH2 does not appear to fold correctly in any 
of the different cellular environments presented in this study. 
However, fusion to hGH as a soluble partner appears to improve expression of VHH2 as 
demonstrated by improved detection of full-length proteins by both anti-His and anti-FLAG 
antibodies (Figure 7-12, panel B). Full-length hGH-VHH2 was detected in the periplasm irrespective 
of CyDisCo and without the need of a signal peptide (Figure 7-12, panel B, 2), in agreement with 
previous data that shows hGH’s “auto export” ability (sections 7.2.2., 7.3 and 7.4.1.). This pathway is 
not understood, and it is still unknown whether the exported proteins are folded or unfolded. This 
translocation of VHH2 does not require DSB formation prior to export although, with CyDisCo, 
improved protein expression was evident. When VHH2 alone was targeted to the Sec or Tat 
pathways, it showed no expression despite CyDisCo. This therefore suggests that expression of VHH2 
was improved, possibly through its enhanced solubility, and further improved by CyDisCo. 
When the fusion was expressed with either OmpASP and TorASP, and without CyDisCo, a mature 
protein was present in the periplasm, suggesting Sec and Tat export respectively (Figure 7-12, panel 
B, 3 and 4). But, with CyDisCo, premature protein was also observed in the periplasm regardless of 
the signal peptide. PDI and Erv1p were also detected in the periplasm, correlating with previous data 
where these proteins are exported by an unspecified mechanism with an OmpASP-substrate 
(Appendix 13). Cross contamination was not a factor as demonstrated by the localisation profiles of 
LacI and MBP. With TorASP, CyDisCo appeared to significantly improve export though proteolytic 
cleavage was also increased (Figure 7-12, panel B, 4). 




Figure 7-12: Localisation of the fusions with VHH2 as protein of interest 
VHH2-His (His-tagged VHH2), the fusion hGH-VHH2-His or the fusion PhoA-VHH2-His with no signal peptide (2) 
or fused with OmpASP (3) or TorASP (4) as well as an empty vector (1) were expressed with (+) and without (-) 
CyDisCo in the MC4100 WT strain. The cells were harvested after 2h induction at 30°C and fractionated using 
the PureFrac method into the cytoplasmic (C), insoluble (I) and periplasmic (P) fractions. The Western-blots 
represent the detection of His-tagged and FLAG-tagged proteins using anti-His and anti-FLAG antibodies 
respectively. Arrows indicate the bands of premature (orange) and mature proteins (blue) when corresponding 
to the theoretical molecular weight size (Appendix 7). Green arrows indicate full-length protein where the 
presence of the absence of the signal peptide is not discernible. PageRuler Plus Prestained Protein Ladder (Life 
Technologies) and MagicMark™ (Life Technologies) molecular weight markers are indicated in kilodalton (kDa). 
 
Using PhoA as a soluble partner, the expression of VHH2 was also improved as demonstrated by the 
presence of soluble protein in the cytoplasm and further enhanced by CyDisCo (Figure 7-12, panel 
C). With OmpASP, export was observed irrespective of CyDisCo indicating Sec export (Figure 7-12, 
panel C, 3) and the PhoA domain of the fusion was found to be active (Figure 7-13, 3). Multiple 
truncated products were also present, and these profiles correlated between fractions (Figure 7-12, 
panel C, 3). This suggests that either cleaved products with an intact PhoA and signal peptide were 
translocated, or the protein was cleaved following export, similar to the PhoA-VHH1 fusion (section 
7.4.1.). Cross-contamination with the cytoplasmic marker LacI was evident and thereby needs to be 
considered during interpretation of this data (Appendix 13).  
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However, with TorASP, minimal export of the full-length protein was noted, only with CyDisCo (Figure 
7-12, panel C, 4). This result is expected as PhoA was shown to require CyDisCo for Tat translocation 
(section 6.3.1.). Most of the soluble protein was detected in the cytoplasm suggesting that most of 
the fusions did not adopt a conformational status accepted by the proofreading ability of Tat, despite 
CyDisCo. Indeed, this protein and also the exported fusion was not active (Figure 7-13, 4), in 
agreement with previous data with respect to PhoA fusions (section 6.3., 7.2., 7.3. and 7.4.1.). 
However, with the latter, the activity could have been below detection level as a very low amount of 
protein was exported. No cross contamination was detected confirming the validity of this data 
(Appendix 13). 
To conclude, VHH2 is naturally unstable but stability was slightly increased when fused to OmpASP or 
TorASP and considerably improved when fused to hGH or PhoA. CyDisCo also positively impacted 
stability resulting in improved protein yields. Though with hGH, the fusion adopts a more stable 
conformation where most of the protein is full-length. Without a signal peptide, this fusion is 
exported, thereby providing further support for an unspecified mechanism for hGH export. With the 
signal peptides, export of both premature and mature proteins complicates interpretation. However, 
with the mounting support that resident proteins exported by the unknown mechanism still retain 
the signal peptide, this suggests that the fusion is exported by both targeted and unknown pathways. 
The use of the Tat-null strain would at least lead to confirmation of Tat export. When VHH was fused 
to PhoA, the Sec and Tat specificity was confirmed with minimal export of the fusion. Moreover, Sec 
export, which handles unfolded polypeptide (section 1.3.1.), was unaffected by the presence of 
CyDisCo. VHH2 was overall shown to be more stable as a fusion, particularly when fused to hGH. 
However, it is not known if these proteins are folding correctly or can actively bind their ligands. 
 




Figure 7-13: PhoA activity of fusions with VHH2 as protein of interest 
The samples origin was described in the Figure 7-12 legend. The activity assays were performed in triplicate 
and measured against a titration curve using a commercial enzyme. The background signals were eliminated 
by subtracting the activity value from the empty vector’s fractions to each corresponding fraction. The bars 
indicate the cytoplasmic (white), insoluble (grey) and periplasmic (black) fractions. 
 
7.5. Proteolytic clipping of the fusion proteins 
During experiments as outlined in this chapter, truncated species of the fusion proteins were a 
common observation detected by both anti-His and anti-FLAG antibodies. When hGH, FABP4 and 
VHH1 were expressed a fused soluble partner, they were observed as full-length, corresponding to 
their respective premature, and/or mature forms and thus, demonstrating their stability. The 
exceptions are PhoA and VHH2 which both showed proteolytic cleavage. Indeed, presence of cleaved 
species was observed for both proteins by anti-His, indicating that N-terminal degradation had 
occurred (Figure 7-2 and Figure 7-12, panel A, 3 and 4).  
With regards to the fusions, truncated species were observed by anti-His for hGH-PhoA (Figure 7-2, 
panel B, His), hGH FABP4 (Figure 7-6, panel B, His), PhoA-FABP4 (Figure 7-6, panel C, His), hGH-VHH2 
(Figure 7-12, panel B, His) and PhoA-VHH2 (Figure 7-12, panel C, His). This suggests that the fusion 
design is not ideal for all recombinant proteins. These proteolytically-clipped species were present 
in each fraction demonstrating that instability of the recombinant protein is not fraction dependent. 
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Moreover, no truncated species were detected in the periplasm by anti-His when PhoA was used as 
a soluble partner irrespective of CyDisCo, indicating that this protein is more stable than hGH as a 
carrier. For instance, only full-length proteins were observed in the periplasmic fractions when 
expressing PhoA-FABP4 whereas proteolytically-clipped products were present when hGH-FABP4 
was expressed (Figure 7-6, panel B and C).  
Furthermore, N-terminus degradation in the cytoplasm means loss of the signal peptide which would 
prevent export. Hence, if classical translocation occurred, periplasmic truncation species were 
originally exported as full-length and sustained degradation. For example, if the truncated species 
observed by anti-His in the periplasmic fraction when expressing OmpASP-hGH-PhoA (Figure 7-2, 
panel B, His, 3) have been exported by Sec, they must have been translocated prior to N-terminal 
degradation. However, the non-classical export mechanism(s), highlighted throughout this chapter, 
could have transported the truncated species from the cytoplasm across the inner membrane. 
Moreover, with anti-FLAG, the degradation patterns do not correlate with the patterns of truncated 
species revealed by anti-His. This suggests that a proportion of the truncation was C-terminally 
cleaved from the FLAG tag (Figure 7-1) especially for PhoA-hGH (Figure 7-4, panel B), hGH-VHH1 and 
PhoA-VHH1 (Figure 7-10, panels B and C). By subtracting the size of the proteins of interest to the 
full-length proteins (Appendix 7), the sizes of the truncated species revealed that degradation 
occurred within both the protein of interest and the linker. Since these proteins expressed alone 
were not cleaved, the fusion rendered them prone to degradation. 
Finally, discounting the molecular weight size of hGH (22.3 kDa) or PhoA (47.3 kDa) from the full-
length protein (Appendix 7) indicates that, in general terms, degradation is likely to have occurred in 
the soluble partner, with respect to anti-His detection, whereas, with anti-FLAG detection, the 
susceptible region is the C-terminal protein and the interconnecting linker region. 
Overall, fusing these proteins together – except PhoA – created protease-sensitive sites present in 
both the soluble partners, proteins of interest and linker. Therefore, the design of the fusion needs 
to be optimised to reduce the truncation events and is further discussed in Chapter 9. 
 
Chapter 7 – Fusions 
142 
 
7.6. Conclusion on fusion proteins 
To investigate whether expressing a recombinant protein as a fusion would improve its export by 
Tat, hGH and PhoA were selected as the soluble partner (Chapter 6). To test this hypothesis, five 
recombinant proteins were selected: the soluble partner PhoA and hGH themselves, FABP4 and two 
VHHs. Table 7-2 summarizes the export resulting from the different conditions tested. Data 
confirmed that hGH is exported without the help of a signal peptide by an unknown mechanism. 
Also, all proteins of interest when -fused to the C-terminus of hGH showed some unexpected degree 
of export without a signal peptide (Table 7-2). This is an interesting observation and questions the 
necessity for a classical export pathway. Although, questions regarding the understanding of this 
pathway and whether the exported proteins are folded into their native conformations remain 
unanswered. Hence, it makes it difficult to interpret data and attribute a role for the secretion 
pathways when using this soluble partner. However, PhoA as a soluble partner happens to be more 
specific with regards to export since no translocation was observed without a signal peptide. As 
expected with OmpASP, all fusions exported albeit mostly poorly, irrespective of CyDisCo. VHH1 is an 
exception, as it appeared to be particularly unstable without CyDisCo. With TorASP, only FABP4 and 
VHH2 showed export, though poor, suggesting that the other proteins were unfolded and were thus, 
rejected by Tat proofreading mechanism (Table 7-2). Overall, the fusion strategy did not improve Tat 
export and this work confirmed that targeting to Sec secretion pathway, the most prolifically used 
pathway for protein export in E. coli was generally more successful than Tat in terms of export. 
Nevertheless, fusing a soluble partner improved the stability of the proteins of interest especially for 
the VHH. 
Protein stability was often improved by fusion to signal peptides and also by co-expressing CyDisCo. 
The chaperone and the DSB formation activities of PDI and Erv1p seemed to enhance the folding of 
the recombinant proteins. However, most of the proteins were not accepted by the Tat proofreading 
mechanism and the PhoA component was not active in the cytoplasm which suggests that CyDisCo 
conferred a stable but non-native conformation. With OmpASP, the CyDisCo proteins had the 
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tendency to co-localise in the periplasm with the periplasmically-targeted protein. Hence, an 
unknown connection between this signal peptide and the CyDisCo chaperones drove to their export 
via an uncharacterised mechanism (discussed in section 9.7.2.). It is not known if this particular signal 
peptide is responsible for export but highlights the need for further evaluation of leader sequences. 
 
Table 7-2: Summary of protein export 
The table represents the export of the proteins presented in this chapter. They were either unfused or fused 
to soluble partner, hGH or PhoA. The data is classified according to its signal peptide or lack of thereof: no 
signal peptide (No SP), the signal peptide of OmpA (OmpASP) or of TorA (TorASP) and co-expressed without (Cy-
) or with (Cy+) CyDisCo. The relative export was represented as no export (-), non-significant export (+/-), poor 
export (+) and good export (++). Grey cells represent the conditions that were not tested. 
 
 
The fusion proteins showed evidence of both N- and C-terminal degradation in the cytoplasmic and 
periplasmic fractions. These truncated products are thought to have arisen from proteolytic 
degradation within the soluble partner, the interconnecting linker and the proteins of interest 
regions (Figure 7-1). The exception for this is the hGH-VHH2 fusion which remarkably was present as 





Cy- Cy+ Cy- Cy+ Cy- Cy+
PhoA - - ++ ++ - +
hGH - +/- + + + +
FABP4 + + + - + +
VHH1 - - + + - -
VHH2 - - +/- +/- - +/-
PhoA + ++ ++ ++ + +
hGH
FABP4 + + + ++ + +
VHH1 - + - - - -
VHH2 + + + + + +
PhoA
hGH - - ++ ++ - -
FABP4 - - + + - +
VHH1 - - - + - -





Construct No SP OmpAS P
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this does highlight that the design of the fusion protein is not optimum for most recombinant 
proteins as will be discussed in section 9.7.1. 
On a more positive note, FABP4 was surprisingly transported across the inner membrane without a 
signal peptide similar to hGH and sfGFP (section 6.4. and 6.5.). The mechanism of transport is not 
understood nor is it known whether this is the same mechanism for all and therefore would be worth 
investigating.  
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8. GENETIC CHARACTERISATION OF THE TAT OPERON 
8.1. Introduction to the genomic locus upstream of the Tat operon 
The Tat operon contains the genes coding for the TatA, TatB, TatC and TatD proteins (77.8 min) while 
the additional tatE gene (14.2 min min) locates elsewhere on the genome (section 1.3.2.1.). The 
presence of a mRNA containing tatA, tatB, tatC and tatD was confirmed by Weiner et al. (1998) in 
the E. coli K12 HB101 strain. No biological evidence of the actual promoter was demonstrated but 
by using the prediction software BPROM (Solovyev, 2011), the estimated promoter region was 
established and is represented in Figure 8-1B. This bacterial promoter contains the consensus -10 
and -35 regions upstream of the transcription start site (de Avila e Silva and Echeverrigaray, 2012). 
These regions are recognized by the housekeeping, sigma factor subunit of the RNA polymerase 
which after binding, initiate transcription (Borukhov and Nudler, 2003). 
The ubiEJB operon is upstream of this operon and codes for proteins involved in the ubiquinone 
biosynthesis pathway which serve the respiratory electron transport chain (Aussel et al., 2014a, Wu 
et al., 2015) (Figure 8-1A). Indeed, a conserved -35 and -10 region was predicted by BPROM 
upstream of ubiE (Figure 8-1D). No other putative promoters were predicted within the operon, 
which supports that the ubiE, ubiJ and ubiB genes are part of the same operon (Solovyev, 2011). 
Having two operons next to one another is not unusual in bacteria but the interest of the following 
work came from a recently developed strain called TatExpress engineered from E. coli K12 W3110 
(Browning et al., 2017). They inserted a cassette containing the tac promoter (de Boer et al., 1983) 
upstream of the predicted promoter site of the tat operon, and downstream of the ubiB stop codon 
as shown in Figure 8-1C. Accordingly, the tac promoter subsequently starts 196 bp downstream from 
the stop codon of the ubiB gene. Thus, natural levels of expression can be still accomplished during 
cell growth from the native promoter whilst overexpression can be achieved upon induction by IPTG. 
The non-coding region of 196 bp is a non-complementary scar region from the strain construction 
which contains restriction enzyme and Flp recombination sites (Browning et al., 2017). 
 




Figure 8-1: Genetic organisation of the Tat operon 
A. Genetic representation of the ubiEJB and tatABCD operon loci flanked by the chromosomal minutes. The 
coloured arrows represent the genes on a relative scale where the tatABCD operon (blue), the ubiEJB operon 
(orange) and the rmuC and rfaH flanking genes (green) are indicated. B. The non-coding nucleotide sequence 
between the ubiB and tatA genes of WT W3110. The stop codon of ubiB (TGA) and the start codon of tatA 
(ATG) are represented in bold on the left and right side respectively. The promoter was predicted with strong 
conservation to the -35 and -10 motif specific for sigma transcription factors and is indicated as underlined. 
The transcription start site (+1) of the downstream tatA gene is indicated by an arrow (Solovyev, 2011). C. The 
non-coding nucleotide sequence inserted by Browning et al. (2017) strictly after the stop codon of the 
upstream ubiB gene to build the TatExpress strain. This sequence contains the tac promoter represented with 
the -35 and -10 motif (plain underlined), the lac operator (dashed underline) and the transcription start site 
(+1) as indicated by an arrow (de Boer et al., 1983). D. The non-coding nucleotide region between the rmuC 
and ubiE genes. The stop codon of rmuC (TGA) and the start codon of ubiE (ATG) are represented in bold on 
the left and right side respectively. The promoter was predicted with strong conservation to the -35 and -10 
motif of sigma transcription factors, indicated as underlined. The transcription start site (+1) of downstream 
ubiE gene is indicated by an arrow (Solovyev, 2011). No Rho-independent terminator was predicted 
immediately downstream of the rmuC gene (Solovyev, 2011). 
 
Transcription termination is operated by two mechanisms in bacteria: intrinsic or Rho-dependent 
terminations (Porrua et al., 2016). The former system corresponds to a GC-rich region, creating a 
hairpin loop in the nascent mRNA transcript downstream from the stop codon of the last gene being 
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transcribed. This can be detected by computational models (Gardner et al., 2011, Solovyev, 2011). 
Conversely, Rho is a bacterial factor which binds to a non-conserved 70-100 nucleotide binding site 
of the nascent transcript (Ciampi, 2006, Porrua et al., 2016, Mitra et al., 2017). Beyond being rich in 
cytosines and accounting for near half of the transcription terminations in E. coli, these sites do not 
have a consensus motif and so remain unpredictable (Ciampi, 2006). 
If a terminator, whether Rho-dependent or-independent, was present downstream of the ubiEJB 
operon and halts with a distinct transcriptional terminator, it would be located in the region after its 
stop codon. Therefore, the transcription initiated from the tac promoter inserted strictly after ubiB 
stop codon would presumably, be terminated shortly after by the terminator region of the ubiB gene. 
However, Browning et al. (2017) demonstrated that the TatExpress strain enabled overexpression of 
TatA upon IPTG induction which suggests the absence of a transcriptional terminator downstream 
of the stop codon of ubiB. Indeed, using available online tools FindTerm and ARNold, no rho-
independent hairpin terminator was identified downstream of the ubiB gene in WT strains (Solovyev, 
2011, Naville et al., 2011). This suggests that if there is a terminator, it is likely to be Rho-dependent 
and cannot be predicted. All of this suggests that as one possible scenario, ubiEJB-tatABCD genes 
could be transcribed as one mRNA transcript with a 78 bp non-coding region between the two 
clusters. In this case, the internal promoter upstream of the tat operon would give a second 
transcript containing tatABCD mRNA. To validate this hypothesis, PCR on cDNA and total RNA 
sequencing was performed on the strain used by Browning et al. (2017). 
 
8.2. Analysis of the non-coding region between the ubiB and the tatA 
genes 
The hypothesis that both ubiEJB and tatABCD operons are transcribed as a single mRNA transcript 
was evaluated. Total RNA was extracted from W3110 WT cells harvested at mid-log phase (section 
2.2.14.) and subsequently cDNA was prepared by reverse-transcription (section 2.2.15.). The latter 
was used as DNA template for PCR amplifications with various sets of primers shown in Figure 8-2. 
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They were designed to ensure specificity by respecting the following criteria: more than 20 
nucleotides in length, guanine/cytosine content percentage near 50 %, fusion temperature above 
55°C and a thymine or adenine nucleotide at the 3’ terminus. The specificity of the primer sequences 
was established using the Vector NTI software (Life Technologies) and the BLAST online tool (Altschul 
et al., 1997). Then, the reaction products were analysed by agarose gel electrophoresis (section 
2.2.6.) and the results are represented in Figure 8-3 and Figure 8-4. The theoretical amplicons 
expected in these figures are depicted in Figure 8-2. 
 
 
Figure 8-2: Theoretical PCR products 
The genetic representation of the ubiEJB and tatABCD operons locus is represented on top. The coloured 
arrows represent the genes on a relative scale where the tatABCD operon and the ubiEJB operon are indicated 
in blue and orange respectively. The forward (F) and reverse (R) primers used in the PCR reactions are indicated 
by black arrows. The theoretical PCR amplicons designated as A to F are indicated below. They are framed by 
their respective size in kilobase pair (kbp) on the left and primers’ name on the right. 
 
In Figure 8-3A, control experiments were conducted to establish the size of the PCR products 
generated using the respective primer pairs F1/R1 and F2/R2 that correspond to the tatABCD operon 
(2.365 kbp; lane A) and the ubiB gene (1.587 kbp; lane B). In lane C, to test the presence of mRNA 
corresponding to the ubiB-tatABCD genes (4.066 kbp), F2/R1 primers were used. A ≈ 4.1 kbp band 
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was observed that corresponds to the predicted size of the PCR amplicon of this region suggesting 
that there is indeed no terminator between ubiB and tatA. To prove further this discovery and 
confirm the presence of ubiB and internal members of the tat operon, tatABC, the DNA from the 
band in lane C (Figure 8-3A) was extracted from the gel (section 2.2.7.) and the resulting purified 
DNA was used as the DNA template to perform Nested PCR. The respective primer pairs F2/R2 
(Figure 8-3B, C1) and F1/R3 (Figure 8-3B, C2) resulted in the generation of a ≈ 1.6 kbp product for 
both. This is the expected size needed to confirm the presence of the tatABC genes as well as the 
ubiB gene. This data supports the supposition that these genes are transcribed as a single mRNA 
transcript. However, the presence of a 1.9 kbp additional band in the C2 lane suggested non-specific 
annealing (Figure 8-3B) despite specificity checks on the primers. 
 
 
Figure 8-3: Experimental evidence of the absence of terminator between ubiB and tatA 
Agarose gels at 1 % loaded with PCR products amplified from cDNA obtained from total RNA extracted from 
W3110 WT cells grew in LB to mid-log phase. A. The pairs of primers F1/R1, F2/R2 and F2/R1 were used in the 
PCR which results were loaded on the lanes A, B and C corresponding to the genes tatABCD, ubiB and ubiB-
tatABCD respectively. Lane C was part of the same gel as lanes A and B but has been purposely over-contrasted 
for visual inspection to compensate the lower amplification yield than lanes A and B. B. The lanes C1 and C2 
contained the PCR products amplified from the amplicon extracted from the lane C, using the pairs of primers 
F2/R2 and F1/R3 corresponding to the genes ubiB and tatABC respectively. The approximate sizes of the bands 
are indicated in kilobase pair (kbp) by blue arrows while the theoretical amplicon sizes are detailed in Figure 
8-2. The molecular weight markers are indicated in kbp. The figure is a composite image where the marker 
lanes reflects the approximate position of the molecular weights. 
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This outcome was reproduced in a more thorough experiment performed in triplicates. A control 
was also used for each condition to confirm that the PCR products originated from cDNA 
amplification and not from contaminating genomic DNA. This negative control was performed by 
replacing the reverse-transcriptase enzyme with water during the reverse transcription step with the 
extracted RNA. Using the pair primers F1/F3 (Figure 8-2), a 1.6 kbp amplicon (Figure 8-4, amplicon 
C2, a1-a3) corresponding to the tatABC genes was generated, while no bands were observed on the 
negative controls (Figure 8-4, amplicon C2, c1-c3). This confirmed that the tatABC genes amplified 
previously (Figure 8-3B, C2) originated from mRNA rather than contaminating genomic DNA. Further 
amplifications of a ≈ 1.9 kbp product with primers F2/R4 (Figure 8-4, amplicon D, a1-a3), and a ≈ 2.5 
kbp product with F3/R4 (Figure 8-4, amplicon E, a1-a3), corresponding to the size of the respective 
ubiB-tatA and ubiJB-tatA regions (Figure 8-2) provided additional confirmation. As before, all controls 
(Figure 8-4, amplicons D and E, c1-c3) were clear demonstrating the absence of genomic DNA 
contamination. Unfortunately however, amplification of the ubiEJB-tatA (3.36 kbp), ubiJB-tatABCD 
(5.462 kbp) regions or even ubiEJB (3.012 kbp)) operon was not successful despite several 
optimisations. The latter included the application of several sets of primers, each pair annealing to 
different sites on the genes, a range of annealing temperatures for the annealing step during the 
PCR, and titration of DMSO concentration to relax the guanine/cytosine rich regions. Nevertheless, 
the data appears to support the absence of a transcriptional terminator between the ubi and tat 
operons. 
 





Figure 8-4: Further confirmation of the absence of terminator between ubiB and tatA 
Agarose gels at 1 % loaded with PCR products amplified from cDNA obtained from total RNA extracted from 
W3110 WT cells grew in LB to mid-log phase. The biological triplicates (a1 to a3) were performed with negative 
controls (c1 to c3) where the reverse transcriptase enzyme was replaced by water. The results of the PCR using 
the respective pair of primers F1/R3, F2/R4 and F3/R4 to amplify the tatABC (Figure 8-3, C2), ubiB-tatA (Figure 
8-3, D) and ubiJB-tatA (Figure 8-3, E) genes were loaded on the lanes D, E and F. The approximate sizes of the 
bands are indicated in kilobase pair (kbp) by blue arrows while the theoretical amplicon sizes are detailed in 
Figure 8-2. The molecular weight markers are indicated in kbp. The figure is a composite image where the 
marker lanes reflects the approximate position of the molecular weights. 
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To add support to ubiEJB and tatABCD forming one large operon, 5’ RACE experiments were 
undertaken. Indeed, this technique allows sequencing of unknown 5’ ends of mRNA requiring only 
knowledge of only a short sequence of the gene (Miller, 2016). 5’ RACE allowed identification and 
characterisation of both eukaryotic and prokaryotic 5’ sequences of RNA transcripts (Allen et al., 
2007, Langley et al., 2017). However, this technique was never optimised for transcript longer than 
1 kbp (Zismann and Nourbakhsh, 2014, Miller, 2016). The aim in this study is to identify an mRNA 
containing the ubiEJB-tatABCD genes (5.5 kbp) which is significantly longer and therefore a high risk 
of failure. 5’ RACE was nonetheless selected to confirm the presence of ubiB and tatA on the same 
mRNA by an unbiased approach. Unfortunately, the amplification steps never reached reads long 
enough to encompass the whole ubiB and tatA genes on the same mRNA transcript, despite 
optimisation of the PCR parameters and primers.  
 
8.3. Phylogenetic study of the ubiEJB-tatABCD locus 
The data gathered in the section 8.2. strongly supports that ubiEJB and tatABCD are transcribed as a 
single mRNA presumably from the predicted promoter upstream of ubiE. This is in addition to the 
tatABCD genes being transcribed as a single transcript from the predicted promoter upstream of 
tatA. The cluster of these genes, belonging to ubiquinone biosynthesis and Tat export, may be 
conserved in other species. The tat region of several bacterial genomes of different bacterial lineage 
were downloaded from https://www.ncbi.nlm.nih.gov/genome/ website and analysed using 
alignment software tools (Geneious). The results represented in Figure 8-5 revealed that, out of the 
10 bacteria, 7 have a chromosomal arrangement similar to E. coli K12 where the ubi operon is located 
strictly upstream from the tat operon: E. coli K12 W3110, Salmonella enterica, Yersinia pestis, Vibrio 
cholerae, Aeromonas hydrophila, Shigella dysenteriae and Shewanella oneidensis. These species 
belong to the same phylum called Gammaproteobacteria subclade III (Figure 8-6). In Shigella 
dysenteriae, Yersinia pestis, Vibrio cholerae, Pseudomonas aeruginosa, Xanthomonas axonopodis 
and Neisseiria meningitidis A, the tatD gene is missing from the tat operon but encoded elsewhere 
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in their genome. This gene is conserved but non-essential and codes for a DNase which was 
demonstrated to have no direct correlation to the Tat translocation machinery (section 1.3.2.3.).  
 
 
Figure 8-5: Comparison of tat regions across several bacterial species 
The tat regions of the Escherichia coli K12 W3110 (NC_007779), Salmonella enterica (NC_003198), Yersinia 
pestis (NC_003143), Vibrio cholerae (NC_002505), Aeromonas hydrophila (NC_008570), Shigella dysenteriae 
(NC_007606), Shewanella oneidensis (NC_004347), Pseudomonas aeruginosa (NC_002516), Xanthomonas 
axonopodis (NC_020800) and Neisseria meningitidis (NC_003112) genomes were aligned using the Geneious 
software. The ubi, tat and other genes are indicated in orange, blue and green respectively. The underlined 
species indicate that their respective locus is on the complementary strand. The name of the genes is contained 
in the arrows with A standing for tatA and X for uncharacterised genes. 
 
In Gammaproteobacteria subclade II, Pseudomonas aeruginosa possesses the hisI and hisE genes 
inserted between the ubi and tat operons (Figure 8-5 and Figure 8-6). These genes code for the 
metabolic proteins, phosphoribosyl-AMP cyclohydrolase and phosphoribosyl-ATP pyrophosphatase 
respectively. Xanthomonas axonopodis and Neisseria meningitidis were found to be distinct, as 
members of the Gammaproteobacteria subclade I and Betaproteobacteria respectively. Both do not 
have the ubi operon located upstream from the tat operon suggesting that the ubi-tat locus is 
conserved within the Gammaproteobacteria subclade III.  
 




Figure 8-6: Phylogenetic tree of the proteobacteria 
The tree was from the https://itol.embl.de/itol.cgi webpage with a focus on the Proteobacteria (Letunic and 
Bork, 2016). The stars indicated the species whose genomes were detailed in the Figure 8-5 with the ubi operon 
located strictly upstream of the tat operon (green) or not (red). 
 
 




Figure 8-7: Alignment of the intergenic regions between ubiB and tatA 
Intergenic regions between the ubiB and tatA genes were aligned using the online alignment tool Clustal 
Omega (Madeira et al., 2019). The regions were selected between the stop codon of ubiB and the start codon 
of tatA, both indicated in bold. The bacterial species represented are, in order, Escherichia coli K12 W3110 
(NC_007779), Salmonella enterica (NC_003198), Yersinia pestis (NC_003143), Vibrio cholerae (NC_002505), 
Aeromonas hydrophila (NC_008570), Shigella dysenteriae (NC_007606) and Shewanella oneidensis 
(NC_004347). The underlined species indicate that their respective locus is on the complementary strand. The 
same bases aligned across 6, 5 and 4 species are highlighted in green, orange and grey respectively. 
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The species analysed in Figure 8-5 and present in the Gammaproteobacteria subclade III were then 
further investigated. The sequences of their intergenic region between ubiB and tatA were aligned 
(Figure 8-6). This figure reveals that the sequence lengths vary from 42 to 211 bp but that the 
sequences appeared relatively conserved in patches of homology around tat promoter. Moreover, 
using the BPROM and FindTerm online tools (Solovyev, 2011), a promoter but no Rho-independent 
terminator was found for each of the members of the Gammaproteobacteria subclade III analysed. 
Within this data set, all members of this phylum present similar features between ubiB and tatA. The 
conservation of this locus may have a biological significance. 
 
8.4. Conclusion regarding the tat operon region 
This work was initiated from uncertainties regarding the transcriptional control in the TatExpress 
strain, as developed by Browning et al. (2017). Indeed, the insertion sequence containing the tac 
inducible promoter strictly after ubiB’s stop codon suggested that there is no transcriptional 
terminator between the ubiB and tatA genes. The possibility of a transcript encompassing both the 
ubiEJB and tatABCD gene clusters was investigated by PCR analysis of cDNA derived from mRNA 
extracted from W3110 WT. Although putative promoters were predicted upstream of ubiE and tatA, 
data suggests that the operon organisation is much larger where two types of transcripts can 
potentially be transcribed due to the absence of a transcriptional terminator between the currently 
annotated ubi and tat operons. These are a ≈ 5.5 kbp and ≈ 2.4 kbp corresponding to ubiEJB-tatABCD 
and tatABCD respectively. Data supporting this theory was discovered from amplification of cDNA, 
corresponding to the ubiJB-tatA and ubiB-tatABCD genes. Moreover, the phylogenetic study 
revealed an evolutionary conservation of the two operons strictly located next to each other within 
the Gammaproteobacteria subclade III of which E. coli is a member. RNA sequencing was attempted 
but did not give meaningful data for interpretation. Therefore, this hypothesis requires further 
confirmation which can be brought by Northern-blot, cDNA sequencing and/or reporter gene assay. 
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Operons are an evolutionary result of clusters of genes with related functions but the connection 
between the ubiquinone synthesis and the Tat export pathway remains unclear (Jacob et al., 1960). 
None of the UbiEJB proteins possess a TatSP and UbiE and UbiJ are cytoplasmic proteins. The closer 
physical link between the operon is that the UbiB and TatABC proteins are located in the inner 
membrane due to α-helix(es) transmembrane domains (Palmer and Berks, 2012, Aussel et al., 
2014a). In terms of role, the proteins may be connected through their shared involvement in the 
respiratory electron transport chain (Patel et al., 2014, Aussel et al., 2014b). Indeed, Tat exports 
several proteins which requires DSBs in order to be active. Such DSBs are formed by the DsbA protein 
in the periplasm (section 1.4.1.1). DsbA is then re-oxidized by the inner-membrane protein DsbB 
which donates the electron received from DsbA to ubiquinone in aerobic conditions (Berkmen, 
2012). The electron is finally transferred to the respiratory chain (Cho and Collet, 2013). Through 
this, a connection might lay between the ubi and tat operons. 
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9. GENERAL DISCUSSION AND PERSPECTIVES 
9.1. Using a robust fractionation method 
The main objective of this project was to evaluate the Tat pathway to export recombinant proteins 
in E. coli. To demonstrate the protein localisation within the cells, the sub-cellular compartments 
were isolated by fractionation and detected by Western blot with specific antibodies. Hence, the 
selection of a method giving pure fractions was crucial. Cross-contamination was detected when 
using the main methods found in the literature and hence, optimisation was carried out to identify 
a robust technique. The PureFrac method (Malherbe et al., 2019) consists of cold osmotic shock with 
MgCl2 for periplasmic extraction followed by subsequent sonication to generate the cytoplasmic 
fraction (Chapter 4). The robustness of these fractions’ purity and high recovery of soluble 
cytoplasmic proteins was demonstrated by tracking the localisation of host control proteins such as 
the cytoplasmic LacI and periplasmic MBP. Throughout this project, 93.6 % of the expressed cells 
treated by PureFrac were successfully fractionated without cross-contamination demonstrating high 
level of robustness and consistency. 
 
9.2. Limitations of this study 
The PureFrac method is the most robust E. coli fractionation method published to date and is 
continuously validated by tracking host protein localisation (section 9.1.). However, there are 
improvements to be made that would positively improve consistency of the data generated. For 
instance, the addition of a wash step to the insoluble pellet arising after the removal of the 
cytoplasmic fraction could improve the purity of the insoluble fraction by eliminating potential 
cytoplasmic contamination. Another limitation in these experiments was to consciously over-expose 
the Western-Blot membranes to avoid missing any data arising from low intensity bands due to low 
protein amount. The exposure times were kept strictly identical between each experiment to 
maintain consistency. The downside was that this resulted in the saturation of the signals which 
prevented running densitometric analysis (Bass et al., 2017). Densitometry could provide 
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quantitative or semi-quantitative protein data from Western-Blot images (Gassmann et al., 2009). 
Finally, this pre-screen methodology was evaluated with only few biological replicates due to the 
number of samples brought by the high number of conditions tested. Biological replicates are 
necessary to demonstrate the consistency of a result. However, in the case of PhoA and hGH 
expressed without a fusion partner, these were repeated as controls in other experiments and show 
data consistency (Figure 6-2, Figure 7-2 for PhoA and Figure 6-9, Figure 7-4 for hGH). 
Regarding the activity assays, these were run with crude fractionated samples and therefore an 
accurate specific activity based on level of protein expressed could not be determined. Specific 
activities of β-galactosidase, PhoA and sfGFP would require the purification of the relevant protein 
prior to the assay. However, in hindsight a semi-quantitative analysis where the specific activity as a 
measure of the total protein per fractionated sample could have been used which could have 
enabled a measurable fraction comparison between experiments. Moreover, regarding PhoA, His 
and Flag purification would be required on the fusion samples since C-terminal degradation was 
observed. However, as the main focus of this study concentrated on preliminary experiments to 
evaluate the Tat pathway for export of recombinant proteins, these assays were not attempted due 
to the size of the sample pools and the small sample volumes. Furthermore, for the other 
recombinant proteins expressed, correctly folded and therefore active proteins can only be 
determined by complex cell-based binding assays in the case of hGH and FABP4, or ligand binding 
assays with respect to the VHHs. Due to the strategic focus of this work, these assays were not 
attempted. However, the importance of this data with respect to the correct folding of proteins is 
appreciated and should be an integral part of further studies to understand the mechanism of export 
of these proteins.  
Other culturing methods could also be considered that may impact the quality of expression and 
export. Indeed initially, the Enpresso® medium (BioSilta) was utilised in an attempt to mimic a fed-
batch system by providing a constant and slow release of the carbon source from a polysaccharide 
(Ukkonen et al., 2017). However, this medium was commercially discontinued during the course of 
this project. Auto-induction media were also considered to screen a high number of conditions (Fox 
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and Blommel, 2009, Studier, 2014). But as these media do not enable precise control over the 
induction period, a necessary factor for reproducibility and to limit inclusion body formation, these 
media were not used.  
Furthermore, the process described in this study from transformation of the expression strains to 
detection by Western-blot of the proteins of interest in the fractions was time-intensive. Ways to 
apply a high-throughput process were investigated including the usage of 24 deep-wells plates 
instead of shake-flasks for cell culture but were unsuccessful. Indeed, in the case of the latter 
example, the plates presented slower growth presumably due to inefficient gas exchange and the 
sample volumes were too low to run the required analysis. However, a miniaturisation of the process 
could still be investigated to pursue this project such as the use of ambr® 15 (Sartorius) or BioLector® 
(m2p-labs) bioreactors. Another method to have a more high-throughput methodology would be to 
remove the fractionation step by having a direct assay to detect the protein of interest into the 
periplasm. 
 
9.3. Exporting recombinant proteins via the Tat pathway 
9.3.1. Direct fusion to a signal peptide 
Several aspects make the periplasm an attractive location to produce recombinant proteins in E. coli 
including DSB formation and a lower amount of host cell proteins (Chapter 3). To target a protein of 
interest to this cellular compartment, the protein is fused to a signal peptide at its N-terminus which 
then targets export via a specific route. The Sec pathway is mainly used but, more recently, interests 
have been raised towards the Tat pathway because of its so-called proofreading mechanism and 
ability to export folded proteins (section 1.3.2.5.). However, successful Tat export has only been 
shown for a few proteins (section 3.1.) which suggests that many proteins fail to export due to the 
proofreading activity. To alleviate this bottleneck, the strategy used in the present work, involved 
the fusion of the protein of interest to a soluble partner. The aim was to improve the solubility and 
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folding of the protein of interest in the cytoplasm, enabling a more successful screening by the Tat 
proofreading. 
NTS were initially considered as the soluble partner for the fusions and five candidates were selected: 
AmiA, HyaA, PaoA, TorA and YcbK (Chapter 5). Only TorA was successfully exported via the Tat 
pathway and the reasons why the other candidates failed to do so remains unidentified. The 
unknown characteristics of the NTS such as their constitutive expression, regulatory elements or 
requirement for chaperones may critically impact their exportability. Therefore, the remaining NTS 
were not considered (Appendix 1). Furthermore, recombinant proteins β-galactosidase, PhoA, sfGFP 
and hGH were considered as reporter protein to play the role of the protein of interest in the fusion 
design (Chapter 6). Unexpectedly, sfGFP and hGH presented export capabilities without the 
requirement of a signal peptide as discussed in section 9.7.2. Despite this, hGH and also PhoA were 
proven to be translocated specifically via the Tat pathway when fused to TorASP. Consequently, the 
fusion strategy was modified, and the successful reporter proteins were used as the soluble partner 
in fusion to proteins of interest (section 9.3.2.). 
9.3.2. Fusion to a soluble partner 
The Table 9-1 summarizes the export results obtained during the present work, with the proteins of 
interest expressed alone and in fusion with hGH and PhoA (detailed in Chapters 5, 6 and 7). The 
present work aimed to evaluate whether the fusion of a TorASP-fused soluble partner would improve 
export via Tat of the protein of interest compared to fusion of solely the TorA signal peptide. Export 
of the fusions using hGH as a soluble partner and without a signal peptide challenged interpretation 
of export observations of the TorASP-hGH fusions proteins (section 9.7.2.). Hence, only the fusions 
using PhoA as a soluble partner were considered with which, no improvement in terms of export 
were observed. Indeed, out of the four proteins of interest fused to TorASP-PhoA (hGH, FABP4, VHH1 
and VHH2), only two proteins (FABP4 and VHH2) have shown signs of export when co-expressed with 
CyDisCo (Table 9-1). Not only did these two proteins export when fused directly to TorASP, but also 
one additional protein, VHH1, was exported. Although, Tat specificity needs to be investigated by 
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using the Tat-null strain and the activity of the proteins of interest needs to be evaluated to assess 
their native conformation. Moreover, the amount of periplasmic proteins appeared relatively low 
compared to the cytoplasmic proteins which may be the result of Tat saturation. Equally, the 
presence of a significant level of protein in the cytoplasm suggests misfolding which might be 
reduced by co-expressing chaperones (Shriver-Lake et al., 2017). 
Overall, over the set of proteins tested in this study, the fusion strategy used to improve export via 
Tat was unsuccessful. Moreover, export appears to be protein dependent. However, before 
definitively ruling out the idea of fusing to a carrier protein, more soluble protein candidates and 
proteins of interest need to be evaluated. Based on the limitations identified in this study, it would 
be prudent to select proteins that have a simple activity assay as this measure is indicative of a 
correct folded protein. Furthermore, it would be interesting to understand why FABP4 and VHH2 
were translocated when fused to TorASP-PhoA whereas hGH and VHH2 were not (Table 9-1). Since 
the cytoplasmic and periplasmic PhoA were not active, the fusion proteins were not correctly folded 
even if the data suggests Tat export. Therefore, TorASP-PhoA-FABP4 and TorASP-PhoA-VHH2 gained 
a stable conformation in the cytoplasm but not native. Hence, the question remains as per why 
TorASP-PhoA-hGH and TorASP-PhoA-VHH1 are not in a similar conformation allowing export. 
9.3.3. General discussion over the suggested use of the Tat pathway in 
biotechnology 
Three proteins were observed to be transported across the inner membrane without a signal 
peptide: sfGFP, hGH and FABP4 (Table 9-1), and are discussed in section 9.7.2. Most of the remaining 
proteins when expressed with OmpASP were observed in the periplasmic fraction and data suggests 
they were exported via the Sec pathway (Table 9-1). But most of the proteins expressed with a TatSP 
were not exported (YcbK, AmiA, HyaA, PaoA, β-galactosidase, VHH1, hGH-VHH1, PhoA-hGH and 
PhoA-VHH1) or exported but not specifically (PoaASP-PhoA and PaoASP-sfGFP) via the Tat pathway 
(Table 9-1) indicating that export via Tat is protein dependent. Tat specific export was justified by 
the presence of the protein of interest in the periplasm in the WT strain but not in the Tat-null strain. 
Rejection from the Tat translocon is attributed to the proofreading mechanism (section 1.3.2.5.) 
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selecting substrates over criteria not yet fully understood. Moreover, the only cases where no export 
was reported when the recombinant protein was fused to OmpASP were with β-galactosidase and 
hGH-VHH1 fusion. In both cases, targeting to the Tat pathway did not offer an alternative to 
unsuccessful Sec targeting. 
The data presented in this study, albeit the number of proteins tested is low, indicates the 
unpredictability of the Tat export mechanism. For instance, two VHHs with similar biophysical 
properties (section 7.4.) presented distinct export profiles (Table 9-1). Indeed, VHH1 presented no 
sign of export with TorASP whereas VHH2 were detected in the periplasm when fused to this signal 
peptide whether it was expressed alone or fused to PhoA or hGH. Although these proteins share 
some similar structural and biophysical motifs, their protein sequences are divergent (Figure 7-9, 
Table 7-1, Appendix 11). Another example is the NTS PaoA which was anticipated to be exported via 
the Tat pathway (Lee et al., 2014). However, despite thorough optimisation, no specific export via 
Tat was obtained to fulfil the expectation and corroborate published results (section 5.2 
Furthermore, the specificity of the export mechanism needs to be established via expression in the 
Tat-null strain. Also, the activity of the exported protein has to be assessed as well as the ratio of 
active periplasmic proteins over the periplasmic proteins. This would determine whether Tat exports 
proteins in a native state or at least, in a confirmation allowing native folding in the periplasm. 
The present data, added to the short list of successfully exported proteins published, suggest a 
limited use of the Tat pathway to produce recombinant proteins. Tat has seemingly many advantages 
over Sec, but the proofreading mechanism which appears to reject many recombinant proteins, 
needs to be further understood in order to better anticipate export of a protein of interest. For 
instance, Ulfig and Freudl (2018) presented the importance of the N-terminal residues of the 
recombinant protein for TatBC binding and thus, translocation (section 1.3.2.4.). Therefore, a 
comparability study of the N-terminal sequence of the successful and unsuccessful candidates may 
help understand the acceptance mechanism of the Tat translocon. Moreover, recombinant proteins 
may require helper factor such as chaperones to be translocated by the Tat pathway which was not 
the focus of this study. 
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Table 9-1: Summary of protein export results 
The table includes the export profile of all the proteins presented in this work: uncharacterised protein YcbK, 
N-acetylmuramoyl-L-alanine amidase (AmiA), small chain of hydrogenase-1 (HyaA), aldehyde oxidoreductase 
iron-sulphur-binding subunit A (PaoA), trimethylamine-N-oxide reductase 1 (TorA), β-galactosidase (β-gal), 
alkaline phosphatase (PhoA), superfolder green fluorescent protein (sfGFP), human growth hormone (hGH), 
fatty acid-binding protein 4 (FABP4), VHH1 and VHH2. Some exports were studied in co-expression without 
(Cy-) or with (Cy+) CyDisCo. The relative exports are represented as no export (-), non-significant export (+/-), 
low export (+) and high export (++). The green boxes represent Tat specific export confirmed by the lack of 
export on a Tat-null strain (section 3.6.), the orange boxes are not Tat-specific export, the blue boxes indicate 




9.4. The evaluation of CyDisCo 
This technology was used to form cytoplasmic DSB without disrupting the reducing pathways by co-
expressing the sulfhydryl oxidase Erv1p and the isomerase PDI. During the present work, the co-
expression of CyDisCo was confirmed to be essential for the Tat export of PhoA in which case this 
protein was observed active in the periplasm (Table 9-2). However, CyDisCo is suspected to not form 
the native DSB on PhoA because of the inactivity of this enzyme in the cytoplasm (Table 9-2). Indeed, 











β-gal - - - - - - - - - - - - - -
PhoA - - ++ ++ - + - +
sfGFP + + + +
hGH - + + + + +
FABP4 + + + - + +
VHH1 - - + + - -
VHH2 - - +/- +/- - +/-
PhoA + ++ ++ ++ + +
hGH
FABP4 + + + ++ + +
VHH1 - + - - - -
VHH2 + + + + + +
PhoA
hGH - - ++ ++ - -
FABP4 - - + + - +
VHH1 - - - + - -




YcbKSP AmiASP HyaASP PaoASP
-
Construct No SP OmpAS P
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been active. Hence, the periplasmic activity of PhoA is likely the result of the Dsb family periplasmic 
chaperones activity conferring native conformation to PhoA (section 1.4.1.1.). Furthermore, since 
cytoplasmic PhoA was not active in the presence of CyDisCo, PhoA was exported via Tat in a non-
native conformation. However, Matos et al. (2014) claimed that PhoA was correctly folded when 
exported by the Tat pathway. In their work, evidence of active cytoplasmic protein was lacking to 
support this claim. 
However, this technology increased PhoA’s expression levels and so, was hypothesized to enable 
DSB formation thanks to the homologous sulfhydryl oxidase but the heterologous isomerase shuffled 
the DSB into a non-native status. This way PhoA adopts a conformation accepted by the proofreading 
system of Tat but remains inactive and then shuffles into its native form in the periplasm. Following 
this hypothesis, PDI could be replaced by an endogenous isomerase like DsbC without its secretion 
peptide to test this theory. Indeed, when TorASP-PhoA was expressed in the SHuffle strain which 
expresses cytoplasmic DsbC, PhoA was found active in the cytoplasm. However, PhoA was inactive 
in the cytoplasm of this strain, when expressed without a signal. Hence, it would be interesting to 
investigate the folding state of these proteins to understand the impact of DsbC on PhoA folding. For 
instance, the structural configuration of cytoplasmic PhoA and TorASP-PhoA could be examined using 
circular dichroism and mass spectrometry.  
Another hypothesis was that the inactivity of the cytoplasmic PhoA could have been the result of the 
sonication explaining also the inactivity of the cytoplasmic sfGFP. Indeed, the cells appeared green 
upon direct observation (Figure 6-8) suggesting active cytoplasmic protein but sfGFP was found 
inactive in the cytoplasmic fraction after fractionation (Figure 6-7). This hypothesis could be assessed 
by lysing the cells using an alternative way like freeze/thaw cycling but with due diligence to 
maintaining the fractions purity. However, CyDisCo improved the solubility of most of the 
recombinant proteins used in this project as seen by the higher intensity of the bands with CyDisCo 
than without. The benefit of co-expressing chaperones on recombinant protein expression was not 
surprising (Ellis et al., 2017, Kang et al., 2012, de Marco, 2007) but these chaperones have proved 
their efficacy in improving the expression of soluble proteins. 
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Table 9-2: Impact of CyDisCo on the activity of PhoA 
The table summarizes the activity of PhoA reported in the present work. PhoA activity was analysed in the 
cytoplasmic (C) and periplasmic (P) fractions from cells expressing protein of interests, potentially fused to a 
soluble partner, fused to no signal peptide (No SP), the signal peptide of OmpA (OmpASP) or TorA (TorASP) and 






No SP OmpASP TorASP 
Reference Cy- Cy+ Cy- Cy+ Cy- Cy+ 
C P C P C P C P C P C P 
- PhoA - - - - - + - + - - - + Figure 6-2B 
- PhoA - - - - - + - + - - - + Figure 6-4B 
- PhoA - - - - - + - + - - - + 
Figure 7-2 
hGH PhoA - - - - - + - + - - - - 
PhoA hGH - - - - - + - + - - - - Figure 7-4 
PhoA FABP4 - - - - - + - + - - - - Figure 7-6 
PhoA VHH1 - - - - - + - + - - - - Figure 7-10 
PhoA VHH2 - - - - - + - + - - - - Figure 7-12 
 
During this project, PDI-cMyc and sometimes Erv1p-cMyc located in the periplasm unexpectedly 
since they do not possess a known signal peptide (Table 9-3). In all cases, the cytoplasmic marker 
LacI was not reported in the periplasm so the periplasmic presence of CyDisCo was not due to cell 
lysis during fractionation but rather due to a specific translocation mechanism during growth. VHH2 
is an exception but in this case, LacI was suspected to contaminate the periplasm due to cell lysis 
during fractionation. No prior observation of the periplasmic localisation of these chaperones has 
been reported. This export was not observed when CyDisCo was expressed alone (Table 9-3) 
indicating that the co-expression of a recombinant protein was somehow involved in the 
translocation of the CyDisCo proteins. The common feature between the recombinant proteins 
triggering CyDisCo export was the presence of OmpASP and/or N-terminal hGH with the exception 
of TorASP-αIL17 (Figure 6-9; Appendix 6; Appendix 8; Appendix 9; Appendix 12 and Appendix 13). 
The signal peptide of OmpA is known to bind to SecB which then recruits chaperones such as GroEL, 
DnaK and TF (section 7.2.2.). Using a similar interaction, the PDI chaperone and, to a lower extent, 
Erv1p might be recruited by OmpASP which would explain the higher translocation rate of the 
chaperones in presence of overexpressed OmpASP-fused proteins. However, this hypothesis does not 
yet explain how the protein crosses the inner membrane. With this signal peptide, only a small 
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proportion of these proteins were found in the periplasm. Hence, the question remains as per what 
it different about these proteins which explains why they were translocated whereas the remaining 
proteins remained in the cytoplasm. PDI and Erv1p were not exported via the Tat pathway since 
OmpASP was demonstrated to be Tat-incompatible (Huang and Palmer, 2017) and a putative signal 
peptide sequence for export in Gram-negative bacteria was not detected on either PDI nor Erv1p 
using signal peptide prediction software SignalP (Nielsen, 2017b) (Table 9-4). The involvement of the 
N-terminus sequence of the CyDisCo chaperones could be evaluated by expression of N-terminal 
truncated mutant. Subsequently, other Sec signal peptides known to interact with cytoplasmic 
chaperones could be tested in place of OmpASP to investigate whether it is the chaperone-recruiting 
ability of a Sec signal peptide which allows export of PDI and Erv1p. Moreover, this uncharacterised 
export might not be limited to the CyDisCo chaperones and hence, looking at the localisation of other 
chaperones such DnaK, GroEL and TF would allow to better grasp this mechanism. 
 
9.5. The conserved large operon 
Evidences supporting the idea that no terminator was present between the ubiEJB and the tatABCD 
operons in E. coli were presented in Chapter 8. Indeed, PCR performed on cDNA demonstrated the 
presence of mRNA containing genes from both operons (section 8.2.). Also, a phylogenetic study 
revealed that the arrangement of these genes on the chromosome is conserved amongst the 
Gammaproteobacteria subclade III phylum which includes E. coli (section 8.3.). Further analysis of 
this locus suggests that the absence of a terminator between these operons is conserved within this 
phylum. 
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Table 9-3: Periplasmic observations of the CyDisCo chaperones 
The table represents the detection of PDI and Erv1p in the periplasmic fractions when expressed from an 
empty vector (no construct) or co-expressed with the detailed constructs. The latter contained a protein of 
interest: alkaline phosphatase (PhoA), human growth hormone (hGH), fatty acid-binding protein 4 (FABP4), 
VHH1 or VHH2. Some of the constructs also contained a fusion partner: hGH, PhoA or none (Ø). The constructs 
were either fused to no signal peptide (No SP), the signal peptide of OmpA (OmpASP) or of TorA (TorASP). The 
relative exports are represented as no export (-), non-significant export (+/-), low export (+) and high export 
(++). 
Reference 
Periplasmic localisation when co-expressed with 






No SP OmpASP TorASP 
PDI Erv1p PDI Erv1p PDI Erv1p 
Figure 6-2 - - Ø PhoA - - - - - - 
Figure 6-4 - - Ø PhoA - - - - - - 
Figure 6-9 - - Ø hGH - - + +/- - - 
Appendix 6 
- - Ø PhoA - - - - - - 
- - hGH PhoA - - + +/- +/- - 
Appendix 8 
- - Ø hGH - - ++ +/- - - 
- - PhoA hGH - - + - - - 
Appendix 9 
- - Ø FABP4 - - - - - - 
- - hGH FABP4 - - +/- - - - 
- - PhoA FABP4 - - - - - - 
Appendix 12 
- - Ø VHH1 - - + +/- + - 
- - hGH VHH1 +/- - +/- - +/- - 
- - PhoA VHH1 - - - - - - 
Appendix 13 
- - Ø VHH2 - - + + - - 
- - hGH VHH2 - - + +/- - - 
- - PhoA VHH2 - - - - - - 
 
Table 9-4: Comparison of N-terminal sequences 
The sequence in blue corresponds to the signal peptide of OmpA. 
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However, more evidence should be brought before drawing a final conclusion with regards to this 
hypothesis. For instance, the cDNA obtained could be sequenced to confirm the presence of the 
genes within the same mRNA. Also, Northern-blot analysis could further confirm that the 
transcription of the ubiEJB operon does not stop between the ubiB and the tatA genes. Most 
importantly, reporter gene assays should be performed to experimentally validate the absence of a 
terminator but also to confirm the presence of an active promoter upstream of both ubiB and tatA. 
To do so, the regions upstream of the ubiE and tatA genes would be cloned separately upstream of 
a reporter gene such as PhoA or β-galactosidase to assess the presence of a functional promoter. 
Similarly, the region downstream of the ubiB gene would be cloned between two reporter genes in 
a polycistronic cassette to evaluate its transcription termination capacity. Moreover, assessing 
whether both predicted promoters are constitutive or induced would shed light on their respective 
function. The promoter upstream of the tat operon would be expected to be constitutive since NTS 
are relevant at multiple cell life cycle stages (section 1.3.2.1.). 
Finally, if both operons can be expressed under the same promoter and this is a conserved 
phenomenon, a common role is likely to exist. To evaluate a potential interaction between the 
proteins encoded by these genes, immunofluorescence, co-immunoprecipitation, pull down assay 
or FRET can be used. Also, RT-qPCR could help determine the transcription levels of these genes 




This project brought a better understanding over recombinant protein production in E. coli regarding 
fractionation methods, the CyDisCo technology and export pathways. Thus, a new method for 
fractionation was developed, with enough robustness to examine protein export. The CyDisCo 
technology did not fulfil its claimed ability to form correct DSB in the cytoplasm. Indeed, it was 
demonstrated to improve protein expression but the recombinant cytoplasmic proteins whose 
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activity was assessed were inactive indicating incorrect folding. Regarding the Tat export pathway, it 
was proven to be difficult to translocate recombinant protein, even its own substrates. The fusion 
strategy did not present any improvement in terms of export but highlights the need for additional 
optimisation. Tat proofreading mechanism appeared very selective and so, recombinant protein 
production using this pathway would first require a greater comprehension of this ability. 
Indeed, the investigation in this study to determine the transcriptional elements controlling 
expression of the Tat machinery may spark some interest. Data suggests the absence of terminator 
between the tat operon and the upstream ubi operon. This feature appears to be conserved amongst 
a certain phylum suggesting of a related function between these genes which remains to be 
determined. 
This work has also revealed that the proteins sfGFP, FABP4 and hGH are able to cross the inner 
membrane without the need for a signal peptide. This discovery might lead to the characterisation 
of a new export mechanism(s). Furthermore, the recombinant proteins fused to the C-terminus of 
hGH were shown to be exported without a signal peptide which may offer an alternative way to 
target proteins of interest the periplasm. Overall, the present study demonstrated that expression 
and export is protein dependent and hence, Tat translation needs to be optimised for each protein 
of interest. Also, the published repertoire of successful Tat export was not increase. 
 
9.7. Future perspectives 
From the work presented in this thesis, two major perspectives appear promising. The first one 
would be the pursuit of the fusion strategy to export recombinant proteins into the periplasm via 
Tat and is discussed in section 9.7.1. The second one would be the identification of the unknown 
mechanism(s) responsible for export of the sfGFP, hGH fusions, and FABP4 proteins without a signal 
peptide and is presented in section 9.7.2. 
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9.7.1. Optimize the fusion design 
Using fusions to enhance protein production and quality is not new and has been used for 
cytoplasmic expressions as well as periplasmic via Sec (Kosobokova et al., 2016, Malik, 2016). 
Although the results shown in section 9.3. may caution the use of a fusion strategy to improve Tat 
export, this work is still a pilot study and hence, there is room for improvements. A major drawback 
observed was the proteolytic clipping (section 7.5.). Indeed, the proteins expressed in fusion showed 
no sign of degradation when expressed alone except PhoA (Chapter 7). Since truncated products 
appeared when these proteins were expressed as fusions, the linker which brings the independently 
stable proteins together could be optimised. This linker was designed to be flexible and long to allow 
space for folding of both proteins. However, proteins folding and hence activity require the linker to 
be either long or short linker and either flexible or rigid (Chen et al., 2013). The current linker contains 
34 residues which is considered relatively long (Chen et al., 2013), so it could be truncated to test a 
shorter length. A specific cleavage site is mandatory and TEV cleavage site is one of the shortest and 
most specific one and hence, should not be altered. However, initial studies should include a control 
protein bearing a linker without a TEV site to investigate if this motif impacts proteolytic cleavage. 
The FLAG detection tag (section 3.2.), however, could be replaced for the shorter more traditional 
version (DYKDDDDK) or by V5 or HA to keep a high detection sensitivity (Kosobokova et al., 2016). 
Furthermore, a variety of linkers using a GS rich sequence for flexibility (Argos, 1990) or a (EAAAK)n 
α-helix type for rigidity could be tested (Bai and Shen, 2006, Amet et al., 2009). Another reason for 
using a more rigid linker is that the proofreading mechanism of Tat was considered to “sense” the 
rigidity of the substrate and dismiss them when too flexible (Jones et al., 2016, Sutherland et al., 
2018). Also, variants without the FLAG tag or the TEV cleavage site could bring a better 
understanding of the impact from these sections compared to the full-length linker. 
To evaluate a new range of linkers, the fusion proteins chosen should be, in theory, capable of being 
exported by Tat. Hence, following the present results (Chapter 6 and 7), a fusion protein containing 
candidates successfully exported via Tat is recommended. For instance, the fusions PhoA-hGH or 
hGH-PhoA could be considered. Indeed, these proteins have been shown to be exported Tat 
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specifically and PhoA was active in the periplasm. Furthermore, the usage of signal peptide of TorA 
should be continued as it exhibited the highest success rate with regards to Tat specific export. 
Another parameter which could reduce the fusions truncation is the culture condition. Indeed, low 
cultivation temperatures can reduce or impair protein degradation due to a poor activity of heat 
shock proteases that are usually induced during protein overproduction in E. coli (Chesshyre and 
Hipkiss, 1989, Costa et al., 2014). Moreover, a lowered induction level would reduce the cellular 
stress which might improve the folding and therefore, the export yield of the protein of interest. On 
a related note, over-expressing the Tat proteins from either a plasmid (Matos et al., 2012) or an 
engineered strain (Browning et al., 2017) might relieve the membrane stress due to jamming the 
export translocases. To this aim, induction at lower temperature for a longer time was tested in 
sections 4.4., 5.2.4. and 5.2.5. However, this condition did not impact positively expression nor 
export and even had a negative impact on PaoA as less proteins was detected after a 16h induction 
at 22°C than 2 or 4 h at 30°C (Figure 5-5). 
9.7.2. Characterise the unknown mechanism(s) of export 
Table 9-1 highlights an unexpected phenomenon: the export of proteins with no signal peptide. 
Through this project, three proteins were identified with “auto-export” properties: sfGFP (section 
6.4.), hGH (section 6.5.) and FABP4 (section 7.3.). Furthermore, hGH-fused proteins were also shown 
to auto export (Chapter 7). The online tool SignalP (Nielsen, 2017b) predicted no putative signal 
peptide sequence in their N-termini. The case of sfGFP was investigated by Zhang et al. (2017) who 
discovered that this protein did not require its 20 N-terminal residues to export. Therefore, the 
“auto-export” is allowed by another means than a N-terminal motif. A similar evaluation could be 
conducted on the remaining “auto-exporters” to assess the presence of an unpredicted N-terminal 
signal peptide. 
Also, Zhang’s team found sfGFP to be located in the extra-cellular medium after a 24 h induction 
period. They demonstrated that the secretion of sfGFP was not the result of cell lysis by the absence 
of detectable cytoplasmic GroEL and periplasmic β-lactamase markers in the extracellular medium 
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(Zhang et al., 2017). The amount of sfGFP observed in the extracellular medium was substantial and 
so, could be the result of cellular stress due to overexpression. To test this possibility, the expression 
level of sfGFP should be lowered, e.g. by using an origin of replication with a very low copy number 
such as SC101 (Friehs, 2004). Also, it would be interesting to extend the induction times of the other 
“auto-exporting” proteins listed here to assess their “auto-secretion”. Moreover, since the sfGFP was 
detected to cross both membranes, identifying all the compartments in which these “auto-
exporters” locate (cytoplasm, inner membrane, periplasm, outer membrane and extra-cellular 
medium) would bring a better understanding on the phenomenon. 
 
 
Figure 9-1: Structures of non-conventional exporting proteins 
The structures of superfolder green fluorescent protein, mCherry, fatty acid binding protein 4, human growth 
hormone, human protein disulphide isomerase and sulfhydryl oxidase Erv1p from Saccharomyces cerevisiae 
represented from 1 to 6 were solved by X-ray crystallography at 1.85, 1.6, 1.08, 2.5 and 2Å respectively except 
Erv1p which was solved by NMR (Dippel et al., 2016, Shu et al., 2006, González and Fisher, 2015, Chantalat et 
al., 1995, Kemmink et al., 1999, Guo et al., 2012). The structures represent the following residues: 1-238, 1-
236, 1-132, 27-217, 136-345, 86-189 respectively. The secondary structures are coloured with the β-sheets in 
yellow, the α-helixes in red and the coil in green. 
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Zhang et al. (2017) did not identify how sfGFP was secreted but they discovered that the β-barrel 
structure (Figure 9-1) was essential for secretion. Hence, they expressed mCherry, a protein with a 
similar β-barrel structure (Figure 9-1), and identified it in the extra-cellular medium (Shu et al., 2006). 
They did not express a protein that does not possess a β-barrel structure, but they discovered that 
sfGFP was no longer secreted when its structure was impaired. This structure is shared with FABP4 
(Figure 9-1) and thus, the involvement of this particular structure could be investigated on FABP4. 
Similar to the strategy from Zhang et al. (2017), the impact of specific mutations impairing the β-
barrel structure on the “auto-export” ability could be assessed. 
Zhang et al. (2017) suggested that sfGFP and mCherry are secreted thanks to their β-barrel structure. 
This theory could apply to FABP4 as well but not to hGH which showed “auto-exported” properties 
but does not share the same 3D structure (Figure 9-1). Therefore, either the theory from Zhang et 
al. (2017) is incomplete or these proteins are exported via different means. The unknown 
translocation mechanism by which hGH can be exported appeared to be used only if this protein is 
on the N-terminal of the fusion but not on the C-terminal (Chapter 7). However, no signal peptide 
was predicted at the N-terminus of hGH (section 6.5.). Furthermore, the data suggests that hGH is 
exported via the Tat pathway when expressed in fusion with TorASP. This was demonstrated by the 
presence of mature protein in the periplasm suggesting that TorASP was processed after Tat 
translocation while data suggests that the unknown pathway does not process the signal peptide. A 
similar profile was observed for sfGFP and FABP4 suggesting a common mechanism of export is used 
by both proteins. This also means that the signal peptide of TorA prevents export via the unknown 
pathway(s). This observation would potentially help characterizing this mechanism. Indeed, mutant 
versions of TorASP can be assessed as well as other TatSP to determine the characteristics of the N-
terminal residues that lead to export via the unknown mechanism. Such mutations could include N-
terminal truncated versions, replacement of the twin arginine by lysine residues, increasing or 
decreasing the net charge and the hydrophobicity of the signal peptide. Moreover, data suggests 
that OmpASP did not prevent the unknown translocation events. Hence, this signal peptide could be 
altered to allow Tat translocation to further investigate the impact of the N-terminal region. This can 
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be achieved by decreasing the hydrophobicity of the h-region (section 1.3.1.1.) and creating the 
consensus twin-arginine motif as inspired by (Cristóbal et al., 1999). 
Also, hGH presented the ability to carry all the recombinant proteins fused to its C-terminus during 
this project (Table 7-2). However, in the case of hGH-PhoA, the reporter protein PhoA was not active 
in the periplasm. This fusion protein was also found in the periplasm when expressed with OmpASP 
and TorASP but the PhoA component was only active in the periplasm from expression of OmpASP-
hGH-PhoA (Table 9-1 and Table 9-2). However, it was not established if the activity came from the 
full-length protein or a truncated species containing PhoA (section 7.2.2.). Since PhoA is naturally a 
dimer, it is possible that fusion to hGH may have hindered dimer formation (section 6.3.), thus 
preventing activity. In order to test this hypothesis, the biological functionality of the other piggy-
backed proteins, FABP4 and the VHHs which are monomeric, could be determined. Nevertheless, 
the present work demonstrated the possibility of exporting recombinant proteins in the periplasm 
and perhaps beyond in a piggy-back fashion by hGH and potentially FABP4 which could be a 
promising alternative for recombinant protein production. 
Another mechanism by which proteins were reported to export without a signal peptide was 
considered. The protein localization (prl) mutations are located on the Sec pathway proteins such as 
SecA, SecE, SecG and SecY (section 1.3.1.). SecY mutations named prlA mutations allow export of 
proteins with defective or even no signal peptide without altering export of natural substrates 
(Derman et al., 1993, Flower et al., 1994, Bost and Belin, 1997, van der Wolk et al., 1998, Smith et 
al., 2005). A patent was granted for particular prl mutations on SecY for exporting antibodies, 
antibody fragments, or antibody-related polypeptides from prokaryotes without a signal peptide 
(Yarranton and Bebbington 2005). However, genome sequencing of the strains used in the present 
project (section 3.6.) revealed that the secY genes contained none of the published prlA mutations 
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Appendix 1: List of NTS from E. coli 
List of 28 natural Tat substrates from Brown et al. (1995) and Tullman-Ercek et al. (2007) supplemented with 
information from UniProt (www.uniprot.org) using only reviewed materials (Swiss-Prot). The table indicates 
the short name of the protein, the molecular size in kDa, the number of cysteine (#Cys), the number of 
disulphide bond (#DSB), the protein’s name, the cofactor(s), the oligomeric state in which the said protein is 
transported via the Tat pathway, the required chaperone and the chromosomal minutes. The listed proteins 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 3: Genomic comparisons between E. coli strains 
List of missing genes compared to the W3110 WT reference genome (AP009048.1, NCBI). *data obtained 
previously (Peters et al., 2003). Names in parentheses correspond to the previous gene names used in the 
publication. † putative gene discovered after the publication. ‡ partially deleted gene. 
Locus W3110 WT MC4100 WT MC4100 WT* MC4100 Tat-null 
A   fimB‡ fimB‡ fimB‡ 
A   fimE‡ fimE‡ fimE‡ 
B   fruB fruB fruB 
B   fruK‡ fruK‡ fruK‡ 
B   setB setB (yeiO) setB 
B   yeiP yeiP yeiP 
B   yeiP yeiQ yeiQ 
B   yeiR yeiR yeiR 
B   yeiU‡ yeiU (b2174)‡ yeiU‡ 
B   yeiW†   yeiW† 
C       TatA 
C       TatB 
C       TatC 
C       TatD 
D   icd‡ icd‡ icd‡ 
D   icdC‡ icdC‡ icdC‡ 
D   intE intE (b1140) intE 
D   lit lit lit 
D   mcrA mcrA mcrA 
D   pin pin pin 
D   stfE stfE (b1157) stfE 
D   tfaE tfaE (ycfA) tfaE 
D   ycfK ycfK ycfK 
D   ymfD ymfD (b1137) ymfD 
D   ymfE ymfE (b1138) ymfE 
D   ymfG ymfG (b1141) ymfG 
D   ymfH ymfH (b1142) ymfH 
D   ymfI ymfI (b1143) ymfI 
D   ymfJ ymfJ (b1144) ymfJ 
D   ymfK ymfK (b1145) ymfK 
D   ymfL ymfL (b1147) ymfL 
D   ymfM ymfM (b1148) ymfM 
D   ymfN ymfN (b1149) ymfN 
D   ymfO ymfO (b1151) ymfO 
D   ymfP ymfP (b1152) ymfP 
D   ymfQ ymfQ (b1153) ymfQ 
D   ymfR ymfR (b1150) ymfR 
D   ymfS ymfS (b1155) ymfS 
D   ymfT ymfT (b1146) ymfT 




Locus W3110 WT MC4100 WT MC4100 WT* MC4100 Tat-null 
F   afuB afuB (b0263) afuB 
F   afuC afuC (yagC) afuC 
F   argF argF argF 
F   b0309 b0309 b0309 
F   b0332 b0332 b0332 
F   betA betA betA 
F   betB betB betB 
F   betI betI betI 
F   betT betT betT 
F   codA codA codA 
F   codB codB codB 
F   cynR cynR cynR 
F   cynS cynS cynS 
F   cynT cynT cynT 
F   cynX cynX cynX 
F   eaeH eaeH eaeH 
F   intF intF (b0281) intF 
F   lacA lacA lacA 
F   lacI lacI lacI 
F   lacY lacY lacY 
F   lacZ lacZ lacZ 
F   mhpA mhpA (b0347) mhpA 
F   mhpB mhpB mhpB 
F   mhpC mhpC (b0349) mhpC 
F   mhpD‡ mhpD (b0350)‡ mhpD‡ 
F   mhpR mhpR (b0346) mhpR 
F   mmuM mmuM (yagD) mmuM 
F   mmuP‡ mmuP (ykfD)‡ mmuP‡ 
F   prpB prpB (b0331) prpB 
F   prpC prpC (b0333) prpC 
F   prpD prpD (b0334) prpD 
F   prpE prpE (b0335) prpE 
F   prpR prpR (b0330) prpR 
F   yagA yagA yagA 
F   yagB yagB yagB 
F   yagE yagE yagE 
F   yagF yagF yagF 
F   yagG yagG yagG 
F   yagH yagH (b0271) yagH 
F   yagI yagI yagI 
F   yagJ yagJ yagJ 
F   yagK yagK yagK 
F   yagL yagL yagL 




Locus W3110 WT MC4100 WT MC4100 WT* MC4100 Tat-null 
F   yagN yagN (b0280) yagN 
F   yagP yagP yagP 
F   paoD paoD (yagQ) paoD 
F   paoC paoC (yagR) paoC 
F   paoB paoB (yagS) paoB 
F   paoA paoA (yagT) paoA 
F   yagU yagU yagU 
F   yagV yagv yagV 
F   yagW yagW yagW 
F   yagX yagX yagX 
F   yagY yagY yagY 
F   yagZ yagZ yagZ 
F   yahA yahA yahA 
F   yahB yahB (b0316) yahB 
F   yahC yahC (b0317) yahC 
F   yahD yahD (b0318) yahD 
F   yahE yahE (b0319) yahE 
F   yahF yahF (b0320) yahF 
F   yahG yahG (b0321) yahG 
F   yahH yahH(b0322) yahH 
F   yahI yahI(b0323) yahI 
F   yahJ yahJ (b0324) yahJ 
F   yahK yahK (b0325) yahK 
F   yahL yahL (b0326) yahL 
F   yahM yahM (b0327) yahM 
F   yahN yahN (b0328) yahN 
F   yahO yahO (b0329) yahO 
F   ykgA ykgA ykgA 
F   ykgB ykgB ykgB 
F   ykgC ykgC ykgC 
F   ykgD ykgD ykgD 
F   ykgE ykgE ykgE 
F   ykgF ykgF (b030) ykgF 
F   ykgG ykgG ykgG 
F   ykgH ykgH ykgH 
F   ykgI ykgI (b0303) ykgI 
F   ykgJ ykgJ (b0288) ykgJ 
F   ykgK ykgK (b0294) ykgK 
F   ykgL ykgL (b0295) ykgL 
F   ykgM ykgM (b0296) ykgM 
F   ykgN†   ykgN† 
G   fnr     
G   uspE     




Locus W3110 WT MC4100 WT MC4100 WT* MC4100 Tat-null 






Appendix 4: PureFrac detailed protocol 
 
Keep samples and buffers on ice throughout the whole protocol and all centrifugation steps are 
carried out at 4°C. Use a single channel pipette with 1 ml tips to remove or transfer small liquid 
volumes without disturbing the pellet. All resuspension steps are performed by pipetting up and 
down gently until all of the pellet is resuspended without creating air bubbles. 
• At harvest, transfer a volume of 
8
𝑂𝐷600
 of the culture to a 50 ml tube. 
• Centrifuge for 15 min at 4816 g. 
• Optional: transfer the supernatant to a new 1.5 ml microfuge tube without disturbing the 
pellet and store at-20°C (media fraction). 
Periplasmic extraction 
• Resuspend the pellet in 850 µl of PBS (NaCl 137 mM, KCl 2.7 mM, Na2HPO4 24.2 mM, 
KH2PO4 5.2 mM at pH7.4, 100 μM N-Ethylmaleimide) and transfer to a 1.5 ml microfuge 
tube. Do not vortex or fractions will become cross-contaminated. 
• Centrifuge for 3 min at 20,817g and carefully discard the supernatant. 
• Resuspend the pellet in 900 µl of Buffer 1 (100 mM Tris pH 8.0, 500 mM sucrose, 0.5 mM 
EDTA pH 8.0, 1 cOmplete™ Protease Inhibitor Cocktail tablet (per 50 ml), 100 μM N-
Ethylmaleimide) and incubate on ice for 5 min. 
• Centrifuge for 3 min at 20,817g and carefully discard the supernatant. 
• Resuspend the pellet in 400 µl of Mg-water (Ultrapure sterile water, 100 μM N-
Ethylmaleimide, 1 mM MgCl2) by pipetting for about 30 sec and incubate on ice for 2 min. 
• Centrifuge for 3 min at 20,817g. 
• Transfer the supernatant to a new 1.5 ml microfuge tube without disturbing the pellet and 
store at-20°C (periplasmic fraction). Make sure not to disturb the pellet to keep the 
periplasmic fraction pure. The protocol can be stopped at this point and the pellet frozen 





• Wash the cells by resuspending the pellet in 1 ml of Buffer 2 (50 mM Tris pH 8.0, 250 mM 
sucrose, 10 mM MgSO4, 1 cOmplete™ Protease Inhibitor Cocktail tablet (per 50 ml), 100 μM 
N-Ethylmaleimide). 
• Centrifuge for 3 min at 20,817g and discard the supernatant. 
• Resuspend the pellet in 750 ml of Buffer 3 (50 mM Tris pH 8.0, 2.5 mM EDTA pH 8.0, 1 
cOmplete™ Protease Inhibitor Cocktail tablet (per 50 ml), 100 μM N-Ethylmaleimide) and 
immediately proceed to the next step. 
• Ultrasonicate with the following cycle parameters while the sample is incubated in an ice 
bath. 
• 10 sec amplitude 8 μm 
• 10 sec resting 
• Transfer the lysate to ultra-centrifuge tubes. 
• Ultra-centrifuge at 186 000 g for 30 min. 
• Transfer the supernatant to a new 1.5 ml microfuge tube and store at -20°C (cytoplasmic 
fraction). 
• Resuspend the pellet in 1 ml of Buffer 3 and store at -20°C (insoluble fraction containing 





Appendix 5: Growth curves of the initial expression of the 5 NTS 
The His-tagged AmiA (dark blue), HyaA (red), PaoA (green), TorA (purple) and YcbK (light blue) were expressed 
with their respective signal peptide in the W3110 WT (square markers), MC4100 WT (cross markers) and 
MC4100 Tat-null (triangle markers) strains as well as the empty vector as control (orange). The culture was 



























Appendix 6: Controls for the localisation of hGH fusions with PhoA as the protein of interest 
The samples obtained in Figure 7-2 were further analysed. The Western-blots represented the detection of 
PDI-cMyc, Erv1p-cMyc, LacI and MBP using anti-His, anti-FLAG, anti-cMyc, anti-LacI and anti-MBP antibodies 
respectively. PageRuler Plus Prestained Protein Ladder (Life Technologies) and MagicMark™ (Life 






Appendix 7: Table of the sizes of the proteins expressed in Chapter 7. 
The composition of the constructs is given in terms of signal peptide, soluble partner and protein of interest 
when applicable. Then, the corresponding protein sizes are indicated for the mature and premature forms 
when relevant in kilodalton (kDa) and well as the number of disulphide bond (DSB). 
Construct Protein size (kDa) 
DSB 
Signal peptide Soluble partner Protein of interest Premature Mature 
- - PhoA - 48.2 2 
OmpASP - PhoA 50.2 48.1 2 
TorASP - PhoA 52.8 48.6 2 
- hGH PhoA - 74.2 4 
OmpASP hGH PhoA 76.2 74.2 4 
TorASP hGH PhoA 78.9 74.7 4 
- - hGH - 23.1 2 
OmpASP - hGH 25.1 23.1 2 
TorASP - hGH 27.8 23.6 2 
- PhoA hGH - 74.3 4 
OmpASP PhoA hGH 76.2 74.2 4 
TorASP PhoA hGH 78.9 74.7 4 
- - FABP4 - 15.5 0 
OmpASP - FABP4 17.6 15.6 0 
TorASP - FABP4 20.3 16.1 0 
- hGH FABP4 - 41.7 2 
OmpASP hGH FABP4 43.7 41.7 2 
TorASP hGH FABP4 46.4 42.2 2 
- PhoA FABP4 - 66.8 2 
OmpASP PhoA FABP4 68.7 66.7 2 
TorASP PhoA FABP4 71.4 67.2 2 
- - VHH1 - 13.8 1 
OmpASP - VHH1 15.7 13.7 1 
TorASP - VHH1 18.4 14.2 1 
- hGH VHH1 - 39.8 3 
OmpASP hGH VHH1 41.9 39.9 3 
TorASP hGH VHH1 44.6 40.4 3 
- PhoA VHH1 - 64.9 3 
OmpASP PhoA VHH1 66.8 64.8 3 
TorASP PhoA VHH1 69.5 65.3 3 
- - VHH2 - 13.8 2 




Construct Protein size (kDa) 
DSB 
Signal peptide Soluble partner Protein of interest Premature Mature 
TorASP - VHH2 18.4 14.2 2 
- hGH VHH2 - 39.8 4 
OmpASP hGH VHH2 41.9 39.9 4 
TorASP hGH VHH2 44.6 40.4 4 
- PhoA VHH2 - 64.9 4 
OmpASP PhoA VHH2 66.8 64.8 4 






Appendix 8: Controls for the localisation of PhoA fusions with hGH as the protein of interest 
The samples obtained in Figure 7-4 were further analysed. The Western-blots represented the detection of 
PDI-cMyc, Erv1p-cMyc, LacI and MBP using anti-His, anti-FLAG, anti-cMyc, anti-LacI and anti-MBP antibodies 
respectively. PageRuler Plus Prestained Protein Ladder (Life Technologies) and MagicMark™ (Life 






Appendix 9: Controls for the localisation of fusions with FABP4 as the protein of interest 
The samples obtained in Figure 7-6 were further analysed. The Western-blots represented the detection of 
PDI-cMyc, Erv1p-cMyc, LacI and MBP using anti-His, anti-FLAG, anti-cMyc, anti-LacI and anti-MBP antibodies 
respectively. PageRuler Plus Prestained Protein Ladder (Life Technologies) and MagicMark™ (Life 






Appendix 10: Structures of sfGFP and FABP4 
The structures of sfGFP and FABP4 were solved at 1.85 and 1.08 Å by X-ray diffraction respectively (Dippel et 
al., 2016, González and Fisher, 2015). The top figures represented sfGFP and the bottom ones represented 
FABP4. The right images corresponded to a 90° rotation form the left ones. The cysteine residues were 






Appendix 11: Primary sequence alignment of the VHHs 
The alignment was performed using the online tool EMBOSS Needle with default parameters (Madeira et al., 






Appendix 12: Controls for the localisation of fusions with VHH1 as protein of interest 
The samples obtained in Figure 7-10 were further analysed. The Western-blots represented the detection of 
PDI-cMyc, Erv1p-cMyc, LacI and MBP using anti-His, anti-FLAG, anti-cMyc, anti-LacI and anti-MBP antibodies 
respectively. PageRuler Plus Prestained Protein Ladder (Life Technologies) and MagicMark™ (Life 






Appendix 13: Controls for the localisation of fusions with VHH2 as protein of interest 
The samples obtained in Figure 7-12 were further analysed. The Western-blots represented the detection of 
PDI-cMyc, Erv1p-cMyc, LacI and MBP using anti-His, anti-FLAG, anti-cMyc, anti-LacI and anti-MBP antibodies 
respectively. PageRuler Plus Prestained Protein Ladder (Life Technologies) and MagicMark™ (Life 










Appendix 14: Alignment of the SecY protein sequences extracted from the project’s strains 
The nucleotide sequences of secY were pulled from the genomic sequencing detailed in section 3.6. and 
translated into their corresponding protein sequence. The latter were then aligned to the W3110 WT reference 
genome (AP009048.1, NCBI) using Clustal Omega (Madeira et al., 2019). 
 
 
